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ABSTRACT

COLIN THANE MCDOWELL. An Imaging Mass Spectrometry Investigation Into
the N-linked Glycosylation Landscape of Pancreatic Ductal Adenocarcinoma and
the Development of Associated Tools for Enhanced Glycan Separation and
Characterization (Under the direction of RICHARD DRAKE)
The severity of pancreatic ductal adenocarcinoma (PDAC) is largely
attributed to a failure to detect the disease before metastatic spread has occurred.
CA19-9, a carbohydrate biomarker, is used clinically to surveille disease
progression, but due to specificity challenges is not suitable for early discovery. As
CA19-9 and other prospective markers are glycan epitopes, there is great clinical
interest in understanding the glycobiology of pancreatic cancer. Unfortunately, few
studies have been able to link glycosylation changes directly to pancreatic tumors
and instead have focused on peripheral glycan alterations in the serum of PDAC
patients. To address this gap in our understanding, we applied an imaging mass
spectrometry (IMS) approach with complementary enzymatic and chemical isomer
separation techniques to spatially assess the PDAC N-glycome in a cohort of
pancreatic cancer patients. Orthogonally, we characterized the expression of
CA19-9 and a new biomarker, sTRA, by multi-round immunofluorescence (IF) in
the same cohort. These analyses revealed increased sialylation, fucosylation and
branching amongst other structural themes in areas of PDAC tumor tissue. CA199 expressing tumors were defined by multiply branched, fucosylated bisecting Nglycans while sTRA expressing tumors favored tetraantennary N-glycans with

v

polylactosamine extensions. IMS and IF-derived glycan and biomarker features
were used to build classification models that detected PDAC tissue with an AUC
of 0.939, outperforming models using either dataset individually. While studying
sialylation isomers in our PDAC cohort, we saw an opportunity to enhance the
chemical derivatization protocol we were using to address its shortcomings and
expand its functionality. Subsequently, we developed a set of novel amidationamidation strategies to stabilize and differentially label α2,3 and α2,6-linked sialic
acids. In our alkyne-based approach, the differential mass shifts induced by the
reactions allow for isomeric discrimination in imaging mass spectrometry
experiments. This scheme, termed AAXL, was further characterized in clinical
tissue specimens, biofluids and cultured cells. Our azide-based approach, termed
AAN3, was more suitable for bioorthogonal applications, where the azide tag
installed on α2,3 and α2,8-sialic acids could be reacted by click chemistry with a
biotin-alkyne for subsequent streptavidin-peroxidase staining. Furthering the use
of AAN3, we developed two additional techniques to fluorescently label (SAFER)
and preferentially enrich (SABER) α2,3 and α2,8-linked sialic acids for more
advanced glycomic applications. Initial experiments with these novel approaches
have shown successful fluorescent staining and the identification of over 100
sialylated glycoproteins by LC-MS/MS. These four bioorthogonal strategies
provide a new glycomic tool set for the characterization of sialic acid isomers in
pancreatic and other cancers. Overall, this work furthers our collective
understanding of the glycobiology underpinning pancreatic cancer and potentiates
the discovery of novel carbohydrate biomarkers for the early detection of PDAC.
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Chapter 1: Introduction
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1.1 Pancreatic Ductal Adenocarcinoma
1.1.1 Development of the Pancreas and Normal Function
The human pancreas develops early in embryogenesis as two separate
outpouchings, dorsal and ventral buds, from the endoderm of the foregut. These
buds gradually rotate and fuse to become a single organ with head and tail sections
by E14 in mice and by day 41 of gestation in humans1. Branching morphogenesis
creates the primary ductal structures of the pancreas while pluripotent progenitor
cell populations differentiate into the three main cell types of the pancreas: acinar
exocrine cells, endocrine islet cells (islets of Langerhans) and ductal epithelium 2.
Acinar cells form clusters around the termini of intralobular ductal epithelium which
conjoin into larger interlobular ducts finally coalescing into the main pancreatic duct
which secretes digestive enzymes directly into the intestinal lumen. Endocrine cells
form distinct puncta known as pancreatic islets which stud the organ and secrete
hormones directly into a mesh of capillaries which vascularize the pancreas 3.
Pancreatic functions can generally be divided into two distinct categories:
exocrine and endocrine. Acinar cells in clusters secrete zymogen granules of the
digestive enzymes responsible for nutrient breakdown in the small intestine,
namely the proteases trypsin and chymotrypsin, lipase for lipids and amylase for
carbohydrates4. Pancreatic islets are composed mainly of five distinct cell types:
α, β, δ, ε, and PP cells which secrete glucagon, insulin, somatostatin, ghrelin and
pancreatic polypeptide, respectively5. Glucagon and insulin work in a
counterbalanced fashion to promote the release of glucose stored as glycogen
from the liver into the blood stream when levels are low, and to regulate the
2

removal of glucose from the blood into glycogen stores when levels are high6.
Somatostatin released from δ cells functions as a master inhibitor of α and β cell
secretions in response to blood glucose levels7. Pancreatic polypeptide (PP)
inhibits pancreatic exocrine secretions and functions mainly as a satiety hormone
while ghrelin stimulates the appetite and fat storage8,9. Together, these exocrine
and endocrine cell types provide dynamic regulatory control of nutrient breakdown
and hormonal nutrient signaling (Figure 1).
1.1.2 Pancreatic Cancer Progression, Etiology and Symptoms
Pancreatic ductal adenocarcinoma (PDAC) is a cancerous malignancy
arising from the transformation of epithelial cells in pancreatic ducts which
constitutes upwards of 90% of all pancreatic neoplasias10. In the United States in
the year 2020 an estimated 58,000 new cases of pancreatic cancer were reported
while 47,000 succumbed to the disease11. Worldwide, the prevalence of pancreatic
cancers is on the rise, with 496,000 new cases and 466,000 deaths in 2020 12.
Proportionally, PDAC affects males more than females, black people more than
other ethnicities and the elderly (60 years and older) over those younger13–15.
Troublingly, the 5-year survival rate for pancreatic cancer remains low (9 – 11%)
despite surgical and therapeutic advances in recent decades, making pancreatic
ductal adenocarcinoma the deadliest amongst other cancers16. The severity of the
disease is mainly attributed to the majority of cases being diagnosed at the
advanced (metastatic, 52%) or locally advanced stage (30%) 17 as there are
currently no effective biomarkers for early detection.

3

Figure 1: Endocrine and Exocrine Functions of the Pancreas. α, β, δ, PP and
ε cells making up pancreatic islets secrete glucagon, insulin, somatostatin,
pancreatic polypeptide and ghrelin, respectively to hormonally regulate blood
glucose and nutrient metabolism. Exocrine acinar cell clusters secrete trypsin,
chymotrypsin, lipase and amylase as part of the digestive system.
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The majority of PDAC cases develop when ductal epithelia undergo
neoplastic

transformation

to

form

precursor

lesions

termed

pancreatic

intraepithelial neoplasias (PanINs), although other less common mucinous lesions
known as intraductal papillary mucinous neoplasias (IPMNs) and mucinous cystic
neoplasias (MCNs) also give rise to the disease18. As PanIN lesions acquire more
mutations they progress through histopathologically classified stages (PanIN-1 →
PanIN-3) defined by nuclear and cytoplasmic atypia and increasingly distorted
papillary architecture leading to invagination of the ductal epithelium and the
eventual occlusion of the ductal lumen19,20. The transition from PanIN3 lesions to
a ductal adenocarcinoma phenotype is fluid and relies on histopathological and
genetic evaluation. PDAC tumors are typically small, solid, immunologically-cold,
hypovascularized masses with dense stromal networks making up the majority of
the mass by volume21. These carcinomas are staged using the TNM system which
evaluates tumor size and arterial involvement (T), metastasis to lymph nodes (N)
and metastasis to distant sites (M) with most cases diagnosed at T3N1M0 (stage
IIB)22,23. The prognosis for patients diagnosed with PDAC is poor, with an average
T1 → T4 time to progression of 14 months in which survival is negatively correlated
with increased age and more advanced disease status at time of diagnosis 24.
Clinical consensus and meta-analyses list tobacco smoking, diabetes mellitus,
obesity, hepatitis B viral infection and heavy alcohol consumption as serious risk
factors for developing pancreatic cancer25.
The above risk factors may in some cases induce acute or chronic
inflammation of the pancreas leading to a condition known as pancreatitis, which
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is

strongly

associated

with

the

development

of

pancreatic

ductal

adenocarcinoma26. Pancreatitis is characterized by increased fibrosis and the loss
of acinar and islet cell populations resulting in abdominal pain and both endocrine
and exocrine deficiencies27. Acute pancreatitis (AP) stems from temporal acinar
cell injury events often resulting in the premature activation of digestive enzymes
which leads to autodigestion of pancreatic tissue, leukocyte recruitment and
chemo/cytokine release as part of the acute phase response28. Recurrent
pancreatic insult and the accumulation of acute events induces sustained
recruitment of macrophages and neutrophils to the pancreas in chronic pancreatitis
(CP)29. Cytokines released by this resident immune population, along with injured
acinar cells, have been shown to activate quiescent pancreatic stellate cells to
transform into myofibroblast-like cells which induce the mostly collagen and
fibronectin-based fibrotic scarring typifying chronic disease30. The sustained
immune-inflammatory response associated with pancreatitis results in DNA
damage, accelerated mutagenesis and often acinar to ductal metaplasia events 31.
This in combination with prolonged and exacerbated secondary oxidative injury
fosters a more favorable environment for the development of the precursor lesions
that precede PDAC32. It is important to note that while pancreatitis is predictive of
the development of pancreatic cancer, less than 10% of PDAC cases are thought
to arise from CP33.
A related causative factor with inflammatory ties is type two diabetes
mellitus (T2DM), where those diagnosed have a relative risk factor or hazard ratio
ranging from 1.5 – 2.0 for the development of pancreatic ductal adenocarcinoma34.
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T2DM is characterized by a resistance to the ability of insulin to suppress hepatic
release of glucose, leading to initially elevated intrapancreatic insulin levels, high
blood glucose concentrations and damage to various organ systems35. Sustained
high insulin levels are associated with β-cell failure and activation of the unfolded
protein response causing senescence and apoptotic events which increase the
likelihood for the development of pancreatic cancer36. The proximity of acinar cells
and ductal epithelium to islets with hyper-elevated insulin production in T2DM
accelerates the proliferation of transformed cells within these populations by
directly stimulating growth signaling through insulin and IGF-1 receptors in a
process known as the proxicrine effect37. Additionally, prolonged inflammatory
signaling in the pancreas in response to T2DM creates a pro-oncogenic
environment similar to that described for pancreatitis38. Complicating etiological
considerations for diabetes is the dual-causal nature of PDAC and diabetes, where
T2DM is a considered a long-term risk for the development of pancreatic cancer
while concomitantly PDAC is considered a long-term risk for diabetes39. Studies of
pancreatic cancer patients have found diabetes to be prevalent in 47% of those
profiled, as compared with only 7% of the normal population 40. It is theorized that
shared risk factors for pancreatic cancer and T2DM may in part explain to the
complex overlap between both diseases41. Impairment of normal pancreatic
function by the progression of PDAC may also play a causative role in the
development of pancreatic cancer associated-diabetes42.
Despite the well-established roles of pancreatitis and diabetes mellitus in
the development of PDAC, 90% of pancreatic cancers are considered sporadic in
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origin43. The accumulation of somatic mutations in pancreatic cells over a lifetime
leads to increasing oncogenic potential through multiple prominent genetic
pathways. Most well characterized amongst these are mutations to the KRAS gene
in the RAS small GTPase family44. Oncogenic KRAS is associated with over 90%
of pancreatic cancers and is known to be the primary driver of neoplastic
transformation in the development of PDAC45. Amongst this family of mutations,
G12D is the most common in pancreatic cancer followed by G12V and G12R, with
less than 10% of KRAS mutations at other sites46. Aspartic acid, valine and
arginine substitutions at the G12 residue hinders the interaction between KRAS
and its associated GAP, preventing GTP hydrolysis and leading to constitutive
activation47. Thus, the KRAS signaling axis drives both MAP/ERK and
PI3K/PDK/AKT pathways resulting in cell survival, proliferation and Warburg
metabolic effects48,49. Targeted therapeutics towards mutant KRAS have been
largely ineffective, although a new wave of interest in KRAS inhibitors has yielded
promising treatment strategies50,51.
While oncogenic KRAS is the canonical progenitor mutation of early PanIN1 lesions, the progression of these precursor lesions towards the more aggressive
PanIN-3 and eventual PDAC phenotype is driven largely by the accumulation of
further somatic mutations. Early PanIN lesions are characterized by mutant KRAS,
telomere shortening and overexpression of HER2 while more advanced PanINs
show aberrant TP53, BRCA2, SMAD4 and CDKN2A (p16) expression52,53.
Overexpression of the heavily glycosylated mucin family proteins MUC1 and
MUC5AC is also associated with PanIN progression54. Increasing oncogenic
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burden and atypical protein expression drives a variety of signaling pathways
which promote the proliferation, cell survival and metastatic escape associated
with aggressive PDAC (Figure 2).
Although most genetic drivers for pancreatic ductal adenocarcinoma occur
as sporadic mutations, a subset of cases arise through familial genetic variations.
Pancreatic cancers with a genetic background can be further subdivided into those
patients with one or more relatives diagnosed with pancreatic cancer (90%, termed
familial pancreatic cancer or FPC) and those without pancreatic cancer in the
family but with a familial genetic syndrome that predisposes them to a high risk for
PDAC55. In FPC, risk for pancreatic cancer increases proportionally with the
number of first degree relatives diagnosed in a patient’s pedigree: 6.4% when two
relatives are affected and 32% when three are affected 56. The genetic causes for
FPC are not well understood and seem to be as varied as in sporadic cases,
although large pedigree studies have implicated hereditary BRCA2, PALB2 and
CDKN2A as common mutations in a significant subset of hereditary pancreatic
cancers57,58. The remaining 10% of inherited cases stem from hereditary genetic
syndromes with increased pancreatic cancer risk, namely hereditary pancreatitis,
Peutz-Jeghers syndrome, Lynch syndrome and familial breast cancer, ovarian
cancer and melanoma syndromes59–63. A hereditary disposition towards pancreatic
cancer warrants increased and earlier surveillance or preemptive partial to full
pancreatectomy in some extremely high risk cases64.
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Figure 2: Genetic, Molecular and Morphological Hallmarks of PanIN Lesion Progression. The accumulation of somatic
mutations, genetic superstructure alterations and increasingly distorted papillary architecture define the progression from
PanIN-1 to PanIN-3 lesions and eventually pancreatic ductal adenocarcinoma.

Symptoms, like the genetic causes of pancreatic cancer, are heterogenous
and show large patient-to-patient variability. Complicating early detection efforts,
the disease initially causes few if any symptoms until it has progressed to an
advanced stage65. Those patients who do present with early symptoms often
describe non-specific complaints like bloating, nausea and back pain which are
attributable to a number of more benign conditions 66. Clinical manifestations
presenting with the highest frequency at the time of pancreatic cancer diagnosis
are jaundice, lower back pain, weight loss, new onset diabetes, abnormal liver
function and nausea67. Jaundice-like symptoms are associated with PDAC tumors
originating in the head or neck of the pancreas which are more likely to cause
biliary duct occlusion and thus present as painless jaundice 68. Abdominal or back
pain are more frequently associated with tumors in the pancreas body, which tend
to invade local vasculature and crowd the retroperitoneal space 69. Particularly
lethal are pancreatic tail tumors, which reside in a more sparsely populated
anatomical neighborhood and thus cause fewer symptoms and tend to grow
unimpeded leading to a more advanced stage at diagnosis 70. Collectively, the
variation in clinical presentation challenges early diagnosis and is one of the major
causative factors in the lethality of PDAC.
1.1.3 Detection and Diagnosis
Following the presentation of symptoms and the clinical suspicion of
disease, pancreatic cancer is typically diagnosed using one or multiple imaging
modalities followed by an invasive tissue biopsy for confirmation of primary tumor
development or of metastatic spread71. Multi-detector computed tomography
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(MDCT), which maps the abdomen via differential X-ray penetrance between
tissue types, is the most common and cheapest imaging option used for clinical
diagnosis and staging but can result in nephrotoxicity from radiation exposure 72.
Magnetic resonance imaging (MRI) and positron emission tomography (PET) are
also used to diagnose PDAC when CT is not suitable for the patient73. Confirmation
of diagnosis is typically established by endoscopic ultrasound-guided fine-needle
aspirate (EUS/FN) with on-site cytopathological evaluation74. EUS/FN can also be
used to monitor disease status during the course of treatment. Standard CT, MRI
and PET instruments are resolution-limited at 0.5 mm, 1.5 mm and 2.5 mm,
respectively, which allows them to distinguish most pancreatic tumors (3 – 7 cm),
however PDAC precursor lesions often escape detection due to their small size (<
0.5 mm) and failure to contrast in comparison to normal pancreatic tissue 75–79.
Additionally, the location of the pancreas in difficult to reach retroperitoneal space
challenges clinical access, meaning that precise tissue biopsies are often difficult
and uncomfortable to obtain repeatedly for surveillance80. Unfortunately for patient
outcomes, the diagnostic utility of imaging is usually after the onset of symptoms,
when metastatic spread of the disease has likely already occurred. Today,
screening for new onset pancreatic cancer by imaging is clinically-recommended
only for a very small subset of extreme risk patients81.
As previously mentioned, pancreatic ductal adenocarcinoma is diagnosed
and staged using the TNM system which considers tumor volume, level of arterial
invasion and metastasis to lymph nodes and distant sites as agreed upon by the
American Joint Commission on Cancer. TNM classifications are used to sort
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patients into one of 5 stages ranging from I – IV, where stages I and IIA are
considered resectable to borderline resectable (11%), stages IIB and III are
considered borderline resectable to unresectable (37%) and stage IV is considered
unresectable and metastatic (52%)82. Stage at diagnosis is a critical determinant
of patient outcomes, where resectable pancreatic cancers have a 42% 5-year
survival rate while unresectable, metastatic PDAC, which tends to metastasize to
the liver, lymph nodes, lung, peritoneum and bone, has an abysmal 3% 5-year
survival83. The current screening shortcomings and subsequently advanced stage
of disease at detection for most PDAC patients – resulting in the poorest patient
survival statistics amongst any cancer – highlight the critical need for novel early
detection methods.
1.1.4 Pancreatic Cancer Biomarkers
CA19-9,

also

known

as

the

sialyl-Lewis

A

(sLeA)

(NeuAc[α2,3]Hex[β1,3]HexNAc[α1,4]Fuc) motif, is to date the only FDA-approved
biomarker for pancreatic cancer84. Elevated in ~70% of PDAC patients, this
epitope realizes its utility as a prognostic indicator for judging a patient’s response
to therapy. In pancreatic ductal adenocarcinoma patients with abnormal CA19-9,
serum CA19-9 levels correlate directly with tumor burden and thus changes in
disease severity are reflected by the biomarker making it a useful surveillance
tool85. However, because CA19-9 is associated with other cancers and non-cancer
maladies like pancreatitis, cystic fibrosis and liver disease, it lacks the specificity
for early detection or diagnosis86. The clinical CA19-9 immunoassay detects the
sLeA epitope on a variety of protein carriers, the most well-characterized of which
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are the mucins MUC1, MUC5AC and MUC16, cluster of differentiation 44 (CD44),
galectin 3 binding protein (LGALS3BP), bile globular membrane (BGM),
apolipoprotein B-100, kininogen and apolipoprotein E87–89. CA19-9 is a sialylated
member of the Lewis histo-blood group antigens, which are similar to the wellknown ABO antigen group for their roles in immunity, infection, cardiobiology and
metabolism90,91. Lewis blood antigens generally fall into two types, Lewis A and
Lewis B, which are determined by an individual’s Lewis (Fucosyltransferase 3,
FUT3) and Secretor (Fucosyltransferase 2, FUT2) enzyme expression status,
respectively92. The Lewis antigens, their associated synthesis enzymes and their
defining linkages are shown in Figure 3. LA+B+ and LA+B- individuals have overall
higher expression of the CA19-9 epitope, whose biosynthesis is critically
dependent on fucosylation by FUT3. Studies have shown that LA-B- persons –
around 5% of the population – often have more severe PDAC, although the
association of total Lewis negative status with non-cancer-related pulmonary
health abnormalities may explain their poorer outcomes 93–95. Unfortunately for
patients, CA19-9 is no longer considered solely a biomarker of pancreatic cancer
but is now recognized as an active promotor of disease progression and severity.
A 2019 study in mice which overexpressed CA19-9 through transduction of FUT3
and β1,3-galactosyltransferase 5 (B3GALT5) – the main two enzymes responsible
for sLeA biosynthesis – demonstrated rapid development and increased severity
of pancreatitis96. Specifically, CA19-9 attached to fibulin 3 had increased
interaction with the epidermal growth factor receptor (EGFR) which is both
necessary and
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Figure 3. CA19-9 and the Lewis Antigens: Structure and Synthesis. The Lewis
antigens, defined initially by the galactose – N-acetylglucosamine linkage into
types I (β1,3) and II (β1,4), are further decorated by various fucosyl- and
sialyltransferases to produce the full histo-blood group spectrum including CA199. Adapted97.
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sufficient to induce pancreatitis and can initiate neoplastic transformation to
pancreatic cancer98,99. Additionally, expression of CA19-9 in KRAS-transgenic
mice from the same study worked synergistically with the oncogene to accelerate
the development of pancreatic cancer. Besides interaction with EGFR, the CA199 epitope has been shown to drive PDAC metastasis through E-selectin-mediated
initiation and can promote tumor growth by increasing local microvessel density 100–
102.

This shift in perspective towards CA19-9 as not just a marker of but an active

participant in pancreatic cancer has sparked interest in therapies targeting the
epitope itself103–106. Use of humanized monoclonal antibodies towards CA19-9
during surgical resection has recently shown success in decreasing recurrence
rates for pancreatic cancer patients107.
A more recently developed biomarker candidate, the sialylated Type 1 Type
2 LacNAc termed sTRA, occurs in a majority of pancreatic tumors where it often
but not always overlaps with CA19-9 expression. This marker has demonstrated
increased performance over CA19-9 in the detection of PDAC and together these
antigens are in development for a new clinical surveillance panel 108–110. Another
marker, CA-125 (MUC16), is a heavily glycosylated mucin glycoprotein which is
elevated in pancreatic cancer patients but faces the same challenges as CA19-9
due to a lack of specificity and association with other cancers111,112. The severity
of pancreatic cancer and the dearth of adequate markers has made the search for
new PDAC markers a popular field of research. A recent review summarized over
300 pancreatic ductal adenocarcinoma biomarker candidates and associated
factors which include a variety of serum glycoproteins, glycolipids, growth factors
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and chemokines, lncRNAs, miRNAs, exosomes and ctDNA as well as urinary,
cystic, salivary, biliary, and fecal-associated molecules113. It is apparent to both
clinicians and researchers that any sole biomarker will likely lack the sensitivity and
specificity to detect PDAC amongst the general population, suggesting that a multimarker panel, in conjunction with associated clinical data, may lead to better
diagnostic efficacy. A 2020 study tested 2047 combinations of 11 cancerassociated markers with increased prevalence in pancreatic cancer which resulted
in a 6-pannel marker consisting of Apolipoprotein A1, CA-125, CA19-9,
carcinoembryonic antigen (CEA), Apolipoprotein A2, and transthyretin (TTR) that
was able to diagnose PDAC with a sensitivity of 0.93 and a specificity of 0.96 for
a total area under the curve (AUC) of 0.993114. As more and more sensitive
biomarkers, panels and algorithms are discovered it is foreseeable that larger atrisk subsets of the general population may be able to be preemptively screened
for the early development of PDAC.
1.1.5 Standard of Care
For patients diagnosed with pancreatic ductal adenocarcinoma, those who
are able to undergo successful surgical resection have the best survival statistics
by a wide margin. Despite this, surgical intervention is possible in less than 20%
of PDAC cases as those patients with locally advanced or metastatic disease are
typically not eligible for tumor resection115. In rare cases tumor extirpation from the
pancreas can be performed, but the majority of surgical interventions in PDAC are
pancreaticoduodenectomies (Whipple’s Procedure) in which the head of the
pancreas and parts of the stomach and gall bladder are removed and the
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remaining stomach, bile duct and pancreas tail are fused directly to the small
intestine116,117. Other interventions include distal and total pancreatectomies when
the patient needs a large amount or all of the pancreas removed to achieve an R0
margin, but these procedures are likely to result in diabetes mellitus and are less
commonly recommended118. In the past decade the definitions of resectability have
been fluid, with many borderline resectable (BLR) PDACs evaluated on a case-bycase basis119. Resectability is typically defined as minimal to no tumor contact with
major vessels, however BLR patients may have venous involvement and/or partial
arterial involvement and still be considered eligible120.
Because survival in pancreatic cancer is so heavily associated with eligibility
for surgical resection, many clinical management strategies focus on using
neoadjuvant chemotherapeutic and radiological treatments to shrink tumor volume
to within surgically appropriate margins121. Gemcitabine in combination with other
cytotoxic agents such as Paclitaxel, Tegafur and Erlotinib has long been
considered the gold standard of care for advanced PDAC cases and thus has been
used neoadjuvantly as well122,123. In recent years, a combination of drugs including
Folinic acid, 5-fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) has shown
improved efficacy in managing PDAC over Gemcitabine, although it was
associated with increased toxicity124,125. The main chemotherapeutic agents in
both FOLFIRINOX and Gemcitabine combinations act as both DNA damaging
agents and as antimetabolites to target the susceptibility of cancer cells to growth
phase or cellular division disruption126. A similar suite of therapies is also used in
an adjuvant fashion to prevent recurrence in patients who have undergone surgical
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resection and is associated with improved survival127. Interventional radiology by
radiofrequency ablation (RFA) or irreversible electroporation (IRE) is also
commonly used as an alternative to or in conjunction with chemotherapy in BLR
cases128. Unfortunately for the majority of patients who are diagnosed at a locally
advanced or metastatic stage, surgical resection is not an option. In these cases
FOLFIRINOX, Gemcitabine and other chemotherapeutics are used in a palliative
fashion to prolong patient survival and improve quality of life129. The importance of
discovering PDAC at a resectable stage, in terms of positive clinical outcomes,
highlights the need for novel early detection strategies. Figure 4 summarizes
diagnoses and their associated treatment sequences, as well as survival statistics,
in pancreatic ductal adenocarcinoma.
1.2 N-linked Glycosylation
1.2.1 N-glycan Biosynthesis

Glycosylation is the enzymatic addition of carbohydrate residues (or
glycans) to a biomolecule, most commonly to a protein or lipid. These sugars can
either be attached as monomers or can be linked together to form long, complex
chains in a non-template driven synthetic manner. Individual sugar moieties used
to produce glycans include, but are not limited to, glucose (Glc), mannose (Man),
galactose

(Gal),

fucose

(Fuc),

N-acetylglucosamine

(GlcNAc),

N-

acetylgalactosamine (GalNAc), and N-acetylneuraminic acid (Neu5Ac)130.
Relevant to glycan synthesis, these carbohydrate monomers exist intercellularly
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Figure 3. Treatment Sequence and Survival Outcomes as a Function of Diagnosis in PDAC. Diagram of the different
treatment options for those diagnosed with pancreatic ductal adenocarcinoma. Survival is directly correlated with
resectability at diagnosis. Adapted131.

as nucleotide sugars, synthesized de novo from dietary monosaccharides or via
recycling and salvage pathways132. Together chains of these sugars form a dense
carbohydrate scaffold on the cell's outer membrane known as the glycocalyx 133.
This dynamic surface is comprised of multiple subclasses of glycosylated
molecules, namely N- and O-linked glycoproteins, glycolipids, glycosaminoglycans
(GAGs) and proteoglycans134. The glycocalyx governs interactions with the local
microenvironment by acting as a barrier, filter, substrate and active chemical or
enzymatic agent. Glycosylated proteins and lipids in this surface are implicated in
cell–cell communication, signal transduction, secretion, interactions with the
immune system, cellular migration and adherence, proliferation and regulation
amongst other processes135,136. Critically, the glycocalyx is sensitive to the
temporal physiological state of the cell and thus reflects internal cellular health137.
Accordingly, it is well known that the composition and structure of the glycocalyx
is regulated in response to a variety of diseases138.
N-linked glycans, attached to asparagine residues as part of N-X-S/T motif
sites on the glycoprotein backbone, are able to play diverse cellular roles due to
their structural heterogeneity (Figure 5). The biosynthesis of N-linked glycans is
dependent on a discrete number of glycosidases and glycosyltransferases, as well
as their sugar monomer substrates, the local concentrations of which often
determine which classes of N-glycans are expressed139. Initially, synthesis begins
on the cytosolic face of the endoplasmic reticulum, where a dolichol phosphate
anchor acts as the attachment point for the addition of successive GlcNAc,
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Figure 5. N-glycan Structural Classes, Motifs and Individual Sugar
Monomers. A) cartoon representations of the various sugar monomers which Nglycans comprise. B) common N-glycan structural motifs referred to in this
dissertation. C) N-glycan structural classes including high mannose, hybrid and bi, tri- and tetra- antennary complex glycans. D) Precise chemical structures for the
cartoonized sugar monomers in A.
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mannose

and

glucose

sugars

catalyzed

by

a

series

of

n-

acetylglucosaminyltransferases, mannosyltransferases, and glucosyltransferases,
respectively, to form an initial Glc3Man9GlcNAc2 chain140. During the formation of
this precursor glycan, a flipase inverts the growing glycan into the ER interior for
the addition of the final sugars141. Once formed, this proto-N-glycan is transferred
by oligosaccharlyltransferase (OST) co-translationally onto a newly synthesized
protein, linked to an asparagine residue which must be followed by an X-S/T
sequence in which X cannot be proline142.
The covalent modification of newly synthesized proteins with this glycan
initiates one of the most important biological processes regulated by N-linked
glycans – protein folding. Specifically, cells use the Glc3Man9GlcNAc2 glycan
precursor as a molecular indicator of successful protein folding events 143.
Sequential trimming of the three terminal glucose monomers occurs concomitantly
as the protein transitions from a nascent amino acid chain to its fully folded
conformation, assisted by the lectin-like protein chaperones calnexin and
calreticulin which bind the monoglucosylated, truncated form of the precursor
glycan144. The final glucose on the partially trimmed Glc1Man9GlcNAc2 glycan is
routinely cycled on and off until the protein is folded successfully, at which point a
mannosidase removes a single terminal mannose and the fully folded protein is
secreted to the Golgi via coated vesicle145.
In the Golgi, the Man8GlcNAc2 glycan is further trimmed by a series of
mannosidases before glycosyltransferases are able to synthesize a complete Nglycan (Figure 6). This process begins with the β1,2/4 addition of N23

Figure 6. N-glycan Biosynthesis in the Endoplasmic Reticulum and Golgi.
MOGS, α-glucosidase I; GANAB, α-glucosidase II; MAN1B1, ER α-mannosidase
I; MAN1A1/2, α-mannosidase I; MGAT1, α-1,3-mannosyl-glycoprotein 2-β-Nacetylglucosaminyltransferase; UDP, uridine diphosphate; MAN2A1, αmannosidase
II;
MGAT2,
α-1,6-mannosyl-glycoprotein
2-β-Nacetylglucosaminyltransferase; FUT8, fucosyltransferase VIII; GDP, guanosine
diphosphate; B4GALT, β-1,4-galactosyltransferase; STnGAL, β-galactoside α-2,3sialyltransferase or β-galactoside α-2,6-sialyltransferase; CMP, cytidine
monophosphate.
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acetylglucosamine (GlcNAc) residues to the N-glycan chitobiose core by the
MGAT enzyme family, which are then further substituted with a galactose (Gal)
monomer by GALT family enzymes146. Β1,4-linked Gal-GlcNAc units constitute Nglycan antennae, the number of which on an individual glycan define the
biantennary (2), triantennary (3) and tetraantennary (4) subclasses of complex Nglycans147. N-acetylglucosamine residues are also in some cases added to the
central mannose of the chitobiose core as bisecting GlcNAc by a specialized β-Nacetylglucosaminyltransferase, MGAT3148. Additional Gal-GlcNAc subunits can be
added to one or more antennae of a tetraantennary N-glycan to form what are
known as poly-N-acetyllactosamine (LacNAc) extensions149. Complex N-linked
glycans may be decorated with fucose residues by a discrete set of enzymes with
differing affinities for an N-glycan’s antennae or core GlcNAc residue. FUT8 is the
sole enzyme responsible for core fucosylation, where fucose is attached α1,6 to
the 1st GlcNAc residue covalently linked to the amino acid backbone150. Outer arm
fucose residues are α1,3 or α1,4 linked to GlcNAc monomers in N-glycan antennae
by a large number of fucosyltransferases151. N-linked glycan branches are often
capped with a terminal neuraminic acid (sialic acid) residue, which generally exist
as either α2,3 or α2,6 linkage isomers installed by specialized sialyltransferases152.
It is important to note that N-glycan biosynthesis does not occur via sequential
installation of sugar monomers in a biologically pre-specified order, rather these
reactions exist concomitantly with glycosyltransferases and glycosidases
competing for substrates and access. The resulting N-glycan is thus dependent on
the specific temporal cellular conditions under which it was synthesized, rather
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than being encoded by the cell. A summary of complex N-glycan biosynthesis
enzymes and their associated modifications is provided in Figure 7.
Although the consensus amino acid motif for N-linked glycans has been well
characterized, there are outstanding questions in the field regarding N-X-S/T site
occupancy and glycan heterogeneity at the same site. Site occupancy is often a
function of position within the amino acid backbone in relation to a protein’s
secondary structure. As the nascent peptide chain beings to fold, N-X-S/T sites
near turns in β-sheets or between secondary superstructural features are more
accessible to glycation by OST and thus are more often N-glycosylated153.
Additionally, the X amino acid in the N-glycosylation motif critically affects the
ability of OST to modify the growing protein. Bulky, hydrophobic amino acid side
chains at the X position sterically hinder enzyme access and can inhibit glycan
transfer while negatively charged glutamate and aspartate actually increase the
affinity of OST for the N-X-S/T site154. As previously mentioned, proline at the X
position confines the amino acid sequence to unreceptive conformations and
prevents the interaction between arginine and the proteoglycan entirely 155. While
secondary structure is more likely to affect N-glycan site occupancy, protein tertiary
structure exerts outsized influence on the heterogeneity of the individual N-glycan
occupying the site. The 3D conformation of the fully folded protein determines
glycosyltransferase and exoglycosidase access to the precursor N-glycan, limiting
the potential mature glycan structures at any one given site. More exposed N-XS/T sites can accommodate larger, multiply branched, fucosylated and or
sialylated N-glycans which cannot be synthesized at less accessible locations on
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Figure 7. Glycosyltransferases Involved in the Synthesis of Complex N-glycans. MGAT3, β-1,4-mannosylglycoprotein
4-β-N-acetylglucosaminyltransferase;
MGAT4,
α1,3-mannosyl-glycoprotein
4-β-Nacetylglucosaminyltransferase; MGAT5, α1,6-mannosyl-glycoprotein 6-β-N-acetylglucosaminyltransferase; B4GALT, β1,4-galactosyltransferase FUT8, fucosyltransferase VIII; ST3GAL, β-galactoside α-2,3-sialyltransferase; ST6GAL, βgalactoside α-2,6-sialyltransferase; UDP, uridine diphosphate; GDP, guanosine diphosphate CMP, cytidine
monophosphate.

the protein156. Complicating analysis, most glycoproteins exhibit microheterogeneity at each individual N-glycan site, where otherwise identical copies of
the same protein may have radically different glycoforms157. This is once again
likely due to temporal changes in enzyme concentrations and substrate availability
during N-glycan maturation.
1.2.2 The Biological Role of N-glycosylation
As a class of post-translational modifications, glycans have biological
utilities which are less specific to individual subtypes but are more broadly a
function of the physical and chemical properties of carbohydrates. The
hydrophilicity of N-glycans and other bulky glycans modifications often contributes
to the solubility of a protein and can be protective against proteolysis158.
Additionally, N-glycans on the protein surface may intrinsically enhance the kinetic
and thermal properties of proteins by stabilizing their underlying energy
landscapes159. In the case of immunoglobulin G (IgG) and other dimerized
proteins, favorable hydrophobic interactions between glycans on individual protein
monomers enhance the overall stability of the quaternary structure160,161.
N-glycans change the overall 3D protein conformation and are commonly a
part of protein – protein interplay where they may serve as a partial to full epitope
for recognition by interactors or otherwise indirectly stabilize the complex162.
Lectins, a class of carbohydrate-binding proteins, can directly recognize whole or
partial N-glycans as part of cell – cell self-recognition events, glycoprotein
trafficking, ECM adhesion and signal transduction amongst other biological
purposes163. Accordingly, changes in N-glycan structural elements by the action of
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glycosyltransferases and exoglycosidases modify the N-glycan as a spatial
epitope and consequently the types of lectins with which a glycoprotein may
interact – thus altering its biological function. Rather than an in-depth discussion
of lectins which is outside the scope of this dissertation, a summary table of Nglycan-associated lectins and their biological functions is provided in Table 1.
Related to their interaction with lectins and other carbohydrate-binding
proteins, N-linked glycans play a crucial role in protein trafficking within the cell164.
Studies have shown that the N-glycosylation of recombinant GFP in HeLa cells
substantially reduces Golgi residence time, suggesting that N-glycans may act as
a signal for exocytic trafficking at the trans-Golgi165. Intracellular translocation of
sensitive lysosomal enzymes is governed by N-glycosylation, where 6’phosphoyrlated oligomannose N-glycans are recognized by the mannose-6phosphate receptor in the Golgi and subsequently trafficked to the lysosome 166,167.
N-glycosylation can even facilitate polarized sorting, where N-glycans are
recognized by chaperone proteins to traffic membrane glycoproteins to the apical
face of epithelial cells as opposed to the basolateral surface168. N-glycan
associated congenital disorders of glycosylation (CDG) – a collection of hereditary
N-glycan processing and modification diseases – in some cases result from
dysregulated protein sorting, secretion or intracellular trafficking169.
More often than an “on” or “off”-like switch, N-linked glycans exhibit a tuning
effect on glycoprotein function, where the addition of different modifications like
fucosylation, branching or bisecting GlcNAc modulates a protein’s biological
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Table 1. N-glycan-Binding Lectin Classes

Lectin Class

Glycan Epitope

Cellular Location

Functions

Calnexin

Glc1Man9

ER

ER protein sorting

C-type

Gal, GalNAc

Cell membrane,
extracellular

Innate immunity (collectins), cell
adhesion (selectins)

F-box Lectins

GlcNAc

Cytoplasm

Misfolded glycoprotein degradation

Ficolins

GlcNAc, GalNAc

Cell membrane,
extracellular

Innate immunity

F-type

Fuc

Extracellular

Innate immunity

Galectins

Β-galactoside

Cytoplasm,
extracellular

ECM glycan crosslinking

Siglecs

Sialic acids

Cell membrane

Cell adhesion

Intelectins

Gal

Cell membrane,
extracellular

Innate immunity, embryogenesis,
fertilization

M-type

Man8

ER

Misfolded glycoprotein degradation

Lysosomal enzyme targeting,
glycoprotein trafficking
Golgi, cell
Hormone turnover, glycoprotein
R-type
Mannose
membrane
trafficking
ER, endoplasmic reticulum; ECM, extracellular matrix; Man-6-P, mannose-6-phosphate;
Adapted170.
P-type

Man-6-P

Golgi
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activity

level,

association

with

other

proteins

or

stability

within

its

microenvironment. These three functions intersect in the case of EGFR. Studies
have shown that when N-glycans on EGFR are core fucosylated, the receptor is
stabilized in the plasma membrane which allows it to form nanodomains with other
EGFR receptors171. These nanodomains increase the signaling activity of EGFR
and thus its downstream processes172. Inhibition of core fucosylation accordingly
destabilizes the receptor, prevents its association with other EGFR and decreases
signaling intensity173. The normal biological functions of N-linked glycans, with their
capacity to regulate cellular processes, are often implicated in the development,
maintenance and progression of disease.
1.2.3 N-glycans in Cancer and Other Diseases
It is now well understood that N-glycosylation changes are not only a
hallmark of cancer but are active drivers of neoplastic transformation, growth,
survival, immune evasion and metastatic escape 174. N-glycan modifications like
branching, fucosylation, sialylation, bisecting GlcNAc and poly LacNAc extensions
have a diverse yet sometimes overlapping set of biological functions, which in
cancer are frequently driven to extremes. Increased nucleotide sugar availability
due to the Warburg metabolic effect and elevated glycosyltransferase expression
driven by oncogenic signaling often results in the synthesis of large, multiply
branched, fucosylated

and

sialylated

N-glycans which typify malignant

disease175,176.
Branched N-glycans, specifically the tetraantennary class synthesized by β1,6-N-acetylglucosaminyltransferase V (MGAT5), are associated with tumor
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progression and metastasis177. Deletion of MGAT5 production in a Mgat5-/- mouse
model reduced N-glycan branching and subsequently suppressed mammary
tumor growth and metastatic potential by decreasing focal adhesion signaling 178.
Many cancers share this phenotype, where MGAT5 overexpression positively
modulates cell-cell adhesion events leading to an increased likelihood of
metastasis179,180. Tetraantennary N-glycans resulting from increased MGAT5
expression also serve as the host glycan for polylactosamine (poly LacNAc)
extensions, which are associated with breast and other cancers181. These LacNAc
epitopes are known leukocyte suppressors and in cancer may facilitate aspects of
immune evasion182. Aberrant fucosylation, both core and outer arm, similarly drives
multiple aspects of cancer biology. As previously mentioned, core fucosylation
directly stabilizes EGFR receptors and leads to increased proliferative signaling in
liver and other cancers amongst other functions183. Outer arm fucosylation has
been shown to be increased in patient sera from breast, lung and ovarian cancer
patients, which may be a signature of Lewis-antigen driven pro-oncogenic affects
as described for CA19-9184. Bisecting GlcNAc residues are also heavily implicated
in cancer. Using glioma cells as a model, researchers in Osaka, Japan showed
that overexpression of MGAT3 led to increased extracellular signal-regulated
kinase (ERK) proliferative signaling185. Conversely, bisecting GlcNAc is more often
recognized as an inhibitor of growth signaling, where the addition of bisecting
GlcNAc residues to cell surface receptors can have protective effects. Bisecting
GlcNAc has been shown to increase receptor endocytosis leading to decreased
growth signaling and may decrease the affinity of MGAT5 for bisecting
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glycans186,187. The role of sialic acids, in cancer and in health, will be explored in
greater detail in later sections.
While the pro-oncogenic functions of N-glycans are often non-specific to a
particular cancer, the molecular and genetic drivers of each individual cancer
subtype result in unique glycosylation abnormalities. For the focus of this review,
a special emphasis will be placed on mass spectrometry-analyzed N-glycosylation
hallmarks. These investigations have revealed distinct N-glycosylation patterns
across tissue subtypes, N-glycan structural motifs associated with particular
cancers as well as N-glycan ions whose detection specifically delineates healthy
versus diseased tissue or discriminates between cancer stages. A summary of
these cancer-associated N-glycan phenotypes is provided in Table 2.
Perhaps no other disease has been more frequently associated with Nglycosylation changes than cancers of the liver, specifically hepatocellular
carcinoma (HCC)188–190. Interest in liver cancer glycosylation stems from initial
studies of alpha-fetoprotein (AFP), which revealed core fucosylation as a critical
indicator of hepatic dysfunction in HCC191,192. Discovered later, fucosylated Golgi
protein 73 (GP73) has been shown to be up to three times more sensitive than
AFP for the detection of HCC193–195. Fucosylation, amongst other structural motifs,
have since been associated with a number of other circulating glycoproteins from
patients with liver cancer196–199. To this end multiple N-glycan imaging mass
spectrometry (IMS) analyses have been directed toward HCC tissue cohorts in
hopes of linking in situ expression of N-glycan species directly with those found in
circulation. In 2018 West et al. surveyed the N-glycome of a large HCC cohort
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Table

2.

Cancer-Associated N-glycan Changes

Revealed by

Mass

Spectrometry.
Cancer

Study

Disease-associated N-glycans

Breast

Scott 2019181

Polylactosamines ↑ (HER2, TN)

Herrera 2019201

Tetraantennary LacNAc ↑ (poor survival)

Scott 2019202

Sialylation ↑ Fucosylation ↓ (necrosis)

Angel 2019203

Hex9HexNAc2 ↑

Holst 2016204

Sialylation ↑

Heijs 2019205

High Mannose ↑

Boyaval 2020206

High Mannose ↑, Sialylation ↑

Drake 2017207

High Mannose ↑, Hex6HexNAc2 ↑

Carter 2020208

High Mannose ↑ (hyperplasia), Fucosylated Biantennary
↑ (hyperplasia)

Powers 2014209

Hex7HexNAc6 ↑, Hex8HexNAc2 ↑

Powers 2015210

Hex7HexNAc6 ↑, Core Fucosylation ↑

West 2018200

Hex7HexNAc6 ↑, Branching ↑, Fucosylation ↑ (poor
survival)

Angel 2019203

Afucosylated bi-/triantennary ↑, Hex9HexNAc2 ↑

West 2020211

Core Fucosylation ↑ (poor survival)

Black 2020212

Hex3dHex1HexNAc4 ↑ (cirrhosis),
Hex5HexNAc4NeuAc2 ↑ (cirrhosis)

Everest-Dass 2016213

High Mannose ↑

Colorectal

Lung

Liver

Ovarian

Briggs 2019214
Pancreatic

Powers 2014209

Hex9HexNAc2 ↑ (stage III), Fucosylation ↑ (stage III),
Bisecting GlcNAc ↑ (stage III), Sialylation ↑ (stage III)
Biantennary ± Fucose ↑ (fibrosis), Undecorated ↑
(necrosis)
Biantennary ↑ (fibrosis)

Powers 2015210

Fucosylation ↑, Branching ↑ Bisecting GlcNAc ↑,
Sialylation ↑, Polylactosamines ↑ (tumor margin),
Undecorated ↑ (necrosis), High mannose ↓
Polylactosamines
↑, Branching ↑, Outer-arm Fucosylation
Renal
Drake 2019216
↓, Hex5dHex1HexNAc4NeuAc1 ↑ (fibrillar capsule)
↑, increased expression relative to normal healthy tissue; ↓, decreased expression relative to
normal healthy tissue; () association with a specific disease or tissue subtype.
McDowell 2020215
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along with cirrhotic and non-transformed tissue samples200. Highly branched Nglycans with one or more fucose modification were expressed abundantly in HCC
samples while in cirrhotic and adjacent normal tissues their expression was
detected minimally or not at all. A later orthogonal analysis confirmed that the
majority of the detected N-glycans with at least one fucose residue in the HCC
TMA, especially those associated with poor survival, are core-fucosylated211.
The role of N-glycosylation in the development, maintenance and
progression of breast cancer has been extensively studied, but there has been
limited translation of results to clinical or diagnostic applications217. In 2018, in situ
analyses of breast cancer tissue microarrays (TMAs) and whole tissue sections by
matrix-assisted laser desorption ionization imaging mass spectrometry (MALDIIMS) revealed increases in polylactosamine containing N-glycans specific to the
aggressive human epidermal growth factor receptor 2 (HER2) and triple negative
(TN) subtypes. This finding has been corroborated by an orthogonal study utilizing
MALDI-IMS which implicated tetra-antennary N-glycans containing just a single Nacetyllactosamine branch with poor survival outcomes in breast cancer patients 201.
Interestingly, mass spectrometry has revealed patterns of N-glycosylation which
are specific to regions of necrosis in breast cancer tissues202. N-glycans localizing
to these areas of cellular remnants were uniquely sialylated and lacked fucose
residues when compared to the high mannose and multiply branched structures of
the tumor tissue. Similar patterns have been observed in other cancer types,
suggesting a possible role for N-glycosylation in the pathways leading to cellular
death218.
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High mannose N-glycans, shown to be increased in breast tumors, have
also been detected in the sera of breast cancer patients using MALDI-MS219. In
this context, the Man9GlcNAc2 structure is especially elevated, which posits the
incomplete trimming of pre-Golgi N-glycan intermediates as a feature of breast
cancer. Other analyses of N-glycosylation in breast cancer serum have detected
N-glycan signatures which delineates recurrent versus non-recurrent cancer,
stage 1 breast cancer from healthy controls and signatures specific to the lymph
node invasive subtype220,221.
In colorectal cancer (CRC), N-glycosylation plays a well-defined oncological
role222. Studies utilizing MALDI-time of flight (TOF) MS have analyzed N-glycans
from CRC tissue homogenate, various CRC cell lines and patient serum 223–225.
These studies detected a wide variety of N-glycan structural features specific to
CRC tumor tissue, including high mannose, core fucosylation, sialylation,
increased branching and even sulfation. These distinctions were born out between
healthy and diseased samples but also across molecular subtypes and disease
stage. Elevated levels of sialylated N-glycans have been shown in CRC tissue
samples204. A proof-of-concept study, which demonstrated both N-glycan and
peptide IMS from the same tissue sections, detected high mannose N-glycans
localized to tumor regions in a representative CRC sample226. These initial findings
were solidified in 2020 by a comprehensive survey of the N-glycome of stage II
CRC by IMS, which confirmed expression of sialylated and high mannose
structures in cancer cells206. This increased expression was shown to be
propagated into the surrounding stroma, suggesting the modification of N-
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glycosylation in the tumor microenvironment ahead of the tumor's invasive front in
advanced stage CRC.
The role of glycosylation changes in lung cancer are well known and initial
studies suggest the existence of disease-specific N-glycosylation227. An early
study which demonstrated the applicability of MALDI-IMS to N-glycan analyses
featured tissue microarrays (TMAs) with lung adenocarcinoma cores matched to
normal lung tissue. In these cores, high mannose N-glycan structures, especially
Hex6HexNAc2, were found to be elevated207. Although not a direct analysis of lung
cancer, a recent study employed the use of radiation to recapitulate pre-neoplastic
transformation which may lead to lung cancer in rhesus macaques 208. Areas of
irradiation-induced hyperplasia in these lung samples analyzed by N-glycan IMS
exhibited elevations in high mannose structures consistent with the human lung
TMA cores from the aforementioned study, as well as fucosylated bi-antennary
structures with and without bisecting GlcNAc residues. This elevation in high
mannose N-glycans has also been observed in a MALDI-TOF MS analysis of lung
adenocarcinoma patient sera across stages, positing that a further IMS evaluation
of the lung cancer N-glycome may discover additional N-glycan features which
map to serum expression for possible use as biomarkers228.
Glycosylation changes in ovarian cancer were first observed in the mid
1960s229. Of recent interest is the translation of N-glycosylation analytical
applications to clinical strategies for ovarian cancer, as N-glycans are known to be
heavily involved in the oncogenesis and maintenance of this disease 214,230
Consistent with other types of cancers, a 2016 study detected increased
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expression of high mannose N-glycans in ovarian cancer tumor tissue as
compared to normal tissue from the same samples213. This same analysis also
detected increases in hybrid-type structures specific to areas of intervening stroma
in this cohort. N-glycans extracted and purified from FFPE ovarian cancer tissue
samples for MALDI-TOF analysis by the Li group supported the specificity of high
mannose N-glycan expression in ovarian tumor tissue231. This analysis also found
that a seven-glycan panel consisting of four high mannose and three fucosylated
complex structures was able to delineate epithelial ovarian cancer from healthy
controls, while a similar yet distinct N-glycan panel could distinguish specific
ovarian cancer grades. N-glycan IMS analyses have also been able to differentiate
early-

versus

late-stage

ovarian

cancer

using

specific

N-glycosylation

signatures232. The high mannose N-glycan Hex9HexNAc2 was detected
abundantly in stage III ovarian cancer samples as compared to stage I tissues.
Additionally specific to late-stage ovarian cancer were fucosylated, bisecting and
sialylated complex species. These glycosylation changes were not only detected
in the whole tissue cohort analyzed in this report, but in corresponding TMAs which
lends additional statistical power to these findings. Taken together these early Nglycan IMS studies suggest glycosylation changes as a feature of ovarian cancer
potentially exploitable for clinical detection and surveillance of this disease.
The first publication of a standardized N-glycan MALDI-IMS workflow was
demonstrated on a normal kidney tissue section which contained both medulla and
cortex tissue regions233. Although the technology was in its infancy, the few Nglycan analytes detected were localized to specific tissue subtypes. A subsequent
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analysis of FFPE murine kidneys demonstrated similar results234. This initial work
was furthered by a more comprehensive 2020 study of clear cell renal cell
carcinoma (ccRCC), which spatially profiled N-glycosylation in a cohort of normal
kidney and renal cell carcinoma tissues216. A defining feature of healthy kidney
tissue from this study was broad structural diversity between tissue subtypes, with
bisecting, high mannose and fucosylated structures localized to the cortex while
bi- and tri-antennary N-glycans with core fucose residues localized to medullary
tissue. Interestingly, the interface between cortex and medulla also had a distinct
glycosylation signature, defined by multiply-fucosylated structures which lacked
bisecting GlcNAc residues. A high spatial resolution analysis from this study
detected tetra-antennary N-glycans with and without sialic acid modifications
specific to kidney glomeruli. These normal-associated structural features were
conspicuously absent from ccRCC tumor tissue, which exhibited increased
expression of tetra-antennary N-glycans with polylactosamine extensions of
varying length. The fibrillar capsule surrounding a Fuhrman grade 2 ccRCC tumor
was characterized by a bi-antennary, monosialylated N-glycan. N-glycan IMS
findings were mapped directly to transcriptomic profiling by RNA sequencing from
a prior study, which revealed altered expression of outer arm fucosyltransferases
FUT3 and FUT6235,236. The decreased expression of these glycosyltransferases in
ccRCC tissue across all stages matches less abundant outer-arm fucosylation of
tumor N-glycan structures observed by IMS. Taken together the findings from this
multi-omic study comprise the most comprehensive analysis to-date of the healthy
and diseased renal N-glycome.
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1.2.3.1 The Glycobiology of Pancreatic Cancer
In the pancreas, a variety of glycan changes have been associated with
PDAC including increases in sialyl-Lewis A (CA19-9)

and sialyl-Lewis X,

truncation of O-linked glycans, increased O-GlcNAcylation and increase N-glycan
fucosylation and branching237. These glycosylation changes are observable
directly in PDAC tumors and their microenvironments and in many cases can be
linked to similar changes in patient sera and plasma 238. Altered expression of the
glycosyltransferases MGAT5, MGAT3, FUT8 ST6GAL1 and ST3GAL3 in
pancreatic cancer have been linked to greater metastatic capacity, suggesting that
N-linked glycosylation may play a particularly significant role in PDAC239–242.
For patients with PDAC, integrins and other ECM adhesion proteins are Nglycosylated at elevated levels, with greater site occupancy and increased
microheterogeneity243. Additionally, proteins associated with critical pancreatic
cancer signaling pathways like nuclear factor-κB (NF-κB), tumor necrosis factor
(TNF) and tumor growth factor β (TGF-β) are heavily N-glycosylated in PDAC
which may increase their stability and resistance to proteolysis and thus sustain
elevated signaling levels244. Inhibiting N-linked glycosylation synthesis in
pancreatic cancer cell lines decreases expression of the receptor tyrosine kinases
(RTKs) insulin-like growth factor-I receptor (IGF-IR) and EGFR by disrupting
protein synthesis and trafficking to the cell surface in the Golgi245. In the serum of
pancreatic cancer patients, glycoproteins have been shown to be heavily
fucosylated and those with more aggressive disease exhibit increased N-glycan
branching246–248. Considerable research effort has gone into identifying N-
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glycosylation

changes

on

serum

glycoproteins

in

pancreatic

ductal

adenocarcinoma, summarized in a 2018 review on serum glycoprotein biomarkers
for PDAC (Table 3)249. Although serum protein glycosylation is often a helpful
indicator of disease progression or severity, the link between N-glycosylation
changes on serum glycoproteins and aberrant N-glycosylation in pancreatic
tumors is not well understood. The majority of serum glycoproteins are hepatic in
origin, thus N-glycan modifications on these proteins are a function of liver biology
rather than pancreatic cancer-derived250. Frequently, changes in serum Nglycosylation in cancer are reflective of acute phase immune and inflammatory
responses in the liver stimulated by immune cell-mediated cytokine storms251,252.
Consequently, there is interest in better understanding the glycosylation landscape
of pancreatic tumors to establish a link between tumor-associated N-glycosylation
and changes to the serum glycoproteome.
Unlike for other cancers, few spatial N-glycome analyses of pancreatic
cancer tumors have been performed. Early experiments using N-glycan IMS
demonstrated biantennary N-glycan structures with and without core fucose
residues specific to areas of fibrosis in pancreatic cancer tissues209. A further
exploration of PDAC N-glycosylation by the same group in 2015 corroborated the
finding of biantennary N-glycans as features of fibrotic tissue regions in pancreatic
cancer210. These proof-of-concept experiments established the utility of N-glycan
imaging mass spectrometry for studying cancer glycosylation but were not specific
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Table 3. Alterations to Serum Protein N-glycosylation in Pancreatic Cancer.
Core
Fucose

Outer Arm
Fucose

α2,3
sialylation

α2,6
sialylation

β2-glycoprotein 1 (P02749)

+

+

+

+

Hemopexin (P02790)†

+

+

+

+

+

+

+

+

Clusterin (P10909)

+

+

Antithrombin III (P01008)

+

+

+

+

Kininogen 1 (P01042)

+

+

+

+

Serum Glycoprotein

Haptoglobin-related protein
(P00739)
Serum amyloid P component
(P02743)†

sLeX

+
+

+
+

α-1B-glycoprotein (P04217)
Haptoglobin (P00738)†

Branching

+
+

+

+

α-1-antitrypsin (P01009)†

+

+

Transferrin (P02787)†

+

α-1-acid glycoprotein 1
(P02763)†

+

Fetuin-A (P02765)

+

+
+

+
+

+

+

Ceruloplasmin (P00450)†

+

RNase 1 (P07998)

+

α-1-antichymotrypsin
(P01011)†

+

+

Thrombospondin 1 (P07996)

+

+

Leukemia inhibitory factor
+
+
+
receptor (P42702)
Centrosome-associated
+
+
protein 350 (Q5VT06)
†
+, increased compared to healthy controls; (), uniport accession number; , acute phase response
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to pancreatic cancer – warranting a more thorough investigation. The need to
understand the spatial biology of N-glycosylation in pancreatic cancer and the
potential clinical implications associated with tumor-derived N-glycan biomarkers
was an original inspiration for the work presented in this dissertation.
1.2.4 Sialic Acids
Sialylation is the addition of N-acetylneuraminic acid (NeuAc) residues to
the branches of N-glycans, O-linked glycans or glycolipids. This major class of
glycan modifications occurs when a sialyltransferase covalently attaches one or
more sialic acid monomers in the form of cytidine monophosphate-linked
nucleotide sugars to a glycan substrate. Sialyltransferases relevant to N-glycans
are generally categorized by which sugar substrates they act upon, either terminal
galactose residues or other sialic acid residues. Sialic acid chains known as
polysialic acids are formed via the sequential addition of α2,8-linked sialic acids by
ST8 α-N-acetyl-neuraminide α-2,8-sialyltransferases II and IV (ST8SIA2,
ST8SIA4)253. Sialyltransferases which decorate terminal galactose can be further
subdivided into those which catalyze an α2,3 linkage (ST3 β-galactoside α-2,3sialyltransferase III, IV and VI, ST3GAL3, ST3GAL4, ST3GAL6) and those which
catalyze an α2,6 addition (ST6 β-galactoside α-2,6-sialyltransferase I and II,
ST6GAL1, ST6GAL2)254. Sialic acids also occur naturally in a hydroxylated form,
n-glycol neuraminic acid (NeuGc), and although these sugars are synthesized by
most mammals, humans have lost that ability over evolutionary time 255.
Nevertheless, NeuGc-decorated glycans still occur sparingly in human tumors and
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in some healthy tissues, likely as a result of dietary consumption of NeuGccontaining animal products256,257.
The role of sialylation in both health and disease has been extensively
characterized258. Sialic acids are unique amongst the N-glycan sugar monomers
for their carboxylic acid group, which is negatively charged a physiological pH. As
such, this sugar is able to engage with different sets of molecular interactors than
are the other neutral sugars which constitute N-glycans259. In the plasma
membrane, electrostatic charge repulsion between sialylated glycoproteins
prevents their association and thus modulates their signaling activity 260.
Conversely, electrostatic adhesion between sialic acids and positively charged
amino acids may reinforce protein – protein interactions261. In cancer,
hypersialylation confers distinct advantages for tumor cells which can generally be
subdivided into four biological processes: immune evasion, apoptotic resistance,
decreased adhesion and increased extravasation. By engaging inhibitory siglecs
on NK cells, T cells and macrophages, sialic acids on the tumor cell surface are
able to counteract the effect of activating receptors and induce quiescent states in
these immune cells262. Sialylation of tumor necrosis factor (TNF) and Fas receptors
has been shown to prevent their internalization – even in the ligand bound state –
thus disabling these apoptotic signaling pathways263. The addition of sialic acid
residues to integrins reduces adhesion between cancer cells and their
microenvironments, which decreases the stability of the tumor mass and increases
shedding of tumor cells into the local vasculature264. These sialylated circulating
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tumor cells can then engage endothelial selectins resulting in extravasation and
colonization to form metastatic secondary sites265.
The α2,3, α2,6 and α2,8

linkages of sialic acids determine their

configuration as spatial isotopes and therefore each epitope’s ability to rotate, bend
and adopt various binding topologies266. Accordingly, sialic acid-binding proteins
are often biased towards – or exclusive to – specific sialic acid linkages267.
Syntheses presented later in this dissertation will capitalize on the topological
differences between these isomers. The biological importance of sialic acid linkage
isomers is exemplified by the case of influenza flu virus trophism: human influenza
A virus selectively binds α2,6-linked sialic acids while the avian influenza A strain
is specific to α2,3 isomers268. In cancer, sialic acids play distinct roles based on
their topology. Increased expression of ST6GAL family sialyltransferases and the
subsequent α2,6-sialylation of glycoproteins is associated with tumor progression,
apoptotic resistance, immune suppression and poor survival in multiple
carcinomas269,270. Antibody-targeted removal of sialic acid isomers from tumors
reduces immunosuppressive phenotypes in cancer models by repolarizing tumorassociated macrophages271. As previously mentioned, α2,6-sialylation of the Fas
death receptor by ST6GAL1 in colorectal carcinoma protects against Fasmediated apoptosis272. ST3GAL enzymes are involved in the biosynthesis of the
α2,3-sialylated pancreatic cancer-associated sLeA and sLeX epitopes, where
increased detection of these markers is associated with advanced disease. In
addition, expression of ST3 sialyltransferases increases tumor proliferation,
differentiation and metastasis in cholangiocarcinoma as well as promotes tumor
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cell adhesion and invasion in gastric cancers273,274. Accordingly, knockdown of
ST3GAL6 prevents myeloma cell bone marrow homing in xenograft mouse
models, prolonging survival275. The differential physiological functions of α2,3- and
α2,6-sialylated proteins and their relation to cancer biology make them attractive
targets for biomarker and molecular mechanistic studies. Challenges in the
analysis of sialic acid isomers – and strategies to overcome them – will be
described in later sections.
1.3 Analysis of N-glycosylation
Approaches to study N-glycans have varied as widely as N-glycans
themselves as the field has advanced over the past 60 years (Figure 8)276. From
the first characterization of asparagine-linked β1-GlcNAc on ovalbumin to modern
day comprehensive analyses of hundreds of N-glycan analytes, the concept of the
N-glycome has evolved substantially and has gained a reputation as one of the
most important yet understudied aspects of cellular biology 277. French
enzymologist François Jacobs was both too early in the eyes of his colleagues and
yet far too late when in 1975 he acknowledged, “Together with nucleic acids and
proteins, carbohydrates represent the third dimension of molecular biology” 278.
Today we recognize

glycomics

–

with

its associated

instrumentation,

methodologies and data analysis challenges – as on par with the more well-known
“omics” fields like metabolomics and proteomics. For the purposes of this
dissertation, the following sections will cover increasingly advanced N-glycan
analysis techniques, beginning with the use of lectins.
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Figure 8. Techniques for the Analysis of N-linked glycans. Broadly, these
analyses are either lectin-based, chromatography-based or mass spectrometry
based, although significant overlap exists between these classes (e.g., liquid
chromatography-coupled mass spectrometry or lectin affinity chromatography).
LC-MS, liquid chromatography-coupled mass spectrometry; MALDI, matrixassisted laser desorption/ionization; TOF, time-of-flight
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1.3.1 Lectins
As previously described, lectins are carbohydrate-binding proteins which
often exhibit antibody-like specificity for their glycan targets. Accordingly, lectins
have long been utilized to detect, visualize and quantify N-glycans in a fashion
analogous to immunolabeling. Lectins were used in some of the first glycomic
experiments and have since been optimized and adapted into a wide variety of
technologies, including microarray and chip formats where immunohistochemical
(IHC), immunofluorescent (IF) or colorimetric readouts are often coupled to these
configurations279. Most lectins commonly used as glycan tools today originated in
plants, although some fungal and animal proteins have proven useful as well 280.
Typical lectins have specificities not for whole N-glycans themselves, but for
particular structural motifs like branching (Griffonia simplificolia lectin-II, GSL-II;
Phaseolus vulgaris L, PHA-L), bisecting GlcNAc (Phaseolus vulgaris E, PHA-E),
sialylation (Sambucus nigra, SNA; Maackia amurensis, MAL), oligomannose
(Concanavalin A, ConA) and fucosylation (Aleuria aurantia lectin, AAL; Lens
culinaris hemagglutinin, LcH; Pisum sativum agglutinin, PSA)281. The specificity for
broad architectural features only, however, limits their use for detailed structural
analyses and thus lectin technologies are largely outdated for precise N-glycomic
work. As a further complication, the affinity of lectins for their carbohydrate
antigens is in the low micromolar range whereas antibodies routinely have
nanomolar to picomolar affinities, therefore lectin binding is often assumed to be
somewhat nonspecific282,283. Despite this, lectins regularly find utility as part of
affinity chromatography columns where they facilitate preferential rather than
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specific enrichment. Often, lectin affinity columns will combine multiple lectins with
differing specificities to non-specifically enrich glycosylated molecules in bulk from
a sample for analysis by liquid chromatography284,285.
1.3.2 Liquid Chromatography
Liquid chromatography (LC) represents a major technological step forward
for the analysis of N-glycans. Chromatographic separation of N-glycoproteins,
chemically or enzymatically released N-glycans and glycan fragments by high- or
ultra-performance liquid chromatography (HPLC, UPLC) can provide information
about N-glycan site occupancy, microheterogeneity, composition and structure. LC
separation is a function of how an analyte partitions between a liquid mobile phase
and solid stationary phase as it passes through a chromatography column.
Separated analytes are then passed by a detector coupled to the column outflow
which

typically

measures

ultraviolet

absorbance,

fluorescence

or

chemiluminescence amongst other readouts286. Common chromatography column
materials for N-glycans and glycoproteins are C18 (reversed phase, RP), porous
graphitized carbon (PGC) and unbonded silica (hydrophilic interaction liquid
chromatography, HILIC) which separate glycan analytes by polarity and
hydrophobicity287. When coupled with sequential exoglycosidase digestions prior
to separation, liquid chromatography analyses can even provide precise N-glycan
structural or linkage information288.
The ability to separate released N-glycans on RP, PGC or HILIC columns
often relies on derivatization of the N-glycan reducing end prior to injection into the
LC system, where 2-aminobenzamide (2-AB), procainamide (ProA), aminoxyTMT,
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rapifluor-MS (RFMS) and permethylation labels are commonly used 289. While
derivatization and labeling results in improved LC separation and detection, these
reactions add substantial sample preparation time and require costly reagents 290.
In the context of potential high throughput diagnostic or clinical applications, such
handicaps preclude the analysis of large sample cohorts in a feasible timeframe or
cost-effective manner291..
1.3.3 Mass Spectrometry
To date, mass spectrometers are some of the most advanced tools applied
to the analysis of N-glycosylation. As the name implies, mass spectrometers detect
molecules of interest by their mass to charge ratio (m/z), which are then displayed
as a spectrum of intensities corresponding to analyte abundance within the
sample. Because these instruments measure a ratio of mass to charge, they
necessarily must sample analytes as charged ions. Therefore, there are typically
three main components of a mass spectrometer: an ionization source, a mass
analyzer and a detector292. Ionization sources commonly impart electro- or
photochemical energy into the analyte matrix to generate ions for detection293.
Downstream of the ion source, mass analyzers use electrostatic or magnetic field
potentials to characterize ion m/z values then gate, reject, select for, separate and
steer analytes of interest through the instrument towards the detector 294. In the
detector, an ion’s mass to charge ratio and abundance are then recorded, often as
a function of charge induction295. The types and configurations of these
components give birth to a wide variety of mass spectrometers with different
speeds, sensitivities and analytical proclivities. Mass spectrometry instruments
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and methodologies for the analysis of N-glycans – discussed further herein – are
generally categorized by their ionization source (electrospray or matrix-assisted
laser desorption) and their mass analyzers or detectors (time of flight or ion
cyclotron).
1.3.3.1 LC-MS
Today, HPLC and UPLC instruments are increasingly coupled to mass
spectrometers for detection of glycan analytes. Liquid chromatography-coupled
mass spectrometry (LC-MS) relies on the ionization of chromatographically
separated analytes before injection into the instrument for detection. Here, an
electrospray ionization (ESI) source is commonly used that applies an electrostatic
potential to an aerosolized spray of solvated molecules of interest, which undergo
desolvation, a transition to the gas phase and ionization296. The principles of
separation used in liquid chromatography applications are equally as relevant
when coupled with mass spectrometry analysis. As previously discussed, Nglycans often must be labeled or derivatized to efficiently separate, ionize and
fragment for LC-MS. Here too the increased sample preparation time impedes high
throughput studies, which are already difficult due to the typically long on-column
separation time required for LC-MS297. The ability for ESI sources to generate
multiply charged ions, however, increases sensitivity of detection of low
abundance analytes298,299. The decision whether to use LC-MS for N-glycan
analysis is therefore largely dependent on the need for experimental sensitivity or
for throughput. One immutable shortcoming of LC-MS for analyses of tissuederived glycans is the loss of spatial context. Tissue sample preparation for LC-
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MS and electrospray ionization necessarily involves homogenization of
glycosylated tissue proteins for chromatographic separation 300. Matrix-assisted
laser desorption ionization imaging mass spectrometry (MALDI-IMS), which
records an N-glycan’s orientation relative to a tissue, is preferred for spatial
characterizations. Accordingly, MALDI-IMS N-glycan analyses will be the focus of
this dissertation. The mass analyzers and detectors for LC-MS are shared by those
for MALDI-IMS and will be discussed in a further section.
1.3.3.2 MALDI-IMS
Imaging mass spectrometry (IMS) was first developed for the analysis of
metal alloys and semiconductors in industrial applications301. Eventually termed
SIMS (secondary ion mass spectrometry), this “ion microscope” technique,
progenitor to all subsequent IMS strategies, involved sputtering a sample’s surface
with a high-energy gaseous ion beam. Collisions with this beam and the
subsequent transfer of energy generated “secondary” ions from the sample which
could then be analyzed in a mass spectrometer302. These initial demonstrations
piqued interest in generating spatial analyte information from biological mediums.
Caprioli and colleagues took advantage of prior research into the combined use of
a high energy laser and a photoabsorbent organic acid matrix to generate ions for
mass spectrometric analysis (collectively referred to as matrix-assisted laserdesorption ionization, MALDI) to generate the first molecular images of biological
tissue specimens in 1997303. The group demonstrated that by rastering the laser
beam across the sample surface in a gridded fashion, pseudo-colored heat maps
could be generated to show the in-situ distributions and abundances of ions of
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interest where each “pixel” represented a mass spectrum from where on the tissue
the laser sampled. MALDI also proved capable of generating more massive ions
than had previous ionization strategies, making it suitable for the analysis of a wide
range of biologically relevant analytes304.
Since these initial demonstrations, MALDI has come to dominate the field
of imaging mass spectrometry. Workflows have been developed for a wide breadth
of sample conditions and analytes of interest305, however a general MALDI imaging
mass spectrometry experiment proceeds as follows: 1. A sample is collected from
the patient during a surgical procedure or posthumously. 2. The tissue specimen
is preserved by snap-freezing in liquid nitrogen (“Fresh Frozen” tissues) or by
fixation in formalin followed by embedment in paraffin wax (“Formalin-Fixed
Paraffin-Embedded” tissues). 3. Embedded or frozen tissues are thinly sectioned
(5 – 20 µm) and mounted on glass slides. 4. Samples are prepared for imaging
dependent on the analyte of interest (this may include clearance of unwanted
analytes, antigen retrieval or chemical/enzymatic release of molecules of interest,
amongst other steps). 5. A crystalline organic acid or similar matrix is applied as a
thin layer over the sample surface. 6. Analytes are ionized by laser desorption for
detection by the mass spectrometer. 7. Collected spectra are spatially mapped for
visualization of molecular distributions. 8. Data is processed by statistical analysis,
image co-registration, peak identification or other software.
Imaging mass spectrometry holds distinct advantages over other imaging
modalities. Imaging by light microscopy limits the number of identifiable analytes
in a single experiment, whereas IMS platforms may detect hundreds of analytes at
53

the same time306. Unlike immunohistochemical or immunofluorescent staining,
IMS experiments do not require lengthy incubations with molecular probes or
extensive washing, fixation and mounting steps, making sample preparation
simpler and quicker. The high-resolution mass analysis afforded by modern mass
spectrometers allows for fine discrimination between analytes of very similar mass
and high confidence in the specificity of molecular assignments, a feature
especially useful in metabolomics and lipidomic investigations307. Advancements
in laser, computational and instrumental technologies allow imaging mass
spectrometry to vastly outperform other imaging strategies in terms of the speed
of data acquisition308. IMS also boasts the broadest range of detectable analytes,
facilitating label free imaging of proteins, lipids, nucleic acids, carbohydrates,
metabolites and pharmaceuticals ranging from less than 100 to more than 100,000
Da309. Additionally, the sensitivity of imaging mass spectrometry platforms allows
for the detection of molecules of interest at femtomolar levels directly from their
biological milieu310. Most critically, the ability to analyze patient tissue specimens
is core to the insights gained from today’s IMS experiments, where diseasemediated molecular and morphological features are directly manifest. Linking
histopathologically-defined tissue structures to the expression of specific
biomolecules potentiates the discovery of disease markers and therapeutic
targets. At its most reductive function, IMS acts as a “molecular microscope” to
reveal the biological and chemical mechanisms underpinning pathophysiology,
resulting in better understanding of the origins, maintenance and progression of
disease.
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Although multiple imaging mass spectrometry strategies have been developed
since the theoretical groundwork for the field had been laid, by far the commonly
utilized technology in the imaging space is MALDI-IMS. N-glycan imaging
experiments utilizing a MALDI source rely heavily on three primary factors:
enzymatic release of N-glycans from the tissue surface, the application of a lightabsorbing organic matrix to the tissue sample and the use of a neodymium-doped
yttrium aluminum garnet (Nd:YAG) or similar laser for ion generation 311,312.
Photoablation of the co-crystallized N-glycans and matrix by the laser results in the
subsequent transfer of sample molecules to the vapor phase, analyte ionization
and ejection into the mass spectrometer313. These characteristics make MALDI an
ideal technology for the generation of N-glycan ions, which had been traditionally
difficult to ionize due to their large size and complex structural properties209,233,314.
The basic N-glycan MALDI IMS schematic is shown in Figure 9. A key component
of the N-glycan IMS workflow is the use of a solvent sprayer to apply a thin
molecular layer of peptide N-glycosidase F (PNGase F) enzyme onto tissue or
cells to release only N-linked glycans from their carrier proteins. Diffusion of the
released glycans is minimal allowing spatial colocalization to tissue regions and
specific cell types. As MALDI is considered the gold standard for spatial N-glycan
analyses, the following section will focus heavily on sample preparation and
instrumentation for MALDI experiments.
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Figure 9. MALDI Imaging Mass Spectrometry for the Analysis of N-glycans. A) MALDI laser striking a grid pixel on an
FFPE tissue section. B) Close up view of MALDI photoablation of the tissue surface and subsequent desorption/ionization
and ejection of N-glycan ions into the mass spectrometer. C) Representative mass spectrum generated from a single MALDI
pixel. D) Mapping of individual pixel spectra back to their original X,Y coordinates generates N-dimensional N-glycan heat
maps.

1.3.3.2.1 Sample Preparation for MALDI IMS of N-glycans
A standardized N-glycan IMS sample preparation workflow is presented in
Figure 10. Current MALDI-IMS workflows are able to accommodate both freshfrozen (FF) and formalin-fixed paraffin-embedded (FFPE) tissue sources from
clinical pathology labs or tissue biorepositories, granting access to a nearly
unlimited supply of specimens for analysis. 5 µm FFPE tissue slices from
pathology blocks or cores from tissue biopsies cut and affixed to glass slides
(indium tin oxide (ITO) -coated for analyses in some TOF instruments) are
dewaxed and rehydrated in a graded series of ethanol and water washes prior to
heat induced epitope retrieval in a citraconic anhydride-based buffer. 8 µm
cryosectioned fresh frozen tissues are rinsed in organic solvents to remove lipids,
salts and other metabolites, thus increasing downstream N-glycan signal. FF
tissues do not require antigen retrieval prior to enzymatic N-glycan release. In
addition to whole-tissue imaging, both FFPE and fresh-frozen tissue samples are
routinely homogenized for N-glycan extraction and purification as previously
mentionied223. Doing so enables the analysis of multiple tissues on the same
MALDI target plate but forgoes the retention of N-glycan spatial information.
Alternatively, liquid-phase extraction of N-glycans from tissue homogenate is
routinely used orthogonally to whole-tissue MALDI-IMS for precise structural
identification via ESI-LC-MS315.
N-glycans are released from their glycoprotein carriers via on-tissue
incubation with peptide N-glycosidase F (PNGase F), which cleaves between
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Figure 10. A Standardized Workflow for N-glycan MALDI-IMS. A) FFPE or FF
tissue slides, B) dewaxing and rehydration, C) heat-induced epitope retrieval, D)
application of peptide N-glycosidase F, E) enzymatic N-glycan release, F)
application of matrix and G) spatial analysis by MALDI-FTICR or MALDI-TOF.
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asparagine and the first GlcNAc residue on the chitobiose core of the N-glycan316.
For N-glycan IMS, the retention of analyte spatial information is accomplished
through a “dry” molecular coating of PNGase F that limits diffusion of released Nglycans across the tissue. Current protocols using an automated sprayer system
to apply this coating are robust and highly reproducible 314. Tissue slides sprayed
with PNGase F are incubated in a pre-warmed (37°C) chamber at ≥80% relative
humidity for a minimum of two hours to remove the N-glycan structures.
Desorption and ionization of analytes into a MALDI mass spectrometer for
detection is dependent on the application of a crystalline chemical matrix, which
absorbs laser energy and transfers it to the substrate below resulting in a transition
to the vapor phase and the ionization of analytes317–319. The most common organic
acids used for N-glycan IMS are α-cyano-4-hydroxycinnamic acid (CHCA) and 2,5dihydroxybenzoic

acid

(DHB)207.

Other

matrix

molecules

like

1,5-

diaminonaphthalene (DAN) and 2′,4′,6′-trihydroxyacetophenone monohydrate
(THAP) have also been used320,321. Because matrix crystal size and consistency
of matrix application are critical determinants of analyte signal intensity and
reproducibility, most current approaches use an automated sprayer for N-glycan
imaging experiments, although the use of sublimation platforms to transform
vapor-phase matrix solution into a solid matrix coating is also widely used 322,323.
Ideally, the CHCA-coated tissue slides are analyzed within a few days after
preparation but can be stored in a desiccator for several weeks.
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1.3.3.2.2 MALDI Instrumentation
N-glycan ions ejected for detection span a wide mass range, with the
simplest sugar chains detected at ~700 m/z and multiply branched, fucosylated
and sialylated structures detected upwards of 4,000 m/z. Complicating N-glycan
mass-spectrometry analysis of these analytes are variable formation of sodium
adducts, isotopic overlap between structures and the presence of sulfate or
phosphate groups on some species. Interference from the chemical matrix lends
additional obscurity. Aside from blunting analyte signal, the process of laser
desorption fragments the matrix and matrix ions are ejected into the mass
spectrometer, leading to potential overlap or obfuscation of N-glycan ions. Nglycans are typically detected in positive mode, however certain special
applications are better suited to negative mode analysis thus demanding
instrument versatility324. Critical to overcoming these challenges is instrument
resolving power, which must be high for fine resolution of analytes close in mass.
To meet these needs, two broad classes of MALDI-outfitted mass spectrometers,
each with their own advantages and disadvantages, are typically used to detect
released N-glycan ions from tissue, those being Fourier transform (FT) and time
of flight (TOF) instruments.
1.3.3.2.2.1 MALDI-TOF
Time of flight (TOF) mass spectrometry, although typically less sensitive,
offers the advantages of higher spatial resolution and increased analysis speed.
TOF instruments accelerate MALDI-ionized N-glycans through an electric field
then maneuver them through a series of pulsers and reflectors to separate the ion
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packets. The time at which these ions hit the detector is then converted to a
measurement of accurate mass303,325. TOF mass spectrometers have a fixed
resolving power across the mass range which is typically less than their FT
counterparts, where resolving power is a measure of an instrument’s ability to
separate equally intense ions which differ only slightly in mass326. Despite this, the
rapid time from the laser-ejection of N-glycan ions to detection increases the
number of pixels which can be analyzed in a given time frame (up to 50X faster
than FT-MS for some instruments), resulting in the practical feasibility of much
higher spatial resolution analyses (< 5 µm)327,328. Because of this speed, TOF
mass spectrometers are routinely used for assessment of N-glycans from tissue
homogenate via spotting on multi-sample target plates in high throughput
experiments. Advantageously for TOF instruments, there is no theoretical bound
to their upper m/z detection limits. As m/z in these instruments is ultimately a
function of flight time, increasing the length of the drift tube allows for detection of
increasingly more massive analytes329. Much of the work presented in this
dissertation was performed on a timsTOF flex (Bruker Daltonics) MALDI-Q-TOF
mass spectrometer, where the Q represents a quadrupole mass analyzer between
the MALDI ion source and detector and “tims” indicates a trapped ion mobility
device upstream of the mass analyzer. Ion mobility separation will be discussed in
later sections.
One difficulty common to all MALDI platforms is the detection of analytes of
very low abundance or very high molecular weight. This complicates the analysis
of mammalian N-glycans, which are synthesized to well past 10,000 m/z via the
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addition of polylactosamine extensions330. Critical factors contributing to this
shortcoming are ionization efficiency and analyte decomposition in the MALDIsource331. When compared to alternative ionization schema such as ESI, laserinduced ionization of analytes in a MALDI instrument is relatively inefficient (1 out
of every ~105 molecules ionized). This is especially true for low-proton affinity
substrates like carbohydrates, which ionize at an efficiency of 10-7 – 10-8 in MALDI
experiments332,333. Recently, a novel MALDI-TOF instrumentation approach has
been developed to overcome this obstacle. Inefficient primary MALDI-ionization is
rectified by an additional, subsequent ionization of the analyte plume by a
secondary laser oriented perpendicular to the axis of ion ejection in laser
positronization-coupled MALDI-IMS (MALDI-2) platforms334. Thus, low abundance
or difficult to ionize structures in the analyte cloud are more likely to be ionized and
detected by the mass spectrometer. This new technology has already shown
applicability for N-glycan analyses, where a MALDI-2 instrument operating in
negative mode demonstrated an order of magnitude more sensitive detection of
N-glycans from brain tissue samples than did a positive mode traditional MALDI
platform205. Another possibility afforded by MALDI-2 outfitted mass spectrometers
is tissue analysis at subcellular resolution. Coupling a secondary positronization
laser with a transition-geometry MALDI mass spectrometer, which positions the
primary laser behind the tissue sample, allows pixel sizes on the order of 600 nm
and thus the analysis of single cells335. Secondary post-ionization is critical for
generating acceptable signal at these low rasters, as the volume of sample ejected
into the instrument decreases proportionally with reduced pixel size 336. MALDI-2
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sources could theoretically be coupled with FT instruments, but currently are only
in use on Bruker Daltonic’s timTOF flex MALDI-2 configuration.
1.3.3.2.2.2 MALDI-FT-ICR and Orbitrap
Both ion-cyclotron resonance (ICR) and Orbitrap mass spectrometers are
categorized as Fourier transform (FT) instruments by the way they deconvolute ion
signal in the detector. ICR mass spectrometers excite N-glycan ions using
alternating radiofrequency pulses inside a powerful magnetic field (typically
ranging from 1-21T), resulting in differential cyclotron resonance frequency of the
ion packets within the detector proportional to their masses 337–339. This amalgam
of resonances is detected by opposed detection plates inside the ICR cell as a
single image current which is then deconvoluted into its component frequencies
and converted into a measurement of accurate N-glycan mass and intensity by
Fourier transformation340. FT-ICR instruments achieve the highest resolving power
(R) in the space (R > 1,600,000) which is proportional to the strength of the
instrument’s magnetic field, however this resolving power drops off for high-mass
analytes (> ~2,000 m/z)307. The composition of N-glycans presented in this
dissertation were confirmed by accurate mass measurements on a 7T solariX
MALDI-FT-ICR-MS (Bruker Daltonics).
Demonstrated in 2000 and commercially released in 2005 to compete with
FT-ICR instruments, Orbitrap mass spectrometers utilize two outer electrodes
surrounding an inner spindle electrode to create a strong linearized electric
field341,342. The shape of these electrodes causes ions injected into the volume
between them to harmonically oscillate along the central spindle, with the
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frequency of this oscillation once again proportional to the masses of the ions 343.
As in ICR cells, a total image current detected along the central spindle is broken
down into individual mass frequencies through Fourier transformation. Although
not as high as ICR instruments, Orbitrap mass spectrometers demonstrate
substantial resolving power (R > 1,000,000) for the fine resolution of N-glycans of
similar mass and outperform ICR detectors in the very high mass range344. Due to
the compact nature of these analyzers and the pulsed injection of ion packets into
the trap, orbitrap mass spectrometers are able to utilize a refined Fourier
transformation through the incorporation of ion phase information, resulting in
increased analysis speed as compared to ICR cells345. Not without their
drawbacks, the reduced analyzer internal volume causes orbitrap instruments to
suffer shape-charge interference from coalescing ion clouds, resulting in mass
shifts and slightly less accurate mass detection346. The unique geometry of
Orbitrap mass spectrometers (such as Thermo Scientific’s Fusion Lumos Tribrid,
used in this dissertation for glycopeptide analysis) allows for the incorporation of
multiple quadrupoles and collision cells into the instrument, potentiating MS/MS
and MSn measurements (discussed further in later sections)347.
1.3.3.2.3 Data Processing for N-glycan MALDI-IMS
Whether generated by MALDI, SIMS or other imaging strategies, mass
spectra datasets from imaging mass spectrometry experiments are challenging to
analyze due to their complexity and sheer data footprint 348. These challenges
require significant computational resources to overcome. For example, a typical
high spatial resolution MALDI-IMS experiment consists of hundreds of thousands
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of individual pixels, where each pixel represents a spectrum comprising hundreds
of thousands of small m/z bins. These spectra require thresholding and
normalization amongst other processing steps and finally spatial mapping to create
a composite dataset of pseudo-colored images for every possible m/z of interest.
Adding to this complexity, most IMS instruments operate vendor-specific software
for initial data processing, making cross-platform comparisons and data sharing
traditionally difficult349.
The recent emergence of vendor neutral IMS processing software eases
these difficulties. Open-source packages like MSiReader, Cardinal, and msIQuant
utilize MATLAB, R and C++ programming, respectively, to analyze imzML data,
the common imaging mass spectrometry file format350–353. Even vendor specific
software like Bruker Daltonic’s SCiLS Lab and Waters’ High Definition Imaging can
accommodate this shared format which allows for the integration of multiple
imaging mass spectrometry datasets from different platforms. The complex
analyses performed by these software packages are critical for extracting the
pathological relevancy of a particular N-glycan’s spatial distribution. Overlaying
high-resolution, annotated images of histological staining with N-glycan IMS data
reveals colocalization of analytes of interest with distinct tissue morphologies 354.
These programs also allow for statistical considerations such as segmentation,
classification and multivariate analyses355,356. New to the space are applications
for the multiplexed integration of orthogonal imaging modalities including
immunohistochemical and immunofluorescence microscopy, autofluorescence
scans and magnetic resonance imaging with N-glycan IMS data to link
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glycosylation differences to biomarkers of interest or specific pathological
features357,358.
Unlike peptide, lipid and small molecule imaging which have been around
for longer and thus enjoy well-developed peak-picking applications, the relative
novelty of N-glycan IMS means that limited software resources are available for
peak assignment359. Currently, most laboratories manually assign N-glycan
structures to mass spectra via the use of an in-house N-glycan database
generated using software such as GlycoWorkbench or GlycoMod or rely on shared
online databases like GlyConnect or GlyTouCan360–363. Software for automated
peak picking of N-glycans from IMS-generated spectra is still in its infancy, but new
applications such as Bruker Daltonic’s Metaboscape have shown promise for
alignment of mass spectra peaks to an extensive database of known N-glycan
masses with matched structures.
1.3.3.3 Tandem Mass Spectrometry

Mass spectrometry approaches typically identify N-linked glycans by
accurate mass alone, which allows for the precise identification of a particular Nglycan’s carbohydrate composition. Lost in these analyses however is precise
information on the linkages which define N-glycan structural features. A traditional
approach to deconvoluting N-glycan structural heterogeneity is fragmentation by
Tandem mass spectrometry (MS/MS or MSn)364. The sequential dissolution of
glycosidic linkages from the complete N-glycan is typically facilitated by collision
induced dissociation (CID) fragmentation (Figure 11). Other tandem mass
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Figure 11. CID Fragmentation For N-glycan Structural Identification. A)
timsTOF mass spectrometer with on-line CID collision cell. B) Accelerated
precursor N-glycan ions collide with an inert gas (e.g., nitrogen) leading to gasphase fragmentation. C) Analysis of the N-glycan fragment ions allows for
reconstruction of the complete N-glycan structure. CID generates B/Y, C/Z and
A/X fragment ions.
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spectrometry strategies such as higher-energy collisional dissociation (HCD) and
electron-transfer dissociation

(ETD)

are

more

commonly employed

for

glycopeptide identification365. Although ESI-based LC-MS/MS traditionally yields
more rich fragmentation information, MALDI-MS/MS systems employing on-line
CID collision cells now routinely provide fragmentation sufficient for structural
identification in imaging experiments366,367. Briefly, tandem mass spectrometry by
CID involves selective isolation of precursor masses of interest via a multi-pole ion
guide followed by introduction of an inert collision gas. Acceleration of precursor
ions through application of an electric potential results in gas-phase fragmentation
upon collisions of N-glycan ions with the neutral gas molecules368. Fragment ions
are then introduced into the mass analyzer for detection. Increasing the collision
voltage yields a proportional increase in N-glycan fragments. CID fragmentation
typically generates both B/Y and C/Z ions and at high energies may also yield A/X
cross-ring fragments of individual sugar monomers369. By observing the sequential
loss of sugar monomers from the complete N-glycan, an accurate understanding
of the specific linkages composing the structure of interest may be inferred. These
structural inferences are made more concrete by multiplexing CID-based
experiments with orthogonal analyses on ion mobility instruments as will be
discussed370.
1.4 Isomer Separation for Mass Spectrometry
While mass spectrometry is widely recognized for its ability to deliver
molecular specificity, individual spectral peaks often contain multiple analytes
which are compositionally identical yet diverse in their configuration. Accordingly,

68

even mass spectrometers with ultra-resolution capabilities cannot resolve these
isomers by mass alone. LC-MS too often fails to separate isomeric compounds, as
their chromatographic retention properties are frequently identical371.
Despite these challenges, interest in characterizing isomers by mass
spectrometry continues to increase due to the biological importance of molecularly
asymmetrical molecules372. This is particularly true for N-glycans, where nonlinear, non-template driven biosynthesis results in a breadth of structural diversity.
Within this heterogeneity are a variety of MS-detected masses that comprise
multiple compositionally identical analytes which differ only with respect to the
anomeric linkage of specific residues373. Terminal versus bisecting GlcNAc
moieties, the specific attachments of sialic acids and core versus outer arm
fucosylation, amongst other characteristics, are typically indistinguishable using
conventional IMS analyses.
In order to separate isomers by mass spectrometry, scientist must design
instruments or experiments which exploit the single largest differentiating factor
between isomers: stereochemistry. Alternate stereochemistry means that
differentially arranged isomers are able to engage in different chemical reactions
and have different 3D orientations in space. The latter characteristic is typically
exploited with instrumentation while derivatization approaches often target
disparate reactivities between isomers. Special attention will be given to the
separation of sialic acid isomers which are the focus of later chapters.
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1.4.1 Instrumentation
Laser ionization of N-glycan ions directly from tissue in MALDI has not
traditionally afforded incorporation of isomeric separation techniques. The recent
introduction of ion mobility separated MS instruments into the MALDI space helps
to deconvolute this complexity374,375. In trapped ion mobility separated (TIMS)
instruments like the timsTOF flex used in this dissertation, N-glycan isomers within
a single m/z ion packet migrate along with an inert drift gas against an oppositely
opposed electric field, where their final equilibrium migratory distance is a function
of their collisional cross sectional (CCS) areas376. Gradual reduction of the counteracting electric field thus elutes these ions in a structural geometry-dependent
manner from the mobility cell into the mass analyzer for detection. This technology
has already demonstrated utility in parsing out N-glycan isomers377.
Traveling wave separation via structures for lossless ion manipulation (TWSLIM), high-field asymmetric waveform IMS (FAIMS) and cyclic IMS instruments
have also recently been used to separate glycan isomers378,379. Both traveling
wave and FAIMS ion mobility instruments are able to separate simple sialylated
glycan isomers, however resolution is inversely proportional to increasing glycan
molecular weight in these technologies380,381. As an N-glycan grows more
complex, the impact of a single sialic acid monomer’s orientation contributes less
and less to the overall glycan topology, CCS and therefore its mobility in IMS.
Consequently, TW and FAIMS technologies struggle to resolve bi-, tri- and
tetraantennary sialylated N-glycan isomers.
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It should be noted that adding a 4th dimension of data (ion mobility) to IMS
experiments exponentially increases the data footprint acquired during a single
run. The data handling challenges associated with this new field of analysis are
complex and require the development of advanced software solutions before the
routine implementation of ion mobility into the imaging space382,383.
1.4.2 Derivatization
Despite the promise of ion mobility separating instruments, their relative
novelty, high cost and functional limitations have restricted their widespread use
for glycomics. Accordingly, glycan-focused research groups have pursued isomertargeted chemical derivatization schemes as a cheaper and more useful
alternative to instrumentation approaches. Differential stereochemistry between
glycan isomers facilitates the selective introduction of disparate mass tags, where
the resulting mass shifts enable resolution by conventional mass spectrometers.
Because of their reactive carboxylate groups, sialic acids are particularly
susceptible to these strategies.
Most sialic acid derivatization schemes focus around a common approach,
where α2,6 isomers react with an external nucleophile while α2,3 isomers undergo
internal lactonization, as summarized by a 2019 review384. Generally, these
methylesterification, ethylesterification and amidation reactions embed a discrete
mass shift in α2,6-linked species as determined by the particular combination of
reactants, while introducing a -18 Da mass shift in α2,3-linked glycoconjugates via
intramolecular dehydration321,385–388. The instability of the α2,3 lactone in these
approaches is well characterized and limits downstream chemical or enzymatic
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steps, thus multiple methods now include a second reaction to intentionally
delactonize α2,3 isomers and introduce a stabilizing mass tag by aminolysis,
permethylation, or amidation389–391. While most of the aforementioned reactions
are typically used to prepare sialylated glycans for LC-MS/MS, Holst et al.
designed a synthesis in 2016 which facilitates in-situ resolution by MALDI imaging
of FFPE tissues (Figure 12)204. Although their scheme was a pioneering application
of sialic acid derivatization technology, the -1 Da mass shift introduced to α2,3
isomers in the secondary reaction causes unfavorable spectral overlap between
α2,3-sialylated structures and neighboring N-glycan analytes in N-glycan IMS
experiments. Because the unstable α2,3 lactone in these syntheses is susceptible
to various amine-containing uncoupling reagents, we theorized that a more useful
mass tag for MALDI-IMS (and expanded approaches) might be incorporated – a
hypothesis that inspired the developmental work later in this dissertation.
1.5 Broad Overview
To summarize, pancreatic ductal adenocarcinoma is an aggressive, highly
lethal cancer affecting significant portions of the US and global population. The
molecular origins of PDAC are predominantly somatic mutations, however
diabetes and pancreatitis are associated with increased risk. These oncogenic
drivers produce the heterogenous and non-specific symptoms of PDAC which
challenge early discovery efforts. Accordingly, diagnosis is often confirmed by
imaging or endoscopic biopsy well after metastatic progression. CA19-9, the sole
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Figure 12. Sialic acid Stabilization and Derivatization by Amidation-Amidation. EDC, HOBt and dimethylamine
catalyze the dimethylamidation of α2,6-linked sialic acids and the internal lactonization of α2,3-linked sialic acids. A
secondary reaction with ammonium hydroxide decyclizes the α2,3-lactone to form a stable amide. Dimethylamidated α2,6
sialic acids are stable and unreactive.

PDAC biomarker, lacks the specificity for disease detection and thus is used in a
surveillance capacity. Surgical resection in combination with adjuvant or
neoadjuvant chemotherapy is the only curative treatment option for PDAC, where
survival is inversely correlated to disease severity at time of detection and directly
linked to tumor resectability. Put simply, the major causative factor in the lethality
of PDAC is the failure to detect the disease early prior to metastasis.
As CA19-9 is a carbohydrate modification on serum glycoproteins,
researchers have long speculated the existence of other, more sensitive glycan
epitopes specific to pancreatic cancer. N-linked glycans – in particular amongst
carbohydrates as a class – are sensitive to the temporal physiological health of the
cell and for this reason are frequently direct manifestations of aberrant cellular
processes in malignant disease. N-glycosylation alterations in PDAC have been
previously characterized, where most studies analyze serum glycosylation. The
link between N-glycan changes in serum and the N-glycobiology of PDAC tumors,
however, has not been established. Better understanding the tumor N-glycome for
correlation with that of serum is therefore an attractive area for biomarker
discovery.
N-glycans are analyzed with a variety of approaches including the use of
lectins, liquid chromatography and mass spectrometry. These techniques should
be recognized for their contributions to our understanding of glycan synthesis,
structure and function in biological systems, however lectins suffer from specificity
issues while LC and LC-MS often require lengthy sample preparation and
separation times. Mass spectrometry is often seen as an ideal platform to study N74

glycosylation for its ability to characterize hundreds of analytes at once while
retaining high throughput functionality. N-glycan imaging by MALDI-IMS adds a
spatial dimension to N-glycan analyses which provides insight into how N-glycans
function as part of morphologically defined tissue structures.
In the intersection between aberrant PDAC glycosylation and N-glycan
imaging mass spectrometry, we saw an opportunity for a first of its kind study to
spatially characterize the pancreatic cancer N-glycome. This novel work applied
N-glycan IMS to a histopathologically annotated cohort of pancreatic ductal
adenocarcinoma patient tissues and was complimented by orthogonal analyses to
characterize fucosylation, sialylation and biomarker expression. Our intention was
to use PDAC-specific N-glycan features uncovered by these analyses to
complement existing pancreatic cancer biomarkers to better discriminate between
pancreatic tumors and benign tissue. Critically, this work may inform future studies
that attempt to link tumor N-glycobiology to the PDAC serum glycome and
ultimately establish novel carbohydrate biomarkers for the early detection of
pancreatic cancer.
Our investigation into the PDAC N-glycome included an analysis of sialic
acid isomers stabilized by amidation reactions. Shortcomings inherent to the
labeling method used led us to think more deeply about strategies to characterize
sialylation isomers. For studies of sialylation, imaging mass spectrometry – and
mass spectrometry in general – suffers from the inability to deliver molecular
specificity as defined by the capacity to resolve sialic acid isomers by mass alone.
Instrumentation and chemical derivatization approaches have been developed to
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discriminate between sialic acid isomers, however the field remains in its infancy.
As such, we believed this space was wide open for the development of novel
derivatization tools targeting sialylated N-glycan isomers. As a credit to the
syntheses before it, our approach adapted a previously published chemical
amidation reaction for the in situ IMS analysis of sialic acid-containing N-glycans
from FFPE tissues204. Our goal was to retain the advantages of the previous
approach while enhancing isomer separation properties in IMS and to potentiate
future bioorthogonal functionalities. Collectively, an investigation into PDAC Nglycosylation and the glycan tools developed from its insights are presented in this
dissertation.
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Chapter 2: Hypothesis
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2.1 Aim 1 Background
Pancreatic ductal adenocarcinoma (PDAC) presents a challenge for clinical
management due to typically late detection of the disease, leading to the lowest
five-year survival rate of any neoplasia at just 10%16. The sole FDA-approved
biomarker for PDAC is carbohydrate antigen 19-9 (CA19-9), which is useful for the
clinical surveillance of pancreatic cancer progression but because of its affiliation
with other malignancies, it is not suitable for specific early detection of PDAC 71.
Another carbohydrate antigen, sialylated tumor-related antigen (sTRA), is under
development to complement CA19-9, but the need for more specific biomarkers to
delineate PDAC remains pressing110. Both CA19-9 and sTRA are carbohydrate
motifs found as part of N- and O-linked glycans which decorate glycoproteins and
glycolipids comprising the glycocalyx. Glycosylation governs complex interactions
between cells and their local microenvironments, and has been implicated in
cancer origination, maintenance, signaling and metastatic escape237,392,393. Nlinked glycans have been shown to be especially sensitive to the development and
progression of pancreatic cancer and therefore there is great clinical interest in
evaluating N-glycans as PDAC biomarkers174.
Although many studies have characterized N-glycan changes associated
with pancreatic cancer, these works typically examine serum glycoprotein changes
which occur concomitantly with the development and progression of the
disease249. Unfortunately, the relationship between N-glycan changes in serum
and those occurring in PDAC tumors is unclear which hinders clinical translation
of these findings. Analyses of the PDAC tumor N-glycome often utilize tissue
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homogenate and thus fail to capture the spatial component of an N-glycan’s
expression. No studies to date have comprehensively explored the relationship of
N-glycans to malignant tissue structures directly from pancreatic cancer tumors,
which may provide insight into glycan or glycoprotein changes associated with
morphological hallmarks of disease development, progression or metastasis.
Matrix-assisted laser desorption ionization imaging mass spectrometry (MALDIIMS) is an ideal technology for this application, where the rastered sampling of Nglycan ions in an imaging format allows for the reconstruction of N-glycan
heatmaps. These images can be overlaid onto histopathologically defined tissue
regions to – for the first time – link pathological features to the expression of
particular N-glycans or N-glycan motifs in pancreatic cancer.
To address this gap in our understanding of PDAC tumor N-glycosylation,
we proposed a comprehensive investigation into the N-glycome of the pancreas
and PDAC by utilizing a MALDI-IMS workflow developed by our lab. Our overall
hypothesis was that there are specific changes in N-glycan structural features like
sialylation, bisecting GlcNAc residues, branching and fucosylation that are distinct
to PDAC and absent from non-diseased tissue. By better understanding the global
glycosylation state of pancreatic cancer we hope to discover novel carbohydrate
biomarkers to enhance the clinical identification of PDAC and its many subtypes.
This hypothesis was examined by the following specific aim.
2.2 Specific Aim 1
Analysis of N-glycosylation patterns in a biomarker-defined FFPE PDAC tissue
cohort by MALDI imaging mass spectrometry.
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The goal of this aim, presented in Chapter 3, was to analyze N-glycan
structural features and spatial localizations in clinically derived formalin-fixed
paraffin-embedded PDAC tissues. We chose to apply our analyses to both PDAC
tissue microarrays as well as tissue slices from their corresponding pathology
blocks. In doing so, we took advantage of MALDI’s high throughput capacity to
assay a large number of patient samples for statistical significance, as well as its
ability to generate spatially encoded information from whole tissue sections.
Critical to this latter function was the use of an automated sprayer system for
enzyme and matrix application, which prevented the lateral diffusion of released
N-glycans away from their in-situ locations. By utilizing a combination of high
spatial resolution (timsTOF flex, Bruker) and high mass resolving power (7T
solariX, Bruker) instruments, we were able to correlate N-glycan analytes to
specific tissue substructures while maintaining high confidence in our spectral
assignments. Anomeric linkages of fucose and sialic acid residues for the Nglycans analyzed in this aim were determined via orthogonal enzymatic and
chemical amidation approaches, respectively204,211. Our N-glycan IMS findings
were further complemented by immunofluorescence (IF) assessment of CA19-9
and sTRA expression from the same tissues. To demonstrate the clinical
biomarker potential for the glycans evaluated in our study, IMS and IF-derived
features were used to build and test classification models for delineation between
healthy and cancerous tissue. In the future, correlations between biomarker
expression and N-glycan structural features may help reveal which glycans and
glycoproteins carry these carbohydrate epitopes. Ultimately, extrapolation of these
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findings may lead to discovery of novel N-glycan markers in PDAC serum or
plasma samples, a critical first step in the development of a clinically relevant
biomarker or biomarker panel for pancreatic cancer.
2.3 Aim 2 Background
The path of discovery in a dissertation is rarely linear. Rather, the evaluation
of results, approaches and technologies during the course of research often
reveals unanticipated opportunities for further exploration. Such is the case for our
study of sialic acids in pancreatic cancer. Sialic acid isomers have biologically
distinct functions in health and disease yet are difficult to study in that they only
differ by their anomeric linkages394. Consequently, resolving these isomers by
mass spectrometry is challenging. Ion mobility-coupled mass spectrometers are
able to partially separate α2,3, α2,6 and α2,8 linkage isomers, however their ability
to resolve sialylated species is inversely proportional to the overall mass of the
sialylated glycan395. Therefore, multi-antennary sialylated N-glycans known to be
overexpressed in pancreatic and other cancers cannot be fully characterized by
conventional mass spectrometry approaches. Chemical derivatization strategies,
which capitalize on differential stereochemistry between sialylated isomers, are
frequently used as an alternative to ion mobility instruments. Through the
installation of distinct mass tags on α2,3 and α2,6-linked sialic acid carboxylate
groups, these reactions generate spectral distance between isomers in the m/z
dimension. Permethylation, esterification and amidation reactions targeting sialic
acid linkage isomers have shown utility in LC-MS, MALDI-TOF and even MALDI-
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IMS experiments, however they often suffer from lengthy sample preparation times
and unfavorable overlap between labeled isomers and other analytes of interest384.
As part of our characterization of PDAC N-glycosylation in Aim 1, we utilized
a previously published in-situ sialic acid derivatization approach to explore the
spatial distribution of sialic acid linkage isomers in pancreatic cancer204. After the
chemical amidation reactions in this method, α2,3 and α2,8-linked sialic acids are
modified with a -0.9845 Da mass tag while α2,6 isomers are mass shifted by
+27.0473 Da. For labeled α2,3 sialic acids, the ~ -1 Da mass shift causes spectral
overlap with N-glycan analytes of similar molecular weight, complicating peak
annotation and data analysis overall. To address this shortcoming, we proposed
the development of our own derivatization reaction with enhanced mass
spectrometry separation features. Our hypothesis was that by incorporating more
functional mass tags into α2,3 isomers, we could 1) better separate isomeric sialic
acid-containing N-glycans in imaging mass spectrometry experiments and 2)
potentiate downstream bioorthogonal applications. The development of this novel
labeling system is the focus of Specific Aim 2.
2.4 Specific Aim 2
Optimization of a novel sialic acid-targeted derivatization strategy for enhanced
imaging mass spectrometry and bioorthogonal functionality.
The goal of this aim was to develop an improved sialic acid-targeted
chemical labeling strategy for N-glycan imaging mass spectrometry applications.
The amidation-amidation reaction for sialic acid isomer derivatization applied in
Aim 1 was used as a starting point. Here, the initial step in this synthesis converts
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α2,3

and

α2,8

sialic

acids

into

intramolecular

lactones,

while

stably

dimethylamidating α2,6 isomers. A second step then decyclizes the unstable
lactone with the introduction of ammonium hydroxide, however in theory the
lactone is susceptible to ring opening by any amine-containing reagent. Prior work
in our lab had explored the use of alkyne and azide-coupled amines to hydrolyze
the α2,3 lactone, which showed great promise on sialylated model compounds and
proteins. Our theory was that by using alkyne- and azide-amine conjugates we
could introduce an azide or alkyne mass tag to α2,3 and α2,8-linked sialic acids.
This dual-purpose label introduces a favorable mass shift for IMS and, critically,
acts as a bioorthogonal, click chemistry compatible handle for more advanced
visualization and enrichment approaches. In the first part of this aim, presented in
Chapter 4, both propargylamine and azido-PEG3-amine secondary reagents were
evaluated for their utility in imaging mass spectrometry experiments on FFPE
tissues. Spectral overlap, detection intensity and derivatization efficiency
performance metrics were defined for these labeling agents and compared to
those for the parent synthesis. The alkyne-based synthesis was further tested on
clinical biofluids and cultured cells. Conversely, our azide-based reaction was
selected for further click chemistry development and immunohistochemical (IHC)
functionality. The bioorthogonal functionality of the azide-introducing scheme was
then tested for compatibility with advanced applications. Two developmental
efforts, both presented in Chapter 5, were pursued 1) for fluorescent labeling and
imaging of azide-tagged α2,3 and α2,8 sialic acids and 2) for solid phase
enrichment of α2,3 and α2,8 sialic acid-containing glycoproteins for glycoproteomic
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analysis. Through the development of this derivatization protocol, we hope to
introduce a novel tool for the study of sialylation into the glycomic space. Current
and future applications of our method will increase our collective understanding of
the biological functions of sialic acids.
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Chapter 3: Detection of Pancreatic Cancer Through Nglycan MALDI-IMS
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3.1 Abstract
The early detection of pancreatic ductal adenocarcinoma is a complex
clinical obstacle yet is key to improving the overall likelihood of patient survival.
Current and prospective carbohydrate biomarkers CA19-9 and sTRA are sufficient
for surveilling disease progression yet are not approved for delineating PDAC from
other abdominal cancers and non-cancerous pancreatic pathologies. To further
understand these glycan epitopes, an imaging mass spectrometry approach was
utilized to assess the N-glycome of the human pancreas and pancreatic cancer in
a cohort of PDAC patients represented by tissue microarrays and whole tissue
sections. Orthogonally, these same tissues were characterized by multi-round
immunofluorescence which defined expression of CA19-9 and sTRA as well as
other lectins towards carbohydrate epitopes with the potential to improve PDAC
diagnosis. These analyses revealed distinct differences not only in N-glycan spatial
localization across both healthy and diseased tissues but importantly between
different biomarker-categorized tissue samples. Unique sulfated bi-antennary Nglycans were detected specifically in normal pancreatic islets. N-glycans from
CA19-9 expressing tissues tended to be bi-, tri- and tetra-antennary structures with
both core and terminal fucose residues and bisecting N-acetylglucosamines.
These N-glycans were detected in less abundance in sTRA-expressing tumor
tissues, which favored tri- and tetra-antennary structures with polylactosamine
extensions. Increased sialylation of N-glycans was detected in all tumor tissues. A
candidate new biomarker derived from IMS was further explored by fluorescence
staining with selected lectins on the same tissues. The lectins confirmed the
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expression of the epitopes in cancer cells and revealed different tumor-associated
staining patterns between glycans with bisecting GlcNAc and those with terminal
GlcNAc. Thus, the combination of lectin-IHC and IMS techniques produces more
complete information for tumor classification than the individual analyses alone
(Figure 13). These findings potentiate the development of early assessment
technologies to rapidly and specifically identify PDAC in the clinic that may directly
impact patient outcomes.
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Figure 13. Combining N-glycan MALDI IMS, Biomarker IHC and Lectin IF.
Graphical Abstract.
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3.2 Introduction
As previously described, pancreatic ductal adenocarcinomas (PDAC) are
aggressive neoplasia diagnosed in approximately 58,000 patients in the United
States with nearly 47,000 recorded deaths during the year 2020, and both metrics
are predicted to continue to increase. PDAC accounts for 7% of total cancer deaths
and has the lowest 5-year survival rate of any cancer at just 9% for all stages
combined11,12. The high mortality associated with pancreatic cancer is due to late
detection of the disease as compared to other cancers, with 30% of patients
diagnosed at the locally invasive stage, 13% at the locally advanced stage and
52% at the metastatic stage17. The typically late identification of PDAC owes to the
heterogeneity of often-mild early-stage symptoms, the location of the pancreas
deep within the abdominal cavity and the lack of reliable biomarkers for early
identification. Currently, the sole FDA-approved biomarker for pancreatic cancer is
carbohydrate antigen 19-9 (CA19-9), increased levels of which are associated with
the majority of PDAC cases. Despite CA19-9’s utility as a prognostic indicator for
judging the effectiveness of a patient’s treatment regiment, the antigen’s
association with other cancers and non-cancer malignancies such as cystic
fibrosis, pancreatitis and liver disease make it unsuitable as a diagnostic predictor
for pancreatic cancer71. The glycan epitope of the CA19-9 antibody appears on the
surface of cancer cells in about 60% of PDACs. Another glycan marker called
sTRA, recently discovered as a biomarker of pancreatic cancer, likewise appears
in the majority of tumors but in a non-identical subgroup of tumors110. Some tumors
have only one of the glycans, some have both and some have neither. Together,
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these two antigens are in development for clinical use as a means of pancreatic
cancer surveillance and differentiation between pancreatic cancer and other
pancreatic diseases. Because CA19-9 and sTRA only recognize sialyl-Lewis A
(sLeA) and a de-sialylated Type 1 Type 2 LacNAc carbohydrate motifs,
respectively, an important aspect of better understanding their ability to recognize
PDAC is the elucidation of specifically which glycans or glycoproteins these
antibodies are binding to, and what role these molecules play in the biological
processes underlying the development of pancreatic cancer.
An important and yet often under-studied aspect of cancer biology – and a
major focus of this dissertation – is the glycocalyx, the dense layer of complex
carbohydrates that plays a significant role in governing the interactions between
cancer cells, immune cells and the local microenvironment. The glycocalyx is
composed of N- and O- linked glycans attached to a wide variety of glycoproteins,
glycosaminoglycans attached to proteoglycans and glycolipids. The majority of
human proteins and lipids have glycan modifications, which play key roles in
protein folding, cell-cell communication, intracellular trafficking and signal
transduction

amongst

other

functions392.

Consequently,

aberrations

in

glycosylation state often result in or are indicators of disease, and many
glycoproteins or glycans are known biomarkers of cancer. Indeed, it has been well
studied that changes in glycan structure and composition can alter the metastatic
capacity and the invasive spread of cancer cells393. Of specific interest to
pancreatic cancer is N-linked glycosylation (attached to the asparagine residue in
Asn-X-Ser/Thr protein motifs) which is known to play a role in immune recognition,

91

cellular mobility and cell signaling. Increases in N-glycan branching, fucosylation
and sialylation have also previously been associated with PDAC237.
In an attempt to better define the N-linked glycome of pancreatic cancer
directly in clinical tissues, we have used matrix assisted laser desorption ionization
imaging mass spectrometry (MALDI-IMS) to identify peptide N-glycosidase
released N-glycans linked spatially and histochemically to pathology features. This
method has been used to map N-glycan distribution across multiple cancer types
using

formalin-fixed

paraffin

embedded

samples181,200,202,207,210,211,213,216,233,393,396.

When

(FFPE)
complemented

tissue
with

histopathological identification, this combined analysis can map correlations
between specific glycans or groups of glycans and different tissue regions and
subtypes including tumor, necrotic and adjacent normal tissues 210. The present
study analyzes the N-glycome of the pancreas and of PDAC. A majority of previous
studies on the role of glycosylation in pancreatic cancer have focused on serum
profiling of N-glycans as well as the truncation of O-linked glycosylation and
increased O-GlcNAcylation237. As outlined in Chapters 1 and 2, comprehensive
spatial mapping of N-glycan distribution in normal and pancreatic cancer tissues is
lacking, and correlative mapping of N-glycans to IHC staining of current and
prospective pancreatic cancer biomarkers has only recently begun to be
explored109. The current study addresses this using a MALDI-IMS approach to
characterize the N-glycans present in healthy pancreatic tissue and a cohort of
pancreatic cancer tissues represented by multiple tissue microarrays (TMAs) and
a subset of the source whole-block tissue slices. Changes in tissue glycans
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associated with PDAC were further correlated with antibody-based assessments
for CA19-9, sTRA and other carbohydrate epitopes in the same tissues. The
cumulative analyses revealed multiple subsets of N-glycans with increased
branching, bisecting N-acetylglucosamine, fucosylation and sialylation in PDACspecific regions of tissues, many of which could be correlated with each
carbohydrate antigen biomarker.
3.3 Materials and Methods
3.3.1 Materials
HPLC-grade acetonitrile, ethanol, methanol, xylene and water as well as
CitriSolv Hybrid were obtained from Fisher Scientific (Pittsburg, PA, USA). 28-30%
Ammonia in H2O, bovine serum albumin (BSA), dimethyl sulfoxide (DMSO),
citraconic anhydride and 1X phosphate buffered saline (PBS) were obtained from
Thermo

Scientific

(Bellefonte,

PA,

USA).

Acetic

acid,

alpha-cyano-4-

hydroxycinnamic acid (CHCA), chloroform, 4′,6-diamidino-2-phenylindole (DAPI),
dimethylamine, hydrogen peroxide (H2O2), 1-hydroxybenzotriazole hydrate
(HOBt), sodium bicarbonate, trifluoroacetic acid (TFA), Triton-X100 and Tween-20
were

obtained

from

Sigma-Aldrich

(St.

Louis,

MO,

USA).

1-(3-

Dimethylaminopropyl)-3-ethylcarbodiimide (EDC) was obtained from Alfa-Aesar
(Ward Hill, MA, USA). Recombinant PNGase F PRIMETM was obtained from NZyme Scientific (Doylestown, PA, USA) and recombinant Endoglycosidase F3
(Endo F3) was obtained from the laboratory of Dr. Anand Mehta (Charleston, SC,
USA) as described207,211. Hematoxylin and eosin (H&E) stains were obtained from
Cancer

Diagnostics

(Durham,

NC,
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USA).

Horseradish

peroxidase-3,3′-

diaminobenzidine (HRP-DAB) staining kits were obtained from R&D Systems
(Minneapolis, MN, USA). CA19-9 mAb was obtained from USBiologicals (Salem,
MA, USA). TRA-1-60 mAb was obtained from Novus Biologicals (Littleton, CO,
USA). Sulfo-cyanine3 NHS and sulfo-cyanine5 NHS esters were obtained from
Lumiprobe (Hunt Valley, MD, USA). TRITC conjugated anti-PHA-E, biotinylated
GSL-II and Cy5-conjugated streptavidin were obtained from EY Laboratories (San
Mateo, CA, USA), Vector Laboratories (Burlingame, CA, USA) and Roche Applied
Science (Penzberg, Germany) respectively. α2-3,6,8 Neuraminidase and 1X
Glycobuffer were obtained from New England Biolabs (Ipswich, MA, USA).
3.3.2 Clinical Pancreatic Cancer FFPE Tissues
Four formalin-fixed paraffin-embedded pancreatic cancer TMAs (n = 53
patients) were provided by the Medical University of South Carolina’s Hollings
Cancer Center Biorepository and Tissue Analysis Shared Resource in accordance
with the National Cancer Institute’s Best Practices for Biospecimen Resources.
51/53 cases of the pancreatic cancer cohort were adenocarcinomas with the
remaining 2/53 cholangiocarcinoma and adenosquamous carcinoma. Each case
was represented by a minimum of 4 cores, 2 from adjacent tissue and 2 from tumor
tissue. Furthermore, 23/53 cases also had representative pre-tumor tissue, 29/53
had metastatic tissue, 22/53 had lymph node tissue and 14/53 had lymph node
tumor tissue. The staging of the cases ranged from T1NOMX (2 cm or smaller
tumor localized to pancreas, absent from regional lymph nodes) to T4N1MX (4 cm
or larger tumor extending into local major arteries, spread to 1-3 regional lymph
nodes) with most cases staged at T3N1MX (4 cm or larger tumor extending beyond
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pancreas, spread to 1-3 regional lymph nodes)397. The majority of the patients’
tumors were moderately to poorly differentiated. 13/53 patients experienced
recurrence, mostly at distant sites such as the lungs and liver. More detailed
information is contained in Table 4. Full tissue slices of thirteen PDAC pathology
blocks that were the original sources of the tumor cores in the TMAs mentioned
above were also analyzed. All cases were adenocarcinomas, the majority of which
were staged at T3N1MX. Normal human pancreas FFPE tissue slides were
obtained from Zyagen (San Diego, CA, USA).
3.3.3 N-glycan MALDI-IMS
3.3.3.1 Tissue Preparation for MALDI-IMS
A standardized protocol was used for tissue preparation, enzymatic
digestion and matrix application by solvent sprayer396. Tissue slides were dewaxed
in xylenes then rehydrated in a gradation of ethanol and water washes prior to
antigen retrieval with citraconic anhydride buffer (25 µL citraconic anhydride, 2 µL
12 M HCL, 50 mL HPLC-grade H2O, pH 3.0 ± 0.5) for 30 minutes in a decloaking
chamber at 95ºC. 15 passes of PNGase F or 10% Endo F3/90% PNGase F at 0.1
µg/µL were then sprayed onto the slides at a rate of 25 µL/min with a 3 mm offset
and a velocity of 1200 at 45ºC and 10 psi using a M5 TMSprayer (HTX
Technologies LLC., Chapel Hill, NC). Tissue slides were then incubated at 37ºC
for 2 h in pre-warmed humidity chambers followed by desiccation prior to matrix
application. 10 passes of 7 mg/mL CHCA matrix in 50% acetonitrile/0.1% TFA was
applied to the desiccated slides at 0.1 mL/min with a 2.5 mm offset and a velocity
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Table 4. Associated Clinical Data for the Pancreatic Cancer Patient Cohort.
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of 1300 at 80ºC and 10 psi using the TMSprayer. After matrix application slides
were desiccated until analysis by MALDI-FTICR MS or MALDI quadrupole timeof-flight mass spectrometry (MALDI-QTOF MS). Post-analysis whole tissue slides
were H&E stained according to a standardized protocol and annotated for
histological classification by an expert pathologist.
3.3.3.2 Amidation-Amidation Stabilization of Sialic Acids
Sialic acids were stabilized by chemical amidation directly on tissue using
an established protocol, with some slight modifications as follows204. Tissue slides
were dewaxed and rehydrated as described above then incubated with 200 µL of
primary reaction solution (22 µL EDC, 42.2 mg HOBt, 15.8 µL dimethylamine, 0.5
mL DMSO) for 1 hour at 60ºC. After incubation tissues were washed with 200 µL
DMSO 3X then incubated with 200 µL of secondary reaction solution (150 µL 2830% Ammonia in H2O, 350 µL DMSO) for 2 hours at 60ºC. Following the second
incubation slides were rinsed sequentially in 100% EtOH for 2min 2X, Carnoy’s
Solution (30% chloroform, 60% EtOH, 10% acetic acid) for 10 min 2X, H 2O for 1
min, 100% EtOH for 2 min 2X and 0.1% TFA in EtOH for 30 seconds. Slides were
then immediately processed for MALDI-IMS as described above starting with
antigen retrieval.
3.3.3.3 MALDI IMS Analysis of N-glycosylation
A Solarix dual source 7T FTICR mass spectrometer (Bruker Daltonics,
Bremen, Germany) (m/z 490-5000) equipped with a 2000 Hz SmartBeam II laser
utilizing a laser spot size of 25 µm was used to detect PNGase F released Nglycans in positive ion mode. Using the Smartwalk feature set at a width of 30 µm
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and one scan per pixel, 200 laser shots per pixel were collected for analysis with
an ion accumulation time of 0.1 s. A 1.2059 s transient with a calculated resolving
power of 160,000 at m/z 400 was used over a mass range of 500-5000 m/z and a
time domain set to 512K word. A timsTOF Flex trapped ion mobility separated
QTOF mass spectrometer (Bruker Daltonics, Bremen, Germany) (m/z 500 – 4000)
operating in positive mode equipped with a 10 kHz Smartbeam 3D laser and a spot
size of 20 µm was used to detect released N-glycans with high spatial resolution
(20 – 40 µm raster). 300 laser shots per pixel were collected with an ion transfer
time of 125 µs, a pre-pulse storage time of 25 µs, a collision RF of 4000 Vpp, a
multipole RF of 500 Vpp and a collision cell energy of 15 eV. Instrument
parameters for collision-induced dissociation (CID) are reported in Figure 14.
3.3.3.4 Data Processing
After MS data acquisition, spectra were imported to SCiLS Lab 2017a and
2020a imaging software for analysis of the mass range m/z 500-4000. SCiLSgenerated N-glycan spectra were normalized to total ion count (ICR Noise
Reduction Threshold = 0.95) which were then matched within ± 5 ppm against an
in-house database of known N-glycans generated using GlycoWorkbench and
GlycoMod for annotation360,361. N-glycan structures annotated in this paper are
compositionally accurate as determined by accurate mass, CID and through prior
structural characterizations by both MALDI-TOF-MS/MS and RP-LC-MS/MS315. A
list of all N-glycans reported in this chapter along with mass error calculations and
representative structures can be found in Tables 5 and 6.
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Figure 14. Structural Annotation of Reported N-glycans by CID Fragmentation. Relevant instrument settings for
collision-induced dissociation are provided, along with example fragmentation patterns. Intended to be used as a key for
CID spectra referenced further in this dissertation.

Table 5. Composition and Mass Accuracy of N-glycans in this Chapter.
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Table 6. N-glycan Structures in this Chapter.

*Presence of core fucose confirmed by EndoF3 analysis
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3.3.4 DAB Immunohistochemical Staining for CA19-9
FFPE (5 µm) whole tissue block slides were dewaxed, rehydrated and
antigen retrieved as described above in preparation for IHC-DAB staining.
Samples were sequentially incubated with 100 µL each of peroxidase blocking
reagent, serum blocking reagent, avidin blocking reagent and biotin blocking
reagent for 5 min, 15 min, 15 min and 15 min respectively. CA19-9 primary
antibody was diluted to 15 µg/mL in PBST (50 µL Triton-X100, 50 mL PBS pH 7.4)
containing 0.025% serum blocking reagent and tissue samples were incubated
with diluted antibody overnight at 4°C. After incubation samples were washed with
PBS, incubated with 100 µL HSS-HRP secondary antibody at room temperature
for 1 hour, then developed with DAB chromogen solution for 5 minutes with
observation under a microscope. Stained samples were rinsed in H2O, dehydrated
in the reverse gradation of ethanol solutions and xylenes, then sealed and
permanently mounted. Slides were subsequently imaged in a Nanozoomer 2.0RS
high resolution slide scanner (Hamamatsu, Hamamatsu-city, Japan) at 40X
magnification across the whole tissue. Scanned images were analyzed using
Image Color summarizer, a freely available online k-means clustering based
algorithm, to generate an unbiased clustering of pixels by color to delineate
between blank slide background, low-intensity CA19-9 staining and high-intensity
CA19-9 staining. Subsequently generated grouped pixel maps were then coregistered in FlexImaging software with the original slide scans used for MALDIIMS analysis to draw regions of CA19-9 staining for import into SCiLS lab software
for analysis.
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3.3.5 Immunofluorescence Staining for CA19-9 and sTRA
Paraffin was removed from 5 µm thick FFPE sections using CitriSolv Hybrid
and then tissue was rehydrated through an ethanol gradient. Following
rehydration, antigen retrieval was achieved through incubating slides in citrate
buffer at 100 °C for 20 minutes. Slides were then blocked in phosphate-buffered
saline with 0.05% Tween-20 (PBST0.05) and 3% bovine serum albumin (BSA) for
1 hour at RT. Primary antibodies against CA19-9 and TRA-1-60 were labeled for
immunofluorescent staining with Sulfo-Cyanine5 NHS ester and Sulfo-Cyanine3
NHS ester respectively. Dialysis was performed following labeling to remove
unreacted conjugate and the primary antibodies were then diluted into the same
solution of PBST0.05 with 3% BSA to a final concentration of 10 µg/mL. Slides
were incubated overnight with this solution at 4 °C in a humidified chamber.
The following day antibody solution was decanted and the slides were
washed twice in PBST0.05 and once in 1X PBS, each time for 3 minutes. The
slides were dried via blotting then incubated with DAPI at 10 µg/mL in 1X PBS for
15 minutes at RT. Two five-minute washes were performed in 1X PBS, and then
slides were cover-slipped and scanned using a fluorescent microscope. All TMA
slides were scanned using Vectra (Perkin Elmer, Waltham, MA, USA), while the
whole tissue sections were scanned using an Axio Scan.Z1 (Zeiss, Oberkochen,
Germany). Each system collected data for each field of view at three different
emission spectra. All image data were quantified using SignalFinder-IF.
Following scanning, slides were stored in a humidified chamber. Coverslips
were removed for the subsequent rounds of staining by submerging the slide in
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deionized water at 37 °C until the coverslip floated free (between 30-60 minutes).
Fluorescence was quenched between rounds by incubating the slides with 6%
H2O2 in 250 mM sodium bicarbonate (pH 9.5-10) twice for 20 minutes at RT.
Subsequent rounds of staining were performed as described above using TRITC
conjugated anti-PHA-E and biotinylated GSL-II as the primary detections. Cy5conjugated streptavidin was used as a secondary to detect the biotinylated GSL-II
for 1 hour at RT. This was done following washing after primary incubation.
To perform sialidase treatment, slides were incubated with a 1:200 dilution
(from a 50,000 U/mL stock) of α2-3,6,8 Neuraminidase in 1X Glycobuffer (5 mM
CaCl2, 50mM pH 5.5 sodium acetate) overnight at 37 °C. Slides were washed as
described above and then antibody detections were performed. Hematoxylin and
eosin staining were performed following a standard protocol.
3.3.6 Statistical Analysis
A total of 327 tissue cores across 4 TMAs representing 53 patients were
analyzed in this study, with each core consisting of 171 individual spectra on
average. Individual spectra pixels in each core were averaged to generate a
representative spectrum for the whole core which was subsequently used for
statistical analysis. Each patient in the study was represented at minimum by n =
2 adjacent normal tissue cores and n = 2 tumor tissue cores. SCiLS Lab was used
to generate area under the peak (AUP) values for TMAs after normalizing glycan
intensity values to total ion current, which were subsequently exported to statistical
software for analysis. Log2 Fold Change (FC) was calculated by comparing
individual glycan intensities between normal and tumor tissues on a patient104

matched basis. To determine statistically significant changes in glycan expression,
AUP values were evaluated using a two-sample t-test assuming unequal variance.
13 whole tissue blocks from which some TMA cores were derived were also used
to draw qualitative conclusions about spatial localization trends across different
PDAC regions. An automated thresholding program, SignalFinder-IF, was used to
identify real signals on fluorescently labeled tissues. The algorithm uses multiround segmentation to separate non-tissue, tissue background, and signal levels
of fluorescence109,398,399. The immunofluorescence data was overlaid onto MALDI
mass and H&E images using the custom-built Overlay program and Canvas 14.
LASSO-regularized logistic regression was performed using the R “glmnet”
package setting the mixing parameter alpha to 1 and setting lambda through cross
validation to 0.0582. The mass only model was similarly performed with a lambda
set to 0.1017. Individual mass comparisons were performed using a paired t-test
between tumor and adjacent normal cores from the same tissue and were plotted
using the R “ggplot” package.
3.4 Results
3.4.1 N-glycan Imaging of Normal Pancreas Tissue
The goal of this chapter was to characterize N-glycan changes in normal
pancreas and pancreatic cancer tissues, thus an initial step was to define the
distribution of N-glycans present in normal pancreas, which comprises distinct
endocrine, exocrine and ductal cell types. A normal human pancreas tissue was
antigen retrieved, sprayed with a molecular coating of PNGase F and coated with
CHCA matrix as described in the Experimental section. Some selected tissues
105

were also treated with endoglycosidase F3 to distinguish core fucosylated
structures from outer arm fucosylated species. The enzymatically released Nglycans were detected first with a MALDI-FTICR mass spectrometer for accurate
mass identification at a low spatial resolution (150 µm raster) then again at a higher
spatial resolution (30 µm raster, offset) using a MALDI-QTOF mass spectrometer
according to a standardized protocol314. Distinct differences in glycan patterning
were observed between endocrine tissue, exocrine tissue and ductal tissue
subtypes (Figure 15A). High-mannose N-glycan structures were primarily localized
to pancreatic exocrine acinar tissue but were detected at lower levels in other
tissue regions as well (Figure 15B). N-glycans associated with inter- and
intralobular ductal tissue were primarily core-fucosylated bi- and tri-antennary
structures (Figure 15C).
A more targeted N-glycan analysis of pancreatic islets (Islets of
Langerhans) was performed for normal human pancreas tissue. Prior to
preparation for MALDI-IMS, tissue was H&E stained and scanned at 40X
magnification before proceeding to antigen retrieval. These high-resolution
histopathological images were co-registered in FlexImaging software to direct
targeted glycan IMS of only pancreatic islets. These same tissues were then reanalyzed at the whole-tissue level to generate a profile of non-islet pancreatic
tissue for comparison. Comparing the N-glycan profiles between islet and non-islet
regions, detection of the most common N-glycans were generally consistent in
both regions, but with lower expression levels for most structures in the islets.
(Figure 16A). There were however a distinct set of sulfated N-glycans which were
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Figure 15. N-glycan imaging of a normal human pancreas. A) Overlay image
of three representative N-glycans corresponding to acinar exocrine tissue (Blue,
Hex9HexNAc2 m/z 1905.6338), ductal tissue (Red, Hex5HexNAc4 m/z
1663.5814) and Islets of Langerhans (White, Hex3dHex1HexNAc6SO 42 m/z
1993.6390) along with accompanying annotated H&E stain. B) High-mannose Nglycans predominantly localized to acinar exocrine tissue. C) N-glycans expressed
predominantly in pancreatic ductal tissue tend to be bi- and tri-antennary structures
with core fucose residues lacking terminal fucosylation.
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Figure 16. Sulfated Terminal GalNAc N-glycans Specific to Pancreatic Islets
of Langerhans. A) Comparative mass spectra of pancreatic Islets of Langerhans
(blue) and non-islet pancreatic tissue (green) from the same normal pancreas
tissue section. Sulfated hybrid N-glycans B) Hex4dHex1HexNAc5SO4, m/z
1952.6125,
C)
Hex3dHex1HexNAc6SO4,
m/z
1993.6390,
D)
Hex3dHex1HexNAc6SO42, m/z 2095.5856, E) Hex3dHex2HexNAc61SO4, m/z
2139.6969, F) Hex3dHex2HexNAc6SO42, m/z 2242.6469 unique to endocrine
islet tissue. G) Targeted imaging of unique islet N-glycans along with
representative H&E staining. H) Non-targeted whole-tissue images of normal
human pancreas showing specific localization of the 3 most abundant hybrid,
sulfated N-glycan structures to Islets of Langerhans tissue (black carats), which
are clearly absent from other pancreatic tissue regions.
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Detected in islets that were either not present or expressed at much lower levels
in non-islet regions. These 5 N-glycans were all sulfated, core fucosylated and had
at least one terminal N-acetylgalactosamine (GalNAc) residue, with some
structures having outer arm fucose (Figure 16B-F). The mass-based structural
predictions for these novel islet glycans were orthogonally confirmed via
fragmentation by on-tissue collision-induced dissociation (CID) (Figure 17).
Sulfated N-glycan structures with terminal GalNAc have been previously reported
to be detected in adult pig islet tissue400. Targeted analysis images of these 5
structures for individual islets are shown in Figure 16G. In addition, whole-tissue
scans of the normal pancreas tissue exhibited specific localization of these unique
sulfated N-glycans to pancreatic islets, which were clearly absent from other nonislet pancreatic tissue regions (Figure 16H).
A normal tissue section was digested with endoglycosidase F3 (Endo F3)
to assess the anomeric linkages of fucose residues in reported structures. Endo
F3 cleaves N-glycans above the first GlcNAc residue on the chitobiose core in the
presence of a fucose residue attached to that primary GlcNAc211. Core fucosylated
structures are thereby freed from their protein carriers with a distinct mass shift
representing the loss of one GlcNAc residue and one fucose residue. By using a
combination of Endo F3 and PNGase F in a 1:10 ratio both core and terminally
fucosylated N-glycan isomers can be released for analysis (Figure 18A). Although
some outer arm fucosylated isomers were detected (Figure 18B), N-glycan
structures with at least 1 fucose residue were predominantly core fucosylated
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Figure 17. CID Fragmentation of Sulfated Terminal GalNAc Islet N-glycans.
Representative CID spectra for Hex3dHex1HexNAc6SO4, m/z 1993.6390 and
Hex3dHex1HexNAc6(SO4)2, m/z 2095.5856.
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Figure 18. Endoglycosidase F3 Reveals Core Fucosylated N-glycans. A) Endo
F3 cleaves N-glycans between GlcNAc residues on the chitobiose core only in the
presence of a core fucose residue and is unable to cleave terminally fucosylated
isomers. B) Terminally fucosylated isomers were detected minimally
(Hex4dHex1HexNAc3 m/z 1444.5071, Hex4dHex1HexNAc4 m/z 1647.5865,
Hex6dHex1HexNAc5 m/z 2174.7715) or not at all (Hex4dHex1HexNAc5SO41 m/z
1952.6125). C) Endo F3 cleavage products from core fucosylated isomers with a
distinct -349.1373 mass shift were observed in much greater abundance for the
four representative structures shown (Hex4HexNAc2 m/z 1095.3698,
Hex4HexNAc3 m/z 1298.4492, Hex4HexNAc4SO41 m/z 1603.4752,
Hex6HexNAc4 m/z 1825.6342) as well as for most structures with at least one
fucose residue in this report
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(Figure 18C), illustrated by the unique islet N-glycan m/z 1952.6125 for which no
outer-arm fucosylated isomers were observed.
3.4.2 N-glycosylation Changes in Pancreatic Ductal Adenocarcinoma
To evaluate PDAC glycosylation by N-glycan MALDI-IMS, representative
whole tissues were analyzed, and data compared with a series of carbohydrate
antigen defined tissue microarray slides. These same samples were also
evaluated for differences in isomeric sialic acid distributions. As an example. a
PDAC tumor tissue staged at T3NXMX was analyzed for N-glycan composition
differences by IMS (Figure 19). N-glycan spatial distributions could be linked with
the histopathologically-annotated primary tumor tissue, necrotic tissue, tumor
margin tissue and adjacent normal tissue regions as shown in the H&E stained
tissue (Figure 19A) adjacent to four N-glycans detected in these regions (Figure
19B). N-glycan structures primarily localized to necrotic tissue tended to be bi-, triand tetra-antennary structures lacking any fucose or sialic acid residues (Figure
19C), which has previously been reported for tumor necrosis regions of other
cancer tissues202. Core-fucosylated tri- and tetra-antennary N-glycan species with
bisecting GlcNAc modifications and terminal GalNAc residues were primarily
localized to adenocarcinoma regions (Figure 19D). The interface between tumor,
necrosis and adjacent normal tissue was defined by tetra-antennary corefucosylated structures with terminal poly LacNAc extensions of increasing length
(Figure 19E), while N-glycans localized to adjacent normal tissue were typically
bi- and tri-antennary structures with core fucose residues (Figure 19F). High
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Figure 19. N-glycan Imaging of a Representative Stage 3 PDAC Tumor
Tissue. A) H&E staining of T3NXMX PDAC tissue with annotations. B) Overlay of
4 representative N glycans corresponding to necrotic tissue (Red, Hex6HexNAc5
m/z 2028.7136), adenocarcinoma (Green, Hex6dHex1HexNAc6 m/z 2377.8509),
tumor margin (White, Hex9dHex1HexNAc8 m/z 3270.1681) and adjacent nontumor tissue (Blue, Hex5dHex1HexNAc4 m/z 1809.6393). C) N-glycan structures
localized to necrotic tissue (top to bottom) Hex7HexNAc6 m/z 2393.8458,
Hex6HexNAc5 m/z 2028.7136 and Hex5HexNAc4 m/z 1663.5814. D) N-glycan
structures
localized
to
adenocarcinoma
tumor
(top
to
bottom)
Hex7dHex1HexNAc7 m/z 2742.9831, Hex6dHex1HexNAc7 m/z 2580.9302 and
Hex6dHex1HexNAc6 m/z 2377.8509. E) N-glycan structures localized to tumor
margin (top to bottom) Hex9dHex1HexNAc8 m/z 3270.1681, Hex8dHex1HexNAc7
m/z 2905.0359 and Hex7dHex1HexNAc6 m/z 2539.9037. F) N-glycan structures
localized to adjacent non-tumor tissue (top to bottom) Hex6dHex1HexNAc5 m/z
2174.7715,
Hex5dHex1HexNAc4NeuAc1
m/z
2100.7347
and
Hex5dHex1HexNAc4 m/z 1809.6393.
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mannose glycans were predominantly localized in normal tissue regions (data not
shown). Structural confirmation for many of these reported N-glycans were
assessed by CID (Figure 20).
An on-tissue sialic acid derivatization reaction was performed on a different
PDAC tumor tissue to assess differential patterns of sialylation. The amidationamidation (AA) chemistry derivatizes the sialic acid 1’ carboxyl group differentially
for α2,3- and α2,6-linked residues, introducing a mass shift which allows for the
delineation of these isomers204. This pancreatic cancer tissue, shown in Figure 21,
contained late stage adenocarcinoma (T3N1MX) tissue surrounded by a network
of tumor stroma as well as Pan-IN lesions and adjacent normal tissue (Figure 21A).
An overlay image of three representative N-glycan structures corresponding to
these regions is shown in Figure 21B. Adjacent normal tissue in this PDAC sample
contained the same abundance of high-mannose structures seen in other tissues
analyzed in this report (Figure 21C), and few sialylated N-glycans were localized
to this region. In contrast, most structures detected in regions of primary tumor or
tumor stroma tissue contained one or more sialic acid residues. The N-glycans
from tumor stroma regions were typically α2,3 sialylated (Figure 21D). This differed
from areas of primary adenocarcinoma, which were a mixture of α2,3 and α2,6
sialylation slightly favoring α2,6 sialylated species (Figure 21E). Interestingly,
differential α2,3 versus α2,6 sialylations of the same base N-glycan structures
indicated distinct spatial localizations of these structures within the same tissue
and even within the same tissue region, suggesting possible compartmentalization
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Figure 20. CID Fragmentation of Representative Base N-glycans. Example
fragmentation of the commonly expressed m/z 1809.6393 and m/z 2523.9088
glycans. 21 additional structures were analyzed by CID (data not shown).
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Figure 21. Sialic Acid Linkage Isomer Expression in an Advanced Stage
PDAC Tissue. 40 µm MALDI-IMS of AA-stabilized sialylated N-glycans. A)
Annotated H&E staining. B) Overlay of three N-glycan structures localized to
adjacent normal tissue (purple, Hex9HexNAc2 m/z 1905.6339), tumor stroma
(green, Hex5dHex1HexNAc4NeuAc1(2,3) m/z 2099.7507) and adenocarcinoma
(red, Hex5dHex2HexNAc5NeuAc1(2,6) m/z 2476.9193). C) High mannose glycan
structures tended to associate with normal adjacent tissue. D) α2,3 oriented sialic
acid-decorated N-glycan structures localized to tumor stroma regions. E)
Adenocarcinoma-associated N-glycans were predominantly α2,6 sialylated
although α2,3 vs. α2,6 sialylation of the same base structures drove different intratumor localization. These same α2,6 sialylated structures were also present within
Pan-IN lesions.

116

Of specific sialyltransferases to distinct tissue regions and subtypes in pancreatic
cancer.
3.4.3 Correlation of PDAC Biomarkers and N-glycan Expression
A

more

comprehensive

assessment

of

the

pancreatic

ductal

adenocarcinoma N-glycome was performed using four tissue microarrays
representing 53 individual patients including matched adjacent normal tissue,
tumor tissue and metastatic tissues as well as some patients with samples of pretumor lesions, normal lymph node tissue and cancerous lymph node tissue. Nglycans were released from these tissue arrays as described above and N-glycan
intensities across the tissue cores were analyzed via MALDI-FTICR-MS. In
conjunction to analysis by imaging mass spectrometry, serial TMA sections were
analyzed via multi-round immunofluorescence for the CA19-9 and sTRA
biomarkers (Figure 22A) followed by H&E staining as previously described109. This
system allows for high-resolution and high-sensitivity quantification of multiple
markers on one tissue section, while also preserving the ability to acquire
brightfield imaging of the cellular histology using H&E staining. An in-house image
processing program called SignalFinder was used to automatically locate and
quantify the signals from each marker. The maps of identified signal can be
overlaid onto the brightfield images to gain information about the types of cells that
produce each marker as well as overlaps in marker expression (Figure 22B).
These analyses drove classification of tumor cores as “Both” (significant CA19-9
expression and significant sTRA expression), “CA19-9 Only” (significant CA19-9
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Figure 22. Quantifying Biomarker Epitopes in Tissue Samples Using
Immunofluorescence. A) Treatment of the sTRA epitope with sialidase exposes
the TRA-1-60 epitope, allowing for detection with anti-TRA-1-60 mAb. B) Tissue
microarrays were used to obtain marker data on primary PDAC and related tissues
from multiple patients. TMAs were stained using multi-round immunofluorescence
with subsequent H&E staining and imaging. Each core was quantified to determine
the percentage of tissue pixels above background.
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expression with low sTRA expression), “sTRA Only” (low CA19-9 expression with
significant sTRA expression) or “Neither” (low in CA19-9 expression and low in
sTRA expression). These designations subsequently informed statistical analyses
of differential N-glycan patterns between varying levels of TMA biomarker
expression.
Tumor cores and their matching non-tumor tissue cores were analyzed in
SCiLS Lab to elucidate differential N-glycan expression between the groups. Heat
map images of specific N-glycan structure distributions, normalized to total ion
count, were generated and then cores were then grouped according to their
biomarker-classified designations for visualization (Figure 23A). N-glycans
significantly associated with CA19-9 expression tended to be core-fucosylated bi, tri- and tetra-antennary structures with bisecting N-acetylglucosamine residues
and multiple outer arm fucoses. These structures were detected less frequently in
tumor cores with high sTRA expression, which instead tended to be tri- and tetraantennary structures lacking outer arm fucosylation. Average Log2 fold change
between patient matched tumor and normal cores is shown in Figure 23B. These
data as well as average intensity data across the four biomarker classified
groupings are provided in Table 7 and were used in further evaluations in the next
section. The same TMAs were also treated by the sialic acid amidation-amidation
stabilization reactions prior to the standard imaging workflow and analyzed by
MALDI-IMS (Figure 23C). Like that shown for the whole tissue, the abundance
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Figure 23. TMA Cores Grouped by CA19-9 and sTRA Expression. A)
Individual patient core pairs analyzed by SCiLS Lab were extracted from each of
the 4 TMAs and grouped in one of four designations based on biomarker
expression. Four representative sorted TMA heatmaps for N-glycans m/z
2581.9339, m/z 2742.9831, m/z 3036.1023 and m/z 3328.2181 are shown.
Average Log2 fold change between patient matched tumor and normal cores
across the four groupings for B) non-sialylated N-glycans and for C) amidationamidation stabilized sialic acid containing N-glycans. Positive values represent
enrichment in tumor tissue.
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Table 7. Log2-FC and AUP Intensity Data for Biomarker-Classified TMA
Cores.
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of α2,3 sialylated glycans was higher relative to α2,6 sialylated glycans (Figure
24), but there was more specificity of the α2,6 glycans to distinguish biomarker
antigen sub-types. In general, levels of sialylation were significantly elevated in all
tumor tissues relative to normal controls (Table 8).
The extensive glycan data generated in the TMAs was further analyzed in
combination with carbohydrate antigen data available for the same tissue cores.
There exists a number of N-glycan differences between adjacent normal and tumor
cores which suggests a potential for expansion of the biomarker repertoire.
Hierarchical clustering of mass data resulted in clusters with distinct glycan
properties and patterns for adjacent normal and cancer cores (Figure 25A). For
example, the masses of clusters 1 and 5, which are more abundant in the tumor
cores relative to adjacent normal, generally have an unbalanced HexNAc, meaning
a terminal GlcNAc or GalNAc. In contrast, the normal-associated glycans of cluster
3 are mainly high-mass, balanced glycans with more than one fucose, and the
tumor-associated glycans of cluster 2 are mainly non-extended, hybrid N-glycans.
This result suggests that specific features may be present on glycans of different
masses which are expressed in the same tissues.
Using LASSO-regularized logistic regression, masses which offered
predictive value complementary to the CA19-9 and sTRA biomarkers were
identified, 9 masses in total with 7 masses being associated with tumor cores
(Figure 25B). The LASSO regression selects a subset of predictors with minimal
collinearity and identifies the most informative masses from the tumor and normal
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Figure 24. Sialic Acid Stabilization of TMA Cores. A-L) Representative α2,3sialylated N-glycan structures enriched in tumor tissue cores as compared to
patient matched normal tissue cores. Log2-FC between patient matched tumor and
normal cores, where positive values represent enrichment in tumor tissue.
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Table 8. Log2-FC and AUP Intensity Data for AA-Stabilized TMA Cores.
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Figure 25. Glycan Structures with Potential Complementary Value to Current
Biomarkers. A) Hierarchical clustering and LASSO-regularized logistic regression
identified families of masses with potential complementary value to known PDAC
biomarkers. Masses selected by LASSO-regularization are highlighted and color
coded for tumor-core associated or normal-core associated. Cores predicted to be
tumor are indicated by a yellow box on the right. B) Individually, the masses
selected by LASSO regularization have significantly different abundances between
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adjacent-normal and tumor cores. C) Receiver operator curves of the use of the
models to distinguish the tumor cores from the adjacent-normal cores indicate an
improved accuracy using the combination of masses and biomarkers. D) Example
cores illustrate the complementary value the masses and the biomarkers. A yellow
box indicates prediction as a tumor core. The addition of the masses correctly
identified a tumor core missed by the biomarkers (2055) and correctly identified a
normal core falsely called tumor by the biomarkers (3891). In other instances, the
combination produced no change (2790) and falsely predicted a normal core to be
a tumor core (2815).
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associated clusters. Each of the selected masses had an abundance that was
significantly different between the tumor and the adjacent-normal cores. When
used in a predictive model in combination with the glycan biomarkers, overall
predictive value was increased relative to using the biomarkers or the masses
alone (Figure 25C). The area-under-the-curve (AUC) in receiver-operator
characteristic (ROC) analysis was 0.939 using the combination, greatly improved
over the value of 0.717 using the biomarkers alone and moderately improved over
the value of 0.910 using the masses alone.
We further examined cores for which the immunostaining and glycan
imaging were complementary to each other. Figure 25D shows cores from 4
tumors and their corresponding, adjacent-normal areas. In the adjacent normal
cores, tissues 2055 and 2790 are examples that were correctly predicted to be
normal by both the biomarker and the combination, while 2815 and 3891 were
incorrectly predicted to be tumor cores by the combination and the biomarker,
respectively. In each of the tumor sections, either the biomarker or the glycans
provided a positive signal. Tissue 2790 represents a strongly predicted tissue by
biomarker alone, while tissue 2815 was predicted more strongly through the high
expression of the lower mass, hybrid and immature N-glycan structures.
In order to obtain more information about interesting glycans identified in
the TMA, whole tissue sections corresponding to the cores highlighted in Figure
25D were analyzed by immunofluorescence. The TMA analysis showed that
glycans with a terminal GlcNAc or GalNAc could be higher in certain tumors. Lectin
immunofluorescence staining provides an additional layer of detail to mass
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abundances, as it allows for distinguishing between mass isomers as well as
binding a range of masses which share glycan motifs. We chose the lectin
Phaseolus Vulgaris Erythroagglutinin (PHA-E) to detect bisecting GlcNAc and the
Griffonia (Bandeiraea) Simplicifolia Lectin II (GSL-II) to detect terminal GlcNAc.
We first co-registered the imaging mass-spectrometry data from the
relevant glycans with stains for CA19-9 expression obtained via HRP-DAB
immunohistochemistry on serial sections (Figure 26A,B). Bi-, tri- and tetraantennary N-glycans with both core and terminal fucosylation were specifically
colocalized with areas of CA19-9 staining as determined by co-registration
analysis in SCiLS Lab (Figure 26C). Segmentation analyses of 72 detected Nglycan structures revealed distinct glycoprofiles between those areas of high
CA19-9 expression and those with little to no expression (Figure 26D,E).
H&E stains on the whole tissue sections revealed diverse tissue
morphologies (Figure 27A). The immunofluorescence stains and MALDI-IMS
analysis showed similar patterns as the selected TMA cores in Figure 25D, with
tissue 2055 featuring low levels of biomarker expression, while the remaining
tissues have regions of high and low expression. By overlaying the biomarker data
on the mass abundances (Figure 27B) one can observe a complex relationship
between the glycans identified by MS and the biomarkers. Tissues 2815 and 3891
have significant diversity, featuring regions with all combinations of high and low
mass abundance and biomarker expression.
The lectins PHA-E and GSL-II had very distinct, largely non-overlapping
staining (Figure 27C), indicating that these two epitopes are characteristic of
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Figure 26. N-glycan Co-localization with CA19-9. A) Representative whole
tissue block sections from which TMA cores were derived were IHC stained for
CA19-9 expression. B) A color-based k-means clustering algorithm was applied to
high-resolution staining images to generate unbiased staining classifications, the
most intense of which (outlined in red) were co-registered with original scans in
Fleximaging and used to draw regions of interest around stained tissue. C) SCiLS
lab software was used to identify and create images of N-glycans colocalized to
areas of CA19-9 staining. Shown are three representative N-glycans
(Hex5dHex2HexNAc4 m/z 1955.6975, Hex6dHex2HexNAc5 m/z 2320.8294,
Hex6dHex3HexNAc5 m/z 2466.8873). D, E) Segmentation analysis across eight
nodes of 72 N-glycan structures showing differential associations of glycans
between CA19-9-staining and non-CA19-9-staining tissue.
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Figure 27. Immunofluorescence Stains Reveal Complex Relationships
Between Biomarkers. Whole tissue sections for patients which contain both
cancer and adjacent normal regions were investigated. A) Hematoxylin and eosin
(H&E) stained tissue sections. B) Immunofluorescence (IF) signal above threshold
for biomarkers CA19-9 and sTRA overlaid on select complementary mass
abundance. C) Lectin stained IF images above threshold. The primary motif for
PHAE (green) is a bisecting GlcNAc with two or three antennae while the primary
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motif for GSL-II (red) is a terminal GlcNAc presented on an unbranched
monosaccharide. D) Selected regions of interest in tissues 2815 and 3891 indicate
mixed relationship between lectin binding, mass abundance, and biomarker
presence. Regions low and high in biomarker (CA19-9 and sTRA) expression are
given for each.
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different types of cells. Regions of interest highlighted in Figure 27D show the
diversity in mass abundance, lectin staining, and biomarker expression. Notably
tissue 2815 shows regions high in m/z 1996.7238 and lectin staining as well as
regions high in m/z 2012.7187 and biomarker expression with little lectin staining.
While tissue 3891 shows regions with high m/z 2012.7187, biomarker expression,
and GSL-II staining as well as regions which are low in the highlighted masses but
show strong PHAE staining. Despite the combined binding specificity for PHAE
and GSL-II for many +HexNAc containing structures, regions exist in all 4
highlighted tissues which have high mass abundance but low lectin binding. While
this may be due to limited sensitivity of the lectins, it could also indicate that these
regions feature mass isomers that do not have the primary binding motifs of these
lectins. Such glycans could include tetra-antennary bisecting GlcNAc glycans,
glycans with terminal GlcNAc presented on a branched chain, blood group A
presenting glycans, and alpha-GalNAc terminated glycans. In sum, the
combination of lectin staining with IMS data gives more information on the glycans
containing the lectin epitopes, and it serves to shed light on the isomeric variants
that are present for particular masses identified.
3.5 Discussion
This chapter describes a novel effort to determine the tissue N-glycome of
the human pancreas and pancreatic cancer using formalin-fixed clinical
specimens. Unique to the pancreas is the finding that high-mannose N-glycan
structures are expressed abundantly in non-diseased organ tissue as well as
normal tissue adjacent to cancerous regions (Figure 15 and Figure 21) but are not
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detected with high abundance in the tumor regions. This is in contrast to other
cancer tissues that all exhibit tumor-localized abundant detection of high-mannose
structures, including prostate, ovarian, bile duct, breast, and colorectal
cancers209,213,219,401. It is suspected that the abundance of high-mannose
structures in these cancers is due to incomplete N-glycan processing402. This does
not appear to be the case for pancreas, but rather a feature of healthy tissue whose
functions have yet to be determined.
The analysis of normal pancreas detected multiple sulfated, terminally
GalNAcylated bi-antennary N-glycan structures in islets (Figure 16). As mentioned
previously sulfated N-glycans of the same composition were reported in adult pig
islet (API) transplant studies. Sulfation is already known to play a role in pancreatic
islets, where in that glycolipid sulfatides are involved in normal insulin secretion
and sulfation of heparin sulfate has been implicated in islet amyloid polypeptide
(IAPP) aggregation in Type 2 Diabetes Mellitus403,404. Sulfated N-glycans on
immunoglobulin G have also been extensively characterized, where these acidic
modifications can lead to fine-tuned immune responses405. Sulfated N-glycan
structures, especially those with sulfo-sLeX motifs, are known to enhance
lymphocyte homing and are implicated in interactions with other immune cell
populations406. Terminal sulfo-GalNAc residues found on N-glycans specific to
pituitary hormones lutropin and thyrotropin are known to govern immune
interactions with macrophages via the C-type mannose receptor MCR1407.
Because the pancreas is a highly dynamic site of immune regulation, it is possible
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that these unique sulfated, terminally-galactosylated islet structures play a role in
normal immune recognition and homeostasis.
Key N-glycan structural themes associated with PDAC compared to nontumor tissues were increased sialylation, poly-LacNAc extensions, branching and
extensive fucosylation of high mass N-glycans. Also observed were structures with
bisecting GlcNAc residues and terminal GalNAc (di-LacNAc) modifications. Low
levels of sialylation were seen in normal tissue whereas α2,3 sialylated N-glycans
were expressed abundantly in TMA tumor cores. α2,6-sialylated structures were
detected at lower levels compared to their α2,3 counterparts but were typically
more specific to primary adenocarcinoma clusters. This is in accordance with
studies of pancreatic cell lines which showed increased but varied α2,3 and α2,6
content across different models as compared to normal pancreatic cells, with α2,3
sialylation implicated in a more metastatic phenotype 315. In addition, analyses of
pancreatic cancer in mouse models have detected β-galactoside α2,6sialyltransferase 1 (ST6GAL1) overexpression and subsequent increases in α2,6
sialic acid linked to aggressive metastasis239,240. A lack of fucose and sialic acid
residues characterized N-glycans in necrotic PDAC tissue in this study, which is
consistent with findings from previous glycan MALDI imaging analyses of breast
cancer tissues and other tumor tissue types that detected similar necrosisassociated glycans202. Increases in N-glycan branching is attributable to increased
alpha-1,6-mannosylglycoprotein

6-beta-N-acetylglucosaminyltransferase

V

(MGAT5) expression which extends tri-antennary structures into tetra-antennary
N-glycans. MGAT5 has been shown to be upregulated in PDAC in response to
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KRAS-mediated oncogenesis177. Similarly, prior studies have demonstrated
increased amounts of α1,3-linked fucose present in certain subsets of pancreatic
cancer cell lines408. A different study reported expression of α-(1,3/1,4)Fucosyltransferase (FUT3), which is one of the FUT enzymes responsible for
adding fucose residues to N-glycan antennae, is upregulated in pancreatic cancers
and is involved in the development of a more metastatic phenotype 409.
Another goal of this aim was to better link N-glycan structures associated
with

biomarker

expression

by

integrating

mass

spectrometry

and

immunohistochemistry data. Consistently, N-glycan structures that colocalized
with CA19-9 immunostaining in tissues (Figure 26) did not contain a sialyl Lewis A
(sLeA) motif (Hex[β1,3](Fuc[α1,4])HexNAc) as assessed by IMS. CA19-9 epitopes
have been detected specifically on mucin glycoproteins MUC5AC and MUC16 in
PDAC patient populations, detection of which bolsters the performance of cancer
identification when combined with clinically utilized CA19-9 panels410. These mucin
glycoproteins are predominantly O-glycosylated, and it may be more likely that the
CA19-9 epitope is present in these O-glycans. Studies of commonly-used
pancreatic cancer cell lines have demonstrated variable levels of CA19-9 and
sTRA expression between cell lines110. Other analyses of normal pancreas and
PDAC cell lines have shown a complex relationship between the expression of
Lewis antigens B, Y, sLeA and sLeX which in some lines correlated with increased
metastatic capacity while in others showed little to no correlation 315. These
heterogeneous results demonstrate the challenges of using one or few PDAC cell
lines to accurately study the common pancreatic cancer biomarkers. Linking
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specific N-glycans to CA19-9 and sTRA biomarker expression levels is currently
inconclusive due to the enormous complexity of the N-glycan structures detected
in the CA19-9 and CA19-9/sTRA tissues. The N-glycans detected represent every
major feature of complex N-glycans including bisecting GlcNAc, LacNAc
extensions, di-LacNAc and multi-fucosylation and sialylation modifications. While
an extensive number of N-glycans were detected in the tumor regions, there are
an unknown number of higher mass glycans of m/z > 5000 that cannot be
effectively detected by MALDI-FTICR directly from tissue without extensive
instrument, method and sample preparation optimization. Stability of sialic acids in
the MALDI process is an additional factor, which is mitigated by softer ionization
environments in the MALDI-FTICR233,364. Stabilization by amidation is a useful tool
for preventing sialic acid loss during ionization can further aid in the differentiation
of isomeric sialic acid linkages204,384. Shortcomings of the amidation-amidation
reaction used in this chapter led us to speculate that additional methods, explored
in Chapter 4, may be created to better characterize sialyation in N-glycan IMS
experiments.
The cumulative data generated from the IMS glycan tissue analyses also
allowed integration of the detection of individual N-glycans with results from
existing antibody-based linear regression models for the classification of PDAC
tumor vs. normal tissue samples110. Improvements in receiver operator curve
(ROC) accuracy and AUC were observed when both IMS glycan masses and
biomarker data were combined to build linear regression models as compared to
models based off those analyses individually. These results demonstrate a
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complex relationship between mass spectrometry and antibody-biomarker
characterization of these tissues which can be exploited to bolster classification
algorithms. Complementary IMS and biomarker staining data enhances the
confidence of tumor vs. non-tumor tissue calls in our modeling. Additionally, cases
where biomarker data is lacking or insufficient can be rescued and correctly
classified by the incorporation of imaging mass spectrometry data into these
models. The ability of these separate techniques to inform one another as well as
compensate for the limitations of either model is demonstrated herein and
suggests future utility for combining cross-disciplinary analyses such as these into
existing PDAC classification assays. The N-glycan distribution maps can also be
used to select other lectins not previously evaluated for staining for more targeted
screening of glycan motifs. The PNGase F-based IMS methods is specific for Nglycan species and combined use with multi-lectin stains can address O-linked
antigens, which are well known in PDAC411. Lectin staining provides the
opportunity to parse out further structural characterizations in our mass
spectrometry data via the ability of specific lectins to recognize specific
carbohydrate motifs. These data layered into analysis by mass spectrometry offers
the possibility of identifying specific N-glycan isomers which are typically
indistinguishable by most imaging mass spectrometry systems.
In summary, our N-glycome analysis of biomarker-defined PDAC tissues
using N-glycan MALDI IMS approaches illustrates the potential to inform more
targeted probing of specific N-glycans and N-glycan structural classes that
correlate with current and prospective carbohydrate biomarkers of PDAC. The
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glycan maps generated can be used in the future to target regions of interest to
identify potential glycoprotein carriers. Combining imaging mass spectrometry with
antibody immunostaining improves detection and classification of PDAC and
informs on expanded directions for each method. Advancements in imaging mass
spectrometry techniques and instrumentation and the use of new enzymes and
chemistries to reveal a broader repertoire of structures, isomers, modifications and
molecules will expand these approaches beyond the N-glycome. The continued
search for new lectins which recognize carbohydrate structures associated with
PDAC, as well as improvements to multi-round immunofluorescence technologies
and advancements in statistical image analysis software, potentiates the discovery
of further, novel subclasses of pancreatic cancer. Observations about PDAC
biomarkers and N-glycan structures from this dissertation and ongoing work may
provide leads to impactful new diagnostic and surveillance strategies critically
needed in the clinic, as well as continued insights into the evolving role of the
glycome in this disease. Critically for this body of work, limitations inherent to the
sialic acid stabilization method used inspired the further glycomic developmental
effort described in Chapters 4 and 5.
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Chapter 4: Isomeric Characterization of Sialic Acids by
Amidation-Amidation Reactions
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4.1 Abstract
Sialic acid isomers attached in either α2,3 or α2,6 linkages to glycan termini
confer distinct chemical, biological and pathological properties, but they cannot be
distinguished by mass differences in traditional mass spectrometry experiments.
Multiple derivatization strategies have been developed to stabilize and facilitate
the analysis of sialic acid isomers and their glycoconjugate carriers by high
performance

liquid chromatography,

capillary

electrophoresis and

mass

spectrometry workflows. Herein, a set of novel derivatization schemes are
described that result in the introduction of bioorthogonal click chemistry alkyne or
azide groups into α2,3 and α2,8-linked sialic acids. These chemical modifications
were validated and structurally characterized using model isomeric sialic acid
conjugates and model protein carriers. Use of an alkyne-amine, propargylamine,
as the second amidation reagent effectively introduces an alkyne functional group
into α2,3-linked sialic acid glycoproteins. In tissues, serum and cultured cells, this
allows for detection and visualization of N-linked glycan sialic acid isomers by
imaging mass spectrometry approaches. Formalin-fixed paraffin-embedded
prostate cancer tissues and pancreatic cancer cell lines were used to characterize
the numbers and distribution of alkyne-modified α2,3-linked sialic acid N-glycans.
An azide amine compound with a poly-ethylene glycol linker was evaluated for use
in histochemical staining. Formalin-fixed pancreatic cancer tissues were amidated
with the azide amine, reacted with biotin-alkyne and copper catalyst, and sialic acid
isomers detected by streptavidin-peroxidase staining. The direct chemical
introduction of bioorthogonal click chemistry reagents into sialic acid-containing
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glycans and glycoproteins provides a new glycomic tool set to expand approaches
for their detection, labeling, visualization and enrichment.
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Figure 28. Bioorthogonal Probes for Sialic Acid Isomers. Graphical Abstract
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4.2 Introduction
As outlined in the introduction, sialic acid (SA) sugar modifications on
glycoproteins and glycolipids is a hallmark of the glycocalyx, the dense
glycoconjugate network present in extracellular matrix and on the surface of the
cell. Sialic acids act as receptors for the influenza virus and other infectious
pathogens, are constituents of well characterized carbohydrate tumor antigens
and are binding motifs for selectins and siglec family proteins amongst other
biological functions412–419. Sialic acid sugars exist in nature as a variety of chemical
compositions, where N-acetylneuraminic acid (NeuAc) is the predominant species
in humans while N-acetylglycoylneuraminic acid (NeuGc), a hydroxylated variant,
is more abundant in all other mammalian species412,420,421. These residues are
attached as monomers to their protein and lipid carriers in α2,3 and α2,6 anomeric
linkages or as polysialic acid chains in α2,8 and α2,9 isoforms421. α2,3-linked sialic
acid occur in cancer as part of the carbohydrate tumor antigens sTRA, sialyl-Lewis
X and sialyl-Lewis A (CA19-9)110,422. Multiple studies have demonstrated the
association between increased α2,6 sialylation and various cancers423,424.
Additionally, α2,3 and α2,6 sialic acids have well documented roles in influenza
virus infections414,425.
Due to their biological and pathophysiological importance, sialic acids have
long been the target of chemical derivatization approaches to enhance functional
studies by mass spectrometry analyses384,421. Historically, the lability of sialic acids
in MS experiments has been a major concern for both laser desorption and
electrospray sources, where the residue is often lost during ionization 384,385,426.
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Sialic acids can be chemically stabilized through amidation or esterification of the
anomeric carboxylate group as demonstrated by multiple groups384,421. In these
reactions, α2,3, α2,8 and α2,9 linked sialic acids preferentially undergo
intramolecular esterification due to the proximity of neighboring hydroxyl groups
and the SA carboxylate, forming 6 member lactone rings421,427. This unstable
lactone can be subsequently decyclized through reaction with primary aminecontaining compounds204,391,428. α2,6-linked sialic acids do not form intramolecular
lactones under these conditions and instead are stably amidated or esterified
depending on the combination of reactants384,421.
Bioorthogonal strategies incorporate chemical groups into living systems
that are normally not present under natural conditions. In the past two decades,
chemoenzymatic, metabolic and chemical labeling approaches have been used to
introduce azide and alkyne bioorthogonal functional groups into sialic acids and
other sugars, as well as to win Nobel Prizes429–431. Small and biologically inert
azide and alkyne groups then lie dormant within the living system until they are
reacted with their reciprocal chemical group, creating stable cycloaddition
products. As an example, azido-labeled sugars can be reacted with bead or
surface-bound alkynes, biotin-alkyne conjugates or alkyne fluorophores.
Accordingly, this approach has relevant applications in microscopy, flow cytometry
and mass spectrometry analyses432. The commercially availability of glycan
precursor analogues has led to an increasing number of studies which capitalize
on this technology to detect both N- and O-glycan alterations433–439.
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In 2016, Holst et al. reported a chemical amidation workflow for in-situ,
linkage-specific sialic acid derivatization directly from FFPE tissues with
applications towards N-glycan MALDI-IMS analyses204. As N-glycan IMS
workflows have evolved, sialic acids stabilization strategies to differentiate α2,3
from α2,6 sialylated N-glycan isomers in spatial profiling experiments have proven
very effective204,206,209,215,233,440,441. The goal of this chapter was to enhance Holst’s
original amidation-amidation workflow (AA), used in Chapter 3, to generate
bioorthogonal α2,3 and α2,8 sialic acids variants. This aim was accomplished
through the use of azide-and alkyne-amine compounds as ring-opening primary
amine reagents towards α2,3 and α2,8 lactone intermediates after initial amidation.
Thus, alkyne or azide functionality is specifically incorporated in α2,3 and α2,8linked sialic acids. α2,6 sialic acid isomers are amidated as in the original synthesis
and are unreactive to the secondary amidation reagents. Isomeric model sialic acid
analogues and sialylated protein conjugates were previously used to optimize the
reactions and confirm their products. The new amidation reactions were evaluated
for use in FFPE tissues, serum and cultured cells, where the click chemistry tag
and associated mass shift introduced to sialylated glycans potentiates multiple
characterization strategies. By the direct chemical modification of specific sialic
acid isomers with click chemistry-compatible bioorthogonal reagents we introduce
a new glycomic tool set with applications for labeling, visualization and enrichment
of sialylated glycoconjugates.
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4.3 Preliminary Development
The experiments presented in this chapter can be divided into two parts.
The initial in-vitro development of these theoretical syntheses was performed by a
former member of our laboratory, Xiaowei (Vivian) Lu, to who much credit is given.
As such, her work served as the basis for extensive further development to assess
the compatibility of the reactions with clinical tissues, immobilized biofluids and
cultured cells for imaging mass spectrometry, immunohistochemical and advanced
labeling applications. Here a synopsis of the initial development work is included,
as preface to the subsequent application effort which is the focus of this chapter.
To introduce alkyne and azide amines into α2,3 sialic acids, the previously
reported amidation-amidation (AA) reaction204 was used as the starting point for
derivatization of commercially available α2,3 and α2,6 isomeric sialyllactose
analogs as model compounds. As summarized in Figure 29, the first step was to
incorporate a 2-aminobenzoate (2-AB) group into both compounds to facilitate
detection and purification. The first amidation step of this reaction was not
changed, in that both compounds were treated with dimethylamine, a 1hydroxybenzotriazole

(HOBt)

catalyst

and

a

1-ethyl-3-(3-

dimethylaminopropyl)carbodiimide (EDC) carboxylic acid activator. This reaction
results in dimethylamidation of the α2,6-linked sialic acid carboxyl group, while
generating a lactone in the α2,3 sialyllactose388,442. The original method used
ammonium hydroxide amidation as a second step to stabilize the lactone. In
contrast, propargylamine, a simple alkyne-amine, or a larger PEG-azide amine
(11-azido-3,6,9-trioxaundecan-1-mine, or azido-PEG3-amine), were used in place
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of ammonium hydroxide as the lactone stabilizing second amidation reagent
(Figure 29). The resulting products were purified and assessed by 1D and 2D
NMRs analysis (data not shown). Both alternate amidation reactions were efficient
(quantitative conversion yield, 80% isolation recovery), with confirmed products of
an alkyne-amino-3’siallylactose-2AB (Compound 8) or azido-PEG3-3’sialyllactose2AB (Compound 9). The specific reagents for both derivatization reactions are
listed in Table 9. In the rest of this dissertation, the propargylamine reaction will be
abbreviated to AAXL (Alkyne-Amidation Expanded Linker for alkyne), and the
azide-PEG3-amine reaction as AAN3 (Azide-Amidation N3 for azide).
Additionally, as it is known that sialic acids in α2,8 isomeric linkages
undergo a similar lactone cyclization reaction as α2,3, an α2,8-polysialic acid
model compound, colominic acid (Compound 12) was reacted with the
propargylamine workflow to generate a multiply alkyne-modified neurominic acid
chain, Compound 14 (Figure 30). The resulting products were purified and
assessed by 1D and 2D NMRs analysis (data not shown).
To investigate lactone formation by the first amidation reaction in AAXL and
AAN3, 2AB-labeled 3’sialyllactose (Compound 4) was reacted with the first
dimethylamine solution for 1 hr at 60°C as described. The crude reaction mixture
was then dissolved in DMSO-d6 for NMR acquisition. A downfield shifted H-2II in
the lactone when compared to the amide indicated the formation of the 2,2 lactone
(Compound 6) instead of the 2,4 lactone (Compound 7). The 2,2 lactone
decomposed in aqueous solvent therefore no further purification was attempted.
1H

NMR indicated a quantitative conversion from Compound 4 to Compound 6.
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Figure 29. Reaction scheme for AAXL, AAN3 and AAXL-click on model
compounds. α2,6-linked and α2,3-linked sialyllactose model compounds were
reductively labeled with 2-aminobenzamide (2-AB) then derivatized by either AAXL
(dimethylamine, propargylamine) or AAN3 (dimethylamine, azido-PEG3-amine).
The AAXL-labeled sialyllactose analog was further modified by click chemistry with
a biotin-azide conjugate. For simplicity, each structure was assigned a compound
number (upper left corner).
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Table 9. AAXL and AAN3 Reactions.
AAXL
Weight or Volume

Mole (mmol)

Concentration (M)

1st AAXL Reaction Solution
EDC
HOBt
Dimethylamine
DMSO

22.0 µL
42.2 mg
15.8 µL
0.5 mL

0.125
0.250
0.125

0.25
0.50
0.25

2nd AAXL Reaction Solution
Propargylamine

300 µL

DMSO

700 µL

AAN3
Weight or Volume

Mole (mmol)

Concentration (M)

1st AAN3 Reaction Solution
EDC
HOBt
Dimethylamine
DMSO

22.0 µL
42.2 mg
15.8 µL
0.5 mL

0.125
0.250
0.125

0.25
0.50
0.25

2nd AAN3 Reaction Solution
NH2-PEG3-N3

300 µL

DMSO

700 µL
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Figure 30. Derivatization of a polysialic acid analog by AAXL. Colominic acid as an analog for α2,8-linked polysialic
acid was reacted by AAXL to produce an alkylated polysialic acid chain.
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The α2,8 polysialic acid analog (Compound 12) underwent a similar lactone
interconversion through the 2,9 lactone intermediate (Compound 13) (Figure 30).
Dimethylamidated 6’sialyllactose-2AB was unreactive to the addition of
propargylamine or azido-PEG3-amine. To test the stability of the converted α2,6
amide, isolated pure dimethylamidated 6’sialyllactose-2AB was incubated in
propargylamine-DMSO (v/v 2/5) at 60°C for 5 hr. After incubation no change was
observed as assessed by NMR, indicating the stability of the amidation product.
To confirm that the incorporated alkyne group could be used for click
chemistry conjugation, purified alkyne-amine-3’sialyllactose-2AB was further
reacted with a biotin-PEG3-azide conjugate through a Cu(I)-catalyzed azidealkyne cycloaddition to yield a 1,4-disubstituted 1,2,3-triazole link between the
sialic acid and the biotin443,444. The structure of the resulting successfully
biotinylated 3’sialyllacotse-2AB (Compound 10) was then confirmed by NMR (data
not shown). The specific reagents and reaction conditions for the CuAAC reaction
on AAXL-modified α2,3-sialic acids are listed in Table 10.
To assess derivatization by AAXL and subsequent click modification in a
more biologically relevant context, commercially available 6’ and 3’sialyllactoseconjugated bovine serum albumin (BSA) (Compound 15, Compound 16) were
treated with the dimethylamine and propargylamine amidation reactions. The
resulting dimethylamidated 6’sialyllactose-BSA (Compound 17) and alkylated
3’sialyllactose-BSA (Compound 18) were then further modified by CuAAC as
previously described for the model compounds. An overall reaction schematic is
shown in Figure 31A. To probe for biotinylation of the α2,3 isomer-containing
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Table 10. CuAAC Reaction Mixture for AAXL.
MW
(g/mol)

Reagent Stock
Prep
(per 1 mL H2O)
17.8 mg
3.2 mg
20.0 mg
21.7 mg
11.0 mg

[Reagent Stock]

Volume [Reagent]
Stock
Solution
A Biotin-PEG3-azide
356.16
50 mM
10.0 µL
1.0 mM
B CuSO4
159.61
20 mM
2.5 µL
0.1 mM
C Sodium ascorbate
198.11
100 mM
25.0 µL
5.0 mM
D THPTA
434.50
50 mM
5.0 µL
0.5 mM
E Aminoguanidine HCl 110.55
100 mM
25.0 µL
5.0 mM
F 10X PBS
432.5 µL
Overall Volume
500.0 µL
Mix B and D, A and F in separate Eppendorf tubes. Sequentially add B&D mixture, E and C to A&F
mixture. Reagents A, B, D, E and F may be prepared ahead of time. 100 mM sodium ascorbate (C)
must be prepared day of.
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Figure 31. AAXL-Derivatization and Click-Biotinylation of Sialylated Model
Proteins. 6’ and 3’-sialyllactose-BSA (bovine serum albumin) were derivatized to
test the specificity of AAXL-click biotinylation for α2,3-linked sialoproteins. A)
reaction schematic for AAXL and subsequent copper-catalyzed azide-alkyne
cycloaddition (CuAAC) with biotin-azide. B) western blot of crude reaction lysates
for Compounds 19 and 20 probed with streptavidin-IR dye confirms biotinylation
specificity for α2,3-sialylated BSA . Biotinylated Aleuria Aurantia lectin as a control
for biotin installation.
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model protein, the resulting crude mixtures from the click reaction were purified by
filtration and analyzed by SDS-polyacrylamide gel electrophoresis and subsequent
western blot (Figure 31B). As a positive control for detection of biotinylation, both
product mixtures were run alongside a commercially available biotinylated Aleuria
Aurantia lectin (b-AAL). Incorporation of a biotin was confirmed for 3’sialyllactoseBSA (Compound 20) using a streptavidin-conjugated IR dye incubated with the
blot (Figure 31B). No specific biotinylation was observed for the CuAAC-reacted
dimethylamidated 6’sialyllactose-BSA (Compound 19), confirming the specificity of
CuAAC for only the alkyne-derivatized α2,3-sialic acid isomers. At this point AAXL
and AAN3 were developed to a point at which they warranted evaluation in Nglycan IMS and other platforms, presented in the bulk of this chapter.
4.4 Materials and Methods
4.4.1 Materials
1-hydroxybenzotriazole hydrate (HOBt, ≥20 wt. % in H2O), 5-fluorouracil
(99%), α-cyano-4-hydroxycinnamic acid (CHCA), aminoguanidine hydrochloride
(98%), copper (II) sulfate (CuSO4, 99%), dimethyl sulfoxide (DMSO), hydrochloric
acid (37% in H2O), Mayer’s hematoxylin solution, N-(3-dimethylaminopropyl)-N’ethylcarbodiimide (EDC, ≥97%), penicillin-streptomycin (P/S), propargylamine
(98%),

sodium

ascorbate

(99%),

sodium

bicarbonate

(99%),

sodium

cyanoborohydride (NaCNBH3, 95%), trifluoroacetic acid (TFA) and tris(3hydroxypropyltriazolylmethy)amine (THPTA, 95%) were obtained from SigmaAldrich (St. Louis, MO). Acetic acid, acetonitrile (ACN, HPLC grade), ammonia (2830 wt. % in H2O), chloroform (HPLC grade), citraconic anhydride, H2O (HPLC
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grade), Cytoseal, fetal bovine serum (FBS, qualified), phosphate-buffered saline
(PBS), RPMI 1640 media +/- L-glutamine, Slip-Rite cover glass, triethylamine
(TEA, 99%) and xylenes (histological grade) were obtained from ThermoFisher
Scientific (Waltham, MA). Ethanol (EtOH, 200 proof) was obtained from Decon
Labs (King of Prussia, PA). 11-azido-3,6,9-trioxaundecan-1-mine (NH2-PEG3-N3,
95%) and D-biotin (98%) were obtained from AK Scientific (Union City, CA). Biotinalkyne (98%) was obtained from Synthonix (Wake Forest, NC). Horseradish
peroxidase-3,3’-diaminobenzidine (HRP-DAB) staining kits were obtained from
R&D Systems (Minneapolis, MN). Recombinant peptide N-glycosidase F (PNGase
F PRIME) and sialidase were obtained by N-zyme Scientific (Doylestown, PA).
Incubation chambers (200 µL) and Lab-Tek II CC2 8-chamber slides were obtained
from Electron Microscopy Sciences (Hatfield, PA). Sialidase (SialEXO) was
obtained from Genovis (Cambridge, MA). Gemcitabine hydrochloride (98%),
Irinotecan hydrochloride hydrate (98%) and Oxaliplatin (98%) were obtained from
Cayman Chemical Company (Ann Arbor, MI). AsPC-1 human pancreatic cancer
cells (CRL-1682), HPAC human pancreatic carcinoma cells (CRL-2119), PANC-1
human pancreatic carcinoma cells (CRL-1469), PL45 human pancreatic
carcinoma cells (CRL-2558) and Trypsin-EDTA solution were obtained from ATCC
(Manassas, VA). 0.4% Trypan Blue was obtained from Lonza (Basel, Switzerland).
L-glutamine (Amide-15N, 98%) was obtained from Cambridge Isotope Laboratories
(Tewksbury, MA). Nexterion Slide H amine-reactive microscope slides were
obtained from applied microarrays (Tempe, AZ).
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4.4.2 AA, AAXL and AAN3 on FFPE Tissue Slides
FFPE tissue slides were heated at 60°C for 1 hr, dewaxed with xylenes and
rehydrated in a series of graded ethanol and water washes, then dried in a vacuum
desiccator for 30 min. The AAXL first reaction solution (200 µL, Table 9) was
applied directly to the dewaxed and rehydrated tissue, then a glass coverslip was
placed on top of the tissue to ensure even distribution of the reagents. Theses
slides were then placed in a sealed container and incubated at 60°C for 1 hr. After
incubation, the cover glass was removed, and the reaction solution was aspirated
from the surface of the slide. Three 400 µL DMSO washes removed any residual
solution, with vacuum aspiration after each. The AAXL second reaction solution,
200 µL of a 300 µL propargylamine/700 µL DMSO stock, was then applied to the
tissue surface and once more a coverslip was placed on top. This secondary
reaction was placed into a sealed container and further incubated for 2 hr at 60°C.
After the second incubation, the coverslip was removed and residual 2nd reaction
solution was aspirated away. The amidated slides were washed in EtOH for 2 min
twice, Carnoy’s Solution (60% EtOH, 30% chloroform, 10% acetic acid) for 10 min
twice, EtOH for 2 min twice, 0.1% TFA in EtOH for 30 sec and H2O for 3 min twice.
The amidated slides could then be immediately incorporated into a MALDI-IMS
workflow or stored in a desiccator for future use. Similar to AAN 3 on the model
compounds, AAN3 on FFPE tissues shares its first step with AAXL but substitutes
an equivalent volume of azido-PEG3-amine (NH2-PEG3-N3) for propargylamine in
the second step. The sole remaining difference between AAXL and AAN3 for FFPE
tissue preparation is the washing steps following the second amidation reaction,
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where a 10 min DMSO wash is included in between the two 10 min washes in
Carnoy’s solution. This extra wash step is necessary to remove any residual azidoPEG3-amine. A previously reported sialic acid amidation strategy upon which ours
were adapted, termed AA, was also performed for comparison 204. This reaction,
like AAN3, differed from AAXL only in its second reaction solution, which utilized
an equivalent volume of 28-30% ammonia in H2O instead of propargylamine.
4.4.3 Tissue Preparation for MALDI-IMS
A standardized tissue preparation workflow was followed, which has been
previously published314. Briefly, derivatized tissue slides underwent heat-induced
epitope retrieval (HIER) in citraconic anhydride buffer, pH 3 for 30 min in a
decloaking chamber at 95°C. After buffer exchanging away the citraconic
anhydride and subsequent drying in a desiccator, 15 passes of PNGaseF PRIME
enzyme at 0.1 µg/µL in HPLC H2O was applied to the tissue slides at a rate 25
µL/min with a velocity of 1200 mm/min and a 3 mm offset at 10 psi and 45°C using
an M5 Sprayer (HTX Technologies, Chapel Hill, NC). Enzyme-sprayed slides were
then incubated in prewarmed humidity chambers for 2 hr at 37°C for
deglycosylation. After incubation, 7 mg/mL CHCA matrix in 50% ACN/0.1% TFA
was applied to the deglycosylated slides at a rate of 100 µL/min with a velocity of
1300 mm/min and a 2.5 mm offset at 10 psi and 79°C using the sprayer. After
matrix application slides were desiccated until analysis.
4.4.4 MALDI-QTOF IMS of Derivatized N-glycans

A timsTOF fleX trapped ion mobility separated QTOF mass spectrometer

158

(Bruker Daltonics, Bremen, Germany) equipped with a 10 kHz SmartBeam 3D
laser operating in positive mode with a spot size of 20 µm was used to detect
derivatized, released N-glycans at a high resolution (20 to 40 µm raster). 300
laser shots per pixel over a mass range of 500 to 4000 m/z were collected for
analysis, with an ion transfer time of 125 µs, a prepulse storage time of 25 µs, a
collision frequency of 4000 Vpp, a multipole frequency of 500 Vpp and a collision
cell energy of 15 eV. For MS/MS analysis by CID, a 10 Da window was used for
precursor isolation and precursors were fragmented with individually optimized
collision energies ranging from 80 to 140 eV.
4.4.5 MS Data Processing and Analysis

Post-acquisition, spectra were imported to SCiLS Lab 2022b Pro (Bruker
Daltonics, Bremen, Germany) for processing mass spectrometry imaging
experiments. The generated N-glycan spectra were then normalized to the total
ion count. Spectra were annotated by matching peaks against an in-house Nglycan database generated using GlycoMod and GlycoWorkbench, which was
modified to include AAXL, AA and AAN3-induced mass shifts in sialic acid
isomers360,361. Structures annotated in this research article are compositionally
accurate as determined by accurate mass. Structural assignments were based off
of CID analyses and

prior characterizations by reversed-phase liquid

chromatography-coupled tandem mass spectrometry, MALDI-TOF-MS/MS and
alternate enzymatic release experiments215,315. A list of the most abundantly
detected sialylated N-glycans reported in this analysis, along with calculated mass
errors, can be found in Table 11.
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Table 11. Composition and Mass Accuracy of Sialylated N-glycans in this
Chapter.
Composition
Theoretical Observed Error ppm
Hex4HexNAc3
1298.4492 1298.4476 1.2322
Hex4dHex1HexNAc3
1444.5071 1444.5089 1.2461
Hex4HexNAc3NeuAc1
1589.5446 1589.5528 5.1587
Hex4HexNAc3(α2,6)NeuAc1
1616.5919 1616.5907 0.7423
Hex4HexNAc3(α2,3)NeuAc1
1626.5762 1626.5769 0.4304
Hex5HexNAc4
1663.5814 1663.5759 3.3061
Hex4dHex1HexNAc3NeuAc1
1735.6025 1735.5996 1.6536
Hex4dHex1HexNAc3(α2,6)NeuAc1
1762.6498 1762.6519 1.1914
Hex4dHex1HexNAc3(α2,3)NeuAc1
1772.6341 1772.6390 2.7642
Hex5dHex1HexNAc4
1809.6393 1809.6397 0.2210
Hex5HexNAc5
1866.6608 1866.6610 0.1071
Hex5HexNAc4NeuAc1
1954.6768 1954.6824 2.8649
Hex5HexNAc4(α2,6)NeuAc1
1981.7241 1981.7284 2.1698
Hex5HexNAc4(α2,3)NeuAc1
1991.7084 1991.7117 1.6569
Hex5dHex1HexNAc5
2012.7187 2012.7180 0.3478
Hex6HexNAc5
2028.7136 2028.7153 0.8380
Hex5dHex1HexNAc4NeuAc1
2100.7347 2100.7324 1.0949
Hex5dHex1HexNAc4(α2,6)NeuAc1
2127.7820 2127.7769 2.3969
Hex5dHex1HexNAc4(α2,3)NeuAc1
2137.7663 2137.7654 0.4210
Hex5HexNAc5NeuAc1
2157.7562 2157.7573 0.5098
Hex6dHex1HexNAc5
2174.7715 2174.7719 0.1839
Hex5HexNAc5(α2,6)NeuAc1
2184.8035 2184.8157 5.5840
Hex5HexNAc5(α2,3)NeuAc1
2194.7878 2194.7710 7.6545
Hex5HexNAc4(α2,6)NeuAc2
2299.8668 2299.8703 1.5218
Hex5dHex1HexNAc5NeuAc1
2303.8141 2303.8026 4.9917
Hex5HexNAc4(α2,6)NeuAc1(α2,3)NeuAc1
2309.8511 2309.8388 5.3250
Hex6HexNAc5NeuAc1
2319.8090 2319.8118 1.2070
Hex5HexNAc4(α2,3)NeuAc2
2319.8354 2319.8311 1.8536
Hex5dHex1HexNAc5(α2,6)NeuAc1
2330.8614 2330.8571 1.8448
Hex5dHex1HexNAc5(α2,3)NeuAc1
2340.8457 2340.8429 1.1961
Hex6HexNAc5(α2,6)NeuAc1
2346.8563 2346.8587 1.0226
Hex6HexNAc5(α2,3)NeuAc1
2356.8406 2356.8345 2.5882
Hex7HexNAc6
2393.8458 2393.8495 1.5456
Hex5dHex1HexNAc4(α2,6)NeuAc2
2445.9247 2445.9153 3.8431
Hex5dHex1HexNAc4(α2,6)NeuAc1(α2,3)NeuAc1 2455.9090 2455.9027 2.5652
Hex6dHex1HexNAc5NeuAc1
2465.8669 2465.8693 0.9733
Hex5dHex1HexNAc4(α2,3)NeuAc2
2465.8933 2465.8898 1.4194
Hex6dHex1HexNAc5(α2,6)NeuAc1
2492.9142 2492.9150 0.3209
Hex6dHex1HexNAc5(α2,3)NeuAc1
2502.8985 2502.9067 3.2762
Hex5HexNAc5(α2,6)NeuAc2
2502.9462 2502.9692 9.1892
Hex5HexNAc5(α2,6)NeuAc1(α2,3)NeuAc1
2512.9305 2512.9593 11.4607
Hex5HexNAc5(α2,3)NeuAc2
2522.9148 2522.8841 12.1685
Hex7dHex1HexNAc6
2539.9037 2539.9076 1.5355
Hex6HexNAc5NeuAc2
2610.9044 2610.9202 6.0515
Hex5dHex1HexNAc5(α2,6)NeuAc2
2649.0041 2648.9881 6.0400
Hex5dHex1HexNAc5(α2,6)NeuAc1(α2,3)NeuAc1 2658.9884 2658.9626 9.7029

Composition
Theoretical Observed Error ppm
Hex6HexNAc5(α2,6)NeuAc2
2664.9990 2664.9964 0.9756
Hex5dHex1HexNAc5(α2,3)NeuAc2
2668.9727 2668.9747 0.7494
Hex6HexNAc5(α2,6)NeuAc1(α2,3)NeuAc1
2674.9833 2674.9866 1.2337
Hex7HexNAc6NeuAc1
2684.9412 2684.9472 2.2347
Hex6HexNAc5(α2,3)NeuAc2
2684.9676 2684.9695 0.7076
Hex7HexNAc6(α2,6)NeuAc1
2711.9885 2711.9765 4.4248
Hex7HexNAc6(α2,3)NeuAc1
2721.9728 2721.9841 4.1514
Hex6dHex1HexNAc5(α2,6)NeuAc2
2811.0569 2811.0583 0.4980
Hex6dHex1HexNAc5(α2,6)NeuAc1(α2,3)NeuAc1 2821.0412 2821.0318 3.3321
Hex7dHex1HexNAc6NeuAc1
2830.9991 2831.0171 6.3582
Hex6dHex1HexNAc5(α2,3)NeuAc2
2831.0255 2831.0171 2.9671
Hex7dHex1HexNAc6(α2,6)NeuAc1
2858.0464 2858.0399 2.2743
Hex7dHex1HexNAc6(α2,3)NeuAc1
2868.0307 2868.0367 2.0920
Hex6HexNAc5NeuAc3
2901.9998 2901.9832 5.7202
Hex6HexNAc5(α2,6)NeuAc3
2983.1417 2983.1438 0.7040
Hex6HexNAc5(α2,6)NeuAc2(α2,3)NeuAc1
2993.1260 2993.1291 1.0357
Hex6HexNAc5(α2,6)NeuAc1(α2,3)NeuAc2
3003.1103 3003.0979 4.1291
Hex6HexNAc5(α2,3)NeuAc3
3013.0946 3013.0747 6.6045
Hex7HexNAc6(α2,6)NeuAc2
3030.1312 3030.1215 3.2012
Hex7HexNAc6(α2,6)NeuAc1(α2,3)NeuAc1
3040.1155 3040.1121 1.1184
Hex7HexNAc6(α2,3)NeuAc2
3050.0998 3050.0848 4.9179
Hex6dHex1HexNAc5(α2,6)NeuAc3
3129.1996 3129.2010 0.4474
Hex6dHex1HexNAc5(α2,6)NeuAc2(α2,3)NeuAc1 3139.1839 3139.1782 1.8158
Hex6dHex1HexNAc5(α2,6)NeuAc1(α2,3)NeuAc2 3149.1682 3149.1609 2.3181
Hex6dHex1HexNAc5(α2,3)NeuAc3
3159.1525 3159.1491 1.0762
Hex7dHex1HexNAc6(α2,6)NeuAc2
3176.1891 3176.1752 4.3763
Hex7dHex1HexNAc6(α2,6)NeuAc1(α2,3)NeuAc1 3186.1734 3186.1694 1.2554
Hex7dHex1HexNAc6(α2,3)NeuAc2
3196.1577 3196.1417 5.0060
Hex7HexNAc6(α2,6)NeuAc3
3348.2739 3348.1882 25.5953
Hex7HexNAc6(α2,6)NeuAc2(α2,3)NeuAc1
3358.2582 3358.2479 3.0671
Hex7HexNAc6(α2,6)NeuAc1(α2,3)NeuAc2
3368.2425 3368.2255 5.0471
Hex7HexNAc6(α2,3)NeuAc3
3378.2268 3378.2327 1.7465
Hex7dHex1HexNAc6(α2,6)NeuAc3
3494.3318 3494.3108 6.0097
Hex7dHex1HexNAc6(α2,6)NeuAc2(α2,3)NeuAc1 3504.3161 3504.3126 0.9988
Hex7dHex1HexNAc6(α2,6)NeuAc1(α2,3)NeuAc2 3514.3004 3514.2848 4.4390
Hex7dHex1HexNAc6(α2,3)NeuAc3
3524.2847 3524.2854 0.1986
Hex7HexNAc6(α2,6)NeuAc4
3666.4166 3666.4334 4.5821
Hex7HexNAc6(α2,6)NeuAc3(α2,3)NeuAc1
3676.4009 3676.3462 14.8787
Hex7HexNAc6(α2,6)NeuAc2(α2,3)NeuAc2
3686.3852 3686.3779 1.9803
Hex7HexNAc6(α2,6)NeuAc1(α2,3)NeuAc3
3696.3695 3696.3753 1.5691
Hex7HexNAc6(α2,3)NeuAc4
3706.3538 3706.3381 4.2360
Hex7dHex1HexNAc6(α2,6)NeuAc4
3812.4745 3812.5034 7.5804
Hex7dHex1HexNAc6(α2,6)NeuAc3(α2,3)NeuAc1 3822.4588 3822.4288 7.8484
Hex7dHex1HexNAc6(α2,6)NeuAc2(α2,3)NeuAc2 3832.4431 3832.4439 0.2087
Hex7dHex1HexNAc6(α2,6)NeuAc1(α2,3)NeuAc3 3842.4274 3842.4212 1.6136
Hex7dHex1HexNAc6(α2,3)NeuAc4
3852.4117 3852.3924 5.0098
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4.4.6 Biofluid N-glycan Profiling

Serum samples were processed as described previously445. Briefly,
samples were diluted 2:1 in 100mM sodium bicarbonate then 1 µL diluted serum
was spotted onto an amine-reactive slide. After immobilizing for 1 hr in a humidity
chamber at RT, the samples were dried in a desiccator, washed with Carnoy’s
solution (60% EtOH, 30% chloroform, 10% acetic acid) for 3 min 3X and rinsed in
HPLC H2O. Slides were desiccated for 30 min until dry, then derivatized by AAXL
using the same protocol as described for FFPE tissues. AAXL-labeled serum
slides were then incorporated into the aforementioned N-glycan IMS workflow at
the point of deglycosylation.
4.4.7 N-glycan IMS of Cultured Cells
N-glycan imaging mass spectrometry experiments on PANC1, ASPC1,
HPAC and PL45 pancreatic cancer cell lines were performed according to a
previously published protocol203. Briefly, 10,000 cells per well were plated into six
of eight wells in an eight-chamber array (with 2 wells reserved for media blanks)
on glass microscope slides and cultured in RPMI 1640 (5% FBS, 1% P/S, +Lglutamine) media under normal conditions. After overnight adherence the media
was removed from the array, the cells were washed in cold PBS and then fixed in
10% neutral-buffered formalin (NBF) for 30 min at RT. After fixation, the arrays
were removed from the slides, cells were briefly washed in PBS then derivatized
by AAXL as described for FFPE tissues. Derivatized, fixed cell slides were then
prepared for N-glycan IMS by the aforementioned protocol. An additional spraying
step incorporated after matrix deposition applied 2 passes of 5 mM ammonium
161

phosphate monobasic at 70 µL/min with a velocity of 1300 mm/s at an offset of 3
mm at 10 psi and 60°C to reduce signal-suppressing matrix cluster formation. After
MS data acquisition, media blanks were subtracted as background for each
detected N-glycan analyte. Significant differences in the expression of sialylated
glycans between the cell lines were assessed by one-way ANOVA using multiple
comparisons in GraphPad Prism 9.3.1 (San Diego, CA). Principal component
analyses (PCA) were performed in SCiLS Lab utilizing six components scaled by
unit variance.
4.4.8 IDAWG Labeling for Cell Turnover
For IDAWG labeling experiments446, all four pancreatic cancer cell lines
were cultured in chambered arrays as previously described. After the cells had
adhered to the slide, RPMI 1640 media containing L-glutamine was replaced with
an L-glutamine-free RPMI 1640 media into which amide-15N L-glutamine was
spiked to a concentration of 2 mM. At the same time, four different
chemotherapeutic agents (4.15 µM 5-fluorouracil, 1.08 µM Gemcitabine, 0.91 µM
Irinotecan, 7.44 µM Oxaliplatin) were individually administered to separate
chambered arrays for each of the four cell lines. The appropriate concentrations
for each drug were assessed prior to the experiment by IC50 measurements based
on a trypan blue exclusion assay for cell viability. At 24-, 48- and 72-hour time
points slides for each of the four cell lines were fixed, derivatized by AAXL, and
prepared for N-glycan MALDI IMS as described above. Spectra were acquired by
MALDI-IMS similarly to that for FFPE tissues but at a raster of 150 µm for a more
high-throughput measurement approach. Again, media blanks were subtracted
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from the cell-containing wells during post-acquisition processing. Heavy-labeled
glycans were annotated from our glycan database modified to include a +0.9937
Da mass shift for every N-acetylglucosamine, N-acetylgalactosamine or Nacetylneuraminic acid in the glycan structure. %15N incorporation was determined
by the percentage of the total light- and heavy-labeled peak intensities which
corresponded to the heavy labeled peak, which was controlled for interference
from the light-labeled isotope peaks with the mass-shifted 15N-labeled peak.
4.4.9 CuAAC on AAXL and AAN3 FFPE Tissue Slides
AAXL and AAN3 labeled tissue slides were rehydrated with 200 µL H2O
applied directly to the tissue surface for 1 min, which was then discarded. The
AAXL-CuAAC reaction mixture was prepared as previously described (Table 10).
A humidity chamber was prepared with a 200 µL incubation chamber placed wellside up. The incubation well was then filled with 200 µL click reaction mixture for
AAXL and the rehydrated tissue slide was pressed tissue-side down onto the
incubation well, sealing the silicone gasket of the incubation well around the tissue.
The humidity chamber was then filled with nitrogen gas, sealed and incubated at
RT overnight in the dark. After incubation, the slides were washed by gentle
shaking in H2O for 3 min 3 times, EtOH for 2 min, Carnoy’s Solution for 10 min
twice, EtOH for 2 min and H2O for 3 min 3 times. The biotinylated slides could then
be immediately stained by histochemistry or stored in a desiccator for future use.
The CuAAC workflow for AAN3 labeled tissue slides proceeded similarly but
utilized 1.0mM biotin-alkyne prepared in DMSO/H2O v/v 1:1 in place of biotinPEG3-azide.

163

4.4.10 Sialidase Treatment of FFPE Tissues
FFPE tissue slides were dewaxed, rehydrated and subjected to HIER as
described above. A humidity chamber was prepared as mentioned for CuAAC. The
incubation well was then filled with 200 µL of 1U/µL sialidase in 20 mM TRIS (pH
6.8) and the antigen retrieved tissue slide was placed on top. The humidity
chambers were then sealed and incubated at 37°C overnight. Following
incubation, residual sialidase solution was discarded and the slides were washed
with H2O for 3 min 3 times. In an attempt to remove any residual sialic acid
residues, the tissues were then subjected to two more rounds of sialidase
incubation as described above in 0.5U/µL sialidase for 8 hr at 37°C each time.
Following the final incubation, tissue slides were washed with H2O for 3 min 3 times
and then stored in a desiccator until labeling.
4.4.11 Histochemical Staining
Histochemical staining was performed with HRP-DAB Kit (R&D Systems,
Minneapolis, MN). After the click reaction, HIER was performed with a decloaker
at 95˚C for 15 min in 10 mM sodium citrate (pH 6.0). Tissue slides were then placed
face up in humidity chambers as described above. Samples were incubated at RT
with 200 µL peroxidase blocking solution (spread across the tissue surface using
a glass coverslip) for 30 min then washed with PBS for 5 min 3X. Slides were then
incubated with 200 µL Odyssey PBS Blocking buffer for 30 min which was then
aspirated away. Blocked slides were incubated with 200 µL HSS-conjugated HRP
for 30 min, then washed thoroughly with PBS for 5 min 4X. For detection, slides
were then incubated in DAB chromogen solution for 15 min followed by two 5 min
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H2O washes. A nuclear counterstain was applied using Mayer’s hematoxylin and
then the slides were washed sequentially with H2O for 3 min, 70% EtOH for 1 min,
EtOH for 15 s, 2% ammonia in water (for bluing) for 10 s, 70% EtOH for 1 min,
95% EtOH for 1 min, EtOH for 1 min 2X and xylenes for 3 min 2X. DAB-labeled
slides were air-dried for 10 min then sealed and permanently mounted. After
overnight drying slides were imaged on a NanoZoomer 2.0-RS high-resolution
slide scanner (Hamamatsu, Hamamatsu-city, Japan) at 40X magnification across
the whole tissue.
4.5 Results
4.5.1 Comparison of AA, AAXL and AAN3 for Tissue N-glycan IMS
After the initial development of AAXL and AAN3, we assessed the
applicability of these syntheses to target sialic-acid containing N-glycans in tissues,
as measured by N-glycan IMS in FFPE tissue sections314. A series of sequentially
cut prostate cancer tissue slides were used for initial characterizations. For IMS,
both the first and second reactions of AAXL and AAN3 occur directly on the surface
of the dewaxed and rehydrated FFPE tissue, where a glass cover slip placed on
top is used to ensure sufficient contact of the derivatization reagents with the
tissue. A standard antigen retrieval protocol was performed next, followed by
spraying of peptide N-glycosidase F, digestion and CHCA matrix application as
previously described314. For comparison, an adjacent slide treated with the original
amidation-amidation (AA) derivatization strategy204 and an underivatized tissue
were similarly prepped for N-glycan IMS. The specific derivatization schemes and
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reagents, as well as the resulting mass shifts for α2,3 and α2,6 sialic acid isomers,
are shown in Table 12.
Initial comparisons for each condition focused on the detection and
distribution of a singly sialylated, biantennary N-glycan (Hex5HexNAc4NeuAc1)
that is abundant and easily detectable in prostate cancer tissues 447. In the
underivatized sample, the glycan appears at m/z 1954.6768 (1663.5814 Da for the
Hex5HexNAc4 base + 291.0954 Da for the sialic acid residue) which represents
the unresolved population both α2,3 and α2,6 isomers (Figure 32A). The tissue
treated with the original AA reaction exhibits a peak at m/z 1953.6948 representing
the amidated α2,3-linked isomer and expected -0.9840 Da mass shift, and a peak
at m/z 1981.7241 corresponding to the dimethylamidated α2,6-linked species
(Figure 32B). Unlike the underivatized, AAXL and AAN3 spectra, the derivatized
α2,3-sialylated peak exhibited what appears to be a non-standard isotopic
distribution pattern, with increased signal at the +1 and +2 isotopes relative to the
original mass. This is likely due to overlap between the derivatized isotopes, any
residual underivatized peak at m/z 1954.6768 as well as the doubly fucosylated
version

of

the

base

Hex5HexNAc4

glycan

at

m/z

1955.6972

(Hex5dHex2HexNAc4). The relative intensities of the underivatized and
derivatized peaks for AA, AAXL and AAN3 are shown in Figure 33.
In the AAXL-treated tissue, m/z 1991.7104 corresponds to the alkyneamine α2,3 isomer while, m/z 1981.7241, like in AA, represents the
dimethylamidated α2,6 isomer (Figure 32C). Use of AAXL avoids the isotopic
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Table 12. Mass Shifts for AAXL, AA and AAN3.

AAXL
1st Step
Reaction
Mixture

2nd

Step

α2,6 sialic
acid
167

Products
α2,3 sialic
acid

AA

AAN3

EDC, HOBt, dimethylamine/DMSO
Propargylamine/DMSO
(v/v 3:7)

Ammonia in H2O
(28%)/DMSO (v/v 3:7)

NH2-PEG3-N3/DMSO
(v/v 3:7)

Figure 32. Determining the suitability of AAXL, AAN3 and AA for N-glycan
IMS applications. Three prostate cancer FFPE tissue serial sections were
derivatized by AAXL, AAN3 and AA alongside a fourth unlabeled section. A) the
undifferentiated Hex5HexNAc4NeuAc1 peak at m/z 1954.6768 (inset) in the nonderivatized tissue (red). B) Hex5HexNAc4(α2,3)NeuAc1 (m/z 1953.6948, inset)
and Hex5HexNAc4(α2,6)NeuAc1 (m/z 1981.7241) in the AA-derivatized tissue
(blue). C) Hex5HexNAc4(α2,3)NeuAc1 (m/z 1991.7104, inset) and
Hex5HexNAc4(α2,6)NeuAc1 (m/z 1981.7241) in the AAXL-derivatized tissue
(yellow). D) Hex5HexNAc4(α2,3)NeuAc1 (m/z 2154.8061, inset) and
Hex5HexNAc4(α2,6)NeuAc1 (m/z 1981.7241) in the AAN3-derivatized tissue
(green). Mass spectrometry images of derivatized, sialylated N-glycans E), m/z
1954.6768; F) m/z 1953.6948; G) m/z 1991.7104; H) m/z 2154.8061; I) m/z
1981.7241 across the unlabeled, AA, AAXL and AAN3 tissues.
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Figure 33. Derivatization Efficiency for AAXL, AA and AAN3. Relative peak
intensities were compared for the derivatized α2,3-sialylated, derivatized α2,6sialylated and remaining underivatized Hex5HexNAc4NeuAc1 species in AA,
AAXL and AAN3. A) 20.20% of the total peak area for Hex5HexNAc4NeuAc1
represented the unlabeled peak at m/z 1954.6768 in the AA-treated sample. B)
AAXL derivatized 94.21% of the Hex5HexNAc4NeuAc1 glycan while C) AAN3 had
a 90.15% efficiency.
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overlap challenges described for AA, as no known glycan analytes appear within
its isotopic distribution at that mass range. The AAN3-derivatized sample also
averts isotopic overlap, with the azide-labeled α2,3-linked species appearing at
m/z 2154.8061 (+200.1273 Da mass shift) (Figure 32D). As in AA and AAXL, the
dimethylamidated α2,6 isomer appears at m/z 1981.7241. Precise structural
confirmations for these and other derivatized N-glycans were assessed by CID
directly from the tissue slides (Figure 34). Relative to AAXL, the α2,3-derivatized
isomer showed lower overall signal intensity in AAN3. For imaging MS applications
the +200.1273 Da mass shift associated with AAN3 could limit detection of larger
mass, multi-sialylated N-glycans448. Other applications of AAN3 will be described,
but for routine mass shifts in IMS applications, the +37.0316 Da AAXL
derivatization is more effective.
Figure 32E-I shows the corresponding glycan intensity maps for the
underivatized, AA, AAXL and AAN3 sialylated isomers. The residual unlabeled
peak at m/z 1954.6768 in the AA, AAXL and AAN3 derivatization scheme is easily
visualized (Figure 32E). Interestingly, although the dimethylamidated α2,6-linked
isomer peak at m/z 1981.7241 appears in all three derivatized data sets, its
expression is markedly lower in the AA-treated tissue when compared to either the
AAXL or AAN3-treated cases (Figure 32I). Ammonium hydroxide has been
demonstrated to release N-linked glycans by β-elimination in previous studies449.
We hypothesize that the use of ammonia hydroxide to decyclize the α2,3-lactone
in AA eliminates a portion of the tissue’s total N-glycans and thus suppresses
overall signal when compared to AAXL and AAN3. This assertion is bolstered by
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Figure 34. Structural Determinations and Labeling Confirmation by CID.
Collision-induced dissociation MS/MS spectra for 4 representative N-glycans
derivatized by AAXL. Glycan fragments containing a derivatized sialic acid are
labeled in purple. A) Hex5HexNAc4(α2,6)NeuAc1, m/z 1981.7241. B)
Hex5HexNAc4(α2,3)NeuAc1,
m/z
1991.7104.
C)
Hex5dHex1HexNAc4(α2,6)NeuAc1,
m/z
2127.7820.
D)
Hex5dHex1HexNAc4(α2,3)NeuAc1, m/z 2137.7663.
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the suppression of non-sialylated glycan signals in the AA-treated tissue as well.
Ultimately, the data suggests that AAXL presents an optimal derivatization strategy
for resolving sialic acid isomers by IMS.
4.5.2 Detection of Multiply-Sialylated, High Mass N-glycans by AAXL
A prostate tumor tissue with larger mass multi-sialylated N-glycans localized
to tumor regions was assessed for how effective AAXL modification was for
stabilizing sialic acids (Figure 35). The tumor regions are highlighted in Figure 35A
and 35B, and this tissue was derivatized with AAXL and prepared for N-glycan
IMS. All isomeric combinations of the doubly sialylated, tri-antennary N-glycan
Hex6dHex1HexNAc5NeuAc2 are shown in Figure 35C-E and are overlaid in
Figure 35F. Figure 35G-K shows the triply-sialylated version of the same base
glycan, with distinct detection of the full spectrum of sialylated isomers. Similar but
non-overlapping distribution patterns for these glycans were observed, possibly
indicating the compartmentalization of α2,3 and α2,6 sialyltransferases to different
tissue regions. Taken together, these experiments demonstrate the potential of
AAXL for the analysis of multiply-sialylated glycans which are normally difficult to
detect and differentiate by traditional IMS approaches.
4.5.3 AAXL Derivatization of Serum Glycoproteins
A slide-based serum N-glycan analysis workflow was evaluated for AAXL
derivatization of serum glycoproteins (Figure 36A)445. AAXL-labeled spotted serum
slides were prepared as described in Materials and Methods and compared to nonderivatized controls and blank wells for background subtraction. Expected mass
shifts of +27.0473 Da and +37.0316 Da for the α2,6- and α2,3 sialic acid isomers,
172
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Figure 35. Detection of Multiply-Sialylated N-glycans After Derivatization by AAXL. A prostate cancer FFPE tissue
section was labeled with AAXL then analyzed by N-glycan IMS. A) post-acquisition H&E staining image. B) enlarged region
of mucinous tumor tissue. Intensity heatmaps for three di-sialylated isomers C) Hex6dHex1HexNAc5(α2,6)NeuAc2 (m/z
2811.0569),
D)
Hex6dHex1HexNAc5(α2,6)NeuAc1(α2,3)NeuAc1
(m/z
2821.0412)
and
E)
Hex6dHex1HexNAc5(α2,3)NeuAc2 (m/z 2831.0255) overlaid in blue, green and red, respectively, in F). Intensity heatmaps
for
four
tri-sialylated
isomers
G)
Hex6dHex1HexNAc5(α2,6)NeuAc3
(m/z
3129.1996),
H)
Hex6dHex1HexNAc5(α2,6)NeuAc2(α2,3)NeuAc1 (m/z 3139.1839), I) Hex6dHex1HexNAc5(α2,6)NeuAc1(α2,3)NeuAc2
(m/z 3149.1682) and J) Hex6dHex1HexNAc5(α2,3)NeuAc3 (m/z 3159.1525) overlaid in blue, green, red and yellow,
respectively, in K).

Figure 36. Analysis of Sialylation Patterns in Human Serum Enabled by
AAXL. Human serum samples were analyzed by N-glycan IMS after derivatization
by AAXL. A) incorporation of AAXL into a standard biofluid N-glycan analysis
workflow between immobilization and deglycosylation. B) mass-shifted α2,6- (m/z
1981.7241)
and
α2,3(m/z
1991.7104)
sialylated
isomers
of
Hex5HexNAc4NeuAc1 detected in AAXL-labeled serum samples. C) Relative
intensities of the unlabeled (m/z 1954.6768, NeuAc1) and mono-sialylated (m/z
1981.7241, α2,6NeuAc1; m/z 1991.7104, α2,3NeuAc1) isomers of
Hex5HexNAc4NeuAc1 as well as the unlabeled (m/z 2319.8090, NeuAc1; m/z
2610.9044, NeuAc2; m/z 2901.9998, NeuAc3) and mono- (m/z 2346.8563,
α2,6NeuAc1; m/z 2356.8406, α2,3NeuAc1), di- (m/z 2664.9990, α2,6NeuAc2; m/z
2674.9833, α2,6NeuAc1α2,3NeuAc1; m/z 2684.9676, α2,3NeuAc2) and trisialylated
(m/z
2983.1417,
α2,6NeuAc3;
m/z
2993.1260,
α2,6NeuAc2α2,3NeuAc1; m/z 3003.1103, α2,6NeuAc1α2,3NeuAc2; m/z
3013.0946, α2,3NeuAc3) isomers of Hex6HexNAc5NeuAc1,2,3 with
accompanying representative images of the most abundant sialylated isomer.
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respectively, were observed in the AAXL-treated serum and absent from the
unlabeled control serum (Figure 36B). Figure 36C shows the relative intensities of
the derivatized and underivatized peaks for the mono-sialylated glycan
Hex5HexNAc4NeuAc1

as

well

as

the

mono-,

di-

and

tri-sialylated

Hex6HexNAc5NeuAc1,2,3 with a representative image of the predominantly
detected isomer for each set appended below. In serum, labeling efficiency
remained comparable to that of FFPE tissues, ranging from 91 – 96%. A lack of
signal in the unlabeled serum samples confirmed the specificity of the AAXLshifted peaks to only the derivatized serum samples. These experiments establish
the utility of AAXL for analyzing sialylation from serum and suggest expanded
applicability of the approach to clinical biofluids.
4.5.4 Applications of AAXL for Studying Sialylation in Cultured Cells
A previously published workflow for N-glycan IMS of fixed cells on glass
microscope slides was adapted for AAXL derivatization203. Briefly, four pancreatic
cancer cell lines (PANC1, ASPC1, HPAC, PL45) were cultured under normal
conditions in chambered array glass slides with MALDI source target frame
compatible dimensions. Ten thousand cells per well were allowed to adhere
overnight followed by fixation in neutral buffered formalin. Fixed cells were then
briefly washed in PBS before undergoing derivatization by AAXL in a protocol
identical to that for FFPE tissues. The overall workflow for culturing, fixing and
derivatizing the cells is outlined in Figure 37A. Representative N-glycan IMS data
of an α2,6- (m/z 2127.7820) and an α2,3- (m/z 2137.7663) sialylated glycan is
shown in Figure 37B and 37C, respectively. AAXL demonstrated quantifiable
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Figure 37. AAXL and IDAWG Analysis Reveals the Glycobiology of Cultured
Cells. Applications of AAXL for studying sialylation in PANC1, ASPC1, HPAC and
PL45 pancreatic cancer cell lines. A) incorporation of AAXL into a standard
workflow for N-glycan IMS of cultured cells. B) a representative α2,6-sialylated Nglycan Hex5dHex1HexNac4(α2,6)NeuAc1 (m/z 2127.7820) with differential
expression patterns between the four profiled cell lines. C) the α2,3-sialylated
isomer Hex5dHex1HexNAc4(α2,3)NeuAc1 (m/z 2137.7663) exhibiting alternate
patterns distinct from its α2,6-counterpart. D) relative quantification of the α2,6(m/z 2127.7820) and α2,3- (m/z 2137.7663) isomers showing significant
differences between the lines profiled. E) AAXL drives more distinct clustering of
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the cell lines in PCA plots. F) isotopic detection of aminosugars with glutamine
(IDAWG) approach followed by AAXL derivatization and N-glycan IMS. G) HPAC
biosynthesis curves assessed by incorporation of 15N isotope into
Hex5dHex2HexNAc4NeuAc1 α2,6- (m/z 2273.8399) and α2,3- (m/z 2283.8242)
isomers. H) AAXL suggests alternative regulation of an isomer-separated N-glycan
in HPAC cells treated with chemotherapeutics.
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expression differences for these isomeric glycans between the cell lines profiled
(Figure 37D). The differences and similarities between the N-glycomes of the four
cell lines were assessed by principal component analysis (PCA) (Figure 37E), with
and without AAXL derivatization. Inclusion of AAXL-derivatized N-glycans in the
PCA result in discrete clusters specific to each cell line. For non-AAXL derivatized
N-glycan PCA analysis, the cell lines aggregate into less-defined clusters with
more overlap. Thus, the inclusion of specific sialic acid isomer linkages helps
distinguish the cell line glycomes from each other in the PCA analysis.
Further, AAXL derivatization was combined with an established stable
isotope labeling by amino acids in cell culture (SILAC)450 using an isotopic
detection of aminosugars with glutamine (IDAWG) labeling experiment 446. As
glutamine

is a

precursor

nitrogen

donor

for the

biosynthesis

of

N-

acetylglucosamine, N-acetylgalactosamine and N-acetylneuraminic acid (sialic
acid), a glycan metabolically synthesized in

15N-glutamine

media would gain a ~1

Da mass shift per incorporated aminosugar. As an example, synthesis of the
common glycan Hex5dHex1HexNAc4 (m/z 1809.6393) in

15N

media would

incorporate four heavy-labeled N-acetylglucosamine monomers that would shift its
mass to 1813.6140 Da, which allows it to be discriminated from a nominal mass
glycan synthesized prior to introduction of the labeled media. The overall
experimental design is outlined in Figure 37F. Briefly, cells were again cultured in
chambered slides with media containing

14N

glutamine and allowed to adhere

overnight. At time zero (T0), the light-labeled media was substituted for media with
heavy-labeled

15N-glutamine

and a previously determined amount of a common
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pancreatic

cancer

chemotherapeutic

agents

(5-fluorouracil,

Gemcitabine,

Irinotecan or Oxaliplatin) were added (Figure 38). Cells were monitored over a
three-day time period where slides were fixed at 24, 48 and 72 hours, derivatized
with AAXL and then prepared for N-glycan IMS. Untreated replicates were
prepared alongside the treated cells as a control for normal N-glycan metabolic
turnover.
Figure 37G shows representative growth curves from the HPAC cell line for
two sialylated N-glycans which differ only in which sialic acid isomer they contain.
Here, %15N incorporation was measured by the intensity of the heavy labeled peak
as a percentage of the total light-labeled and heavy-labeled peak intensities over
time, which was controlled for overlap between the +5 isotope of the
and

the

+5

Da

mass-shifted

Hex5dHex2HexNAc4(α2,6)NeuAc1

15N-labeled

(14N

m/z

glycan.

The

2273.8399,

14N

glycan

α2,6-sialylated

15N-labeled

m/z

2278.8083) exhibited relatively linear biosynthesis in the untreated condition over
the 72H period resulting in 49% labeled out of the total population at the end of the
experimental duration. Treatment with the chemotherapeutics seemed to increase
the relative production of this α2,6-sialylated glycan as compared to the control
cells, where at 72H all treated conditions were between 79 – 93% labeled. The
α2,3-linked Hex5dHex2HexNAc4(α2,3)NeuAc1 (14N m/z 2283.8242,

15N-labeled

m/z 2288.7926) exhibited an opposite effect, where treatment with any of the
therapeutics decreased the initial synthesis rate as compared to the untreated
control, yet both untreated and treated cells had synthesized similar amounts of
the α2,3-sialylated isomer after 72H (84 – 95% incorporation). These data suggest
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Figure 38. Dose Response Curves to Establish Chemotherapeutic IC50.
PANC1, ASPC1, HPAC and PL45 cell lines were treated with 1 nM, 10 nM, 100
nM, 1 µM, 10 µM and 100 µM 5-fluorouracil, Gemcitabine, Irinotecan or Oxaliplatin
and cell viability was assessed at 72H by trypan blue exclusion assay. Curve fitting
for IC50 determination using 4-parameter variable slope non-linear regression
analysis of log10-transformed concentrations versus percent survival.
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the specific, differential regulation of two N-glycans distinguished exclusively by
their sialic acid isomers in response to chemotherapeutic antagonists (Figure 37H).
Overall, we demonstrate the potential for AAXL to augment established cell culture
experiments to provide mechanistic insights into the fundamental regulation of
sialylation.
4.5.5. Comparison of AAXL and AAN3 for Click-enabled IHC

As the AAXL and AAN3 derivatizations are effective in FFPE tissues, the
ability to biotinylate the derivatized α2,3-linked sialic acids was evaluated for use
with established streptavidin-based staining methods451. In initial experiments,
AAXL-treated FFPE pancreatic cancer tissue sections were further reacted with a
biotin-azide conjugate in the presence of a CuSO 4 catalyst as described for the
model sialylated compounds and proteins. Similarly, adjacent tissue slides were
treated with AAN3 and reacted with biotin-alkyne. The resulting biotinylated α2,3linked sialic acids were then used to capture a streptavidin-fused HRP for staining
with DAB chromogen (Figure 38). As shown in Figure 39A, the AAXL-biotinylated
tissue had minimal DAB staining, while the AAN3-biotinylated tissue had robust
staining (Figure 39B). The reaction condition summary for AAN3 and the biotinalkyne conjugate are provided in Table 13. As a control, a serial tissue section was
treated with both AAN3 and the biotin-alkyne, omitting the copper catalyst (Figure
39C). Without CuSO4 the azide-alkyne cycloaddition does not occur, and
accordingly, no DAB staining was observed in this control tissue. An additional
control was done on a different tissue section pre-treated with pan-sialidase to
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Figure 39. Comparing AAXL and AAN3 for Histochemistry Applications. Pancreatic cancer FFPE tissue serial sections
were derivatized by AAXL or AAN3 then biotinylated by click chemistry for streptavidin-based histochemical staining
alongside technical controls. A) the AAXL-treated tissue showed little to no DAB staining after click and probing with
streptavidin-HRP. B) intense DAB chromogen staining after click-enabled HC in the AAN3-derivatized tissue. C) omission
of the CuSO4 click-catalyst prevented biotinylation and subsequent DAB staining. D) exoglycosidase removal of sialic acids
by neuraminidase attenuates AAN3 staining.

Table 13. CuAAC Mixture for AAN3.
MW
(g/mol)
A
B
C
D
E
F

Reagent Stock
Prep
(per 1 mL H2O)
7.0 mg†
3.2 mg
20.0 mg
21.7 mg
11.0 mg

[Reagent Stock]

Volume
Stock
Solution
20.0 µL
2.5 µL
25.0 µL
5.0 µL
25.0 µL
422.5 µL
500.0 µL

[Reagent]

Biotin-alkyne
281.12
25 mM
1.0 mM
CuSO4
159.61
20 mM
0.1 mM
Sodium ascorbate
198.11
100 mM
5.0 mM
THPTA
434.50
50 mM
0.5 mM
Aminoguanidine HCl 110.55
100 mM
5.0 mM
10X PBS
Overall Volume
† in DMSO/H O, v/v 1:1
2
Mix B and D and A and F in separate Eppendorf tubes. Sequentially add B&D mixture, E and C to
A&F mixture. Reagents A, B, D, E and F may be prepared ahead of time. 100 mM sodium
ascorbate must be prepared day of.
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remove sialic acids prior to AAN3 derivatization and biotinylation. As shown in
Figure 39D, the sialidase treated tissue showed minimal to no DAB staining after
click-enabled histochemistry, Thus, the data suggests that AAN3 and biotin alkyne
treatments have little to no reactivity to non-sialylated targets.
4.6 Discussion
In the present study, we have developed a multi-functional isomer-targeted
sialic acid derivatization strategy compatible with clinical tissues, biofluids and
cultured cells. The AAXL and AAN3 approach synergizes the established
workflows for amidation of the lactone intermediate in α2,3-linked sialic acids421,427,
bioorthogonal sugar azides and alkynes432, and N-glycan imaging mass
spectrometry204,206,441 resulting in new tools with unique features. First, it can be
used to specifically introduce bioorthogonal groups into α2,3 and α2,8 sialic acids
attached to proteins, and likely lipids, but not α2,6 sialic acids and other
carboxylate containing moieties. Second, the AAXL and AAN 3 reactions will
incorporate an alkyne or azide onto sialic acids without the need for a living system
with active metabolic machinery or externally added glycosyltransferases and
substrates. As demonstrated, the method can be applied to tissues preserved as
formalin-fixed paraffin embedded blocks, the standard used worldwide for storing
surgical specimens. Thus, there are potentially millions of clinical and experimental
tissue samples available as targets for the approach. Fixed cells (Figure 37),
biofluids (Figure 36) and tissues prepared by other methods than FFPE fixation
are additional targets. Third, the reagents used for the direct AAXL and AAN3
chemical reactions are affordable, readily available and components of established
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chemical labeling workflows. Incorporation of AAXL/AAN3 into a standard N-glycan
IMS workflow adds only 4 hours of sample preparation with routine labeling
efficiencies of 95% in clinical tissues and biofluids (Figure 33, Figure 36).
Currently, AAXL uses a propargylamine handle which is small and ionizes
well, making it ideal for IMS applications (Figure 32). We anticipate that
applications of AAXL to tissues and biofluids could lead to clinically useful tools to
characterize sialylated cancer biomarkers more accurately by increasing the
specificity with which isomeric configurations are detected, particularly in MALDI
mass spectrometry-based assays. In solution, like that done for the standards and
model glycoproteins, AAXL is very effective at introducing an alkyne for further
reactions (Figure 29, Figure 31). For other applications that require click chemistry
conjugation directly on the tissue slide, the short alkyne chemical handle installed
by AAXL may not provide enough distance from the hydrophobic tissue surface to
facilitate efficient reaction with the aqueous click chemistry reagents. Overall, DAB
staining with AAXL on tissues has been variable and inconsistent (Figure 39A). In
contrast for AAN3, which contains a PEG linker extending the azide further away
from the tissue, it may be more ideally suited for further click chemistry conjugation
of imaging reporters. The AAN3 treated pancreatic tissue showed intense DAB
chromogen staining indicating a successful HRP capture and thus a highly
effective biotinylation of α2,3-sialic acids (Figure 39B) with specificity (Figure 39C
and 39D). Another possibility for these types of applications is use of amine-azides
(or amine-alkynes) separated by a cleavable linker452,453. A theoretical system
employing a cleavable label could allow for efficient biotinylation and subsequent
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histochemical staining, then, once chemically or enzymatically cleaved, act as a
small, IMS-compatible mass tag to generate multiplexed data from the same tissue
section.
In summary, we have developed a novel set of sialic acid derivatization
approaches which can be tuned for IMS or bioorthogonal click labeling applications
depending on the secondary labeling agent used. AAXL is applicable to multiple
sample types and has demonstrated utility in differentiating between sialic acid
isomer in imaging mass spectrometry experiments. AAXL compliments biofluid Nglycan imaging workflows developed in our lab which are already being explored
for their clinical utility. We envision a role for AAXL in detecting sialylated disease
biomarkers as part of a clinical diagnostic evaluation of plasma or serum Nglycosylation. AAN3 enables the visualization of α2,3-and α2,8-sialylated glycans
by histochemical staining and is better suited for on- tissue click chemistry
reactions than is AAXL. Currently, distinguishing whether an AAXL or AAN3labeled sialic acid observed by IMS or histochemistry is in the α2,3 or α2,8
configuration is a work in progress. Differential treatment with isomer-specific
sialidases to clear the tissue of one or more isomeric linkage prior to labeling and
staining is being evaluated. Introduction of the bioorthogonal click chemistry
reagents by AAXL and AAN3 affords many new research strategies for sialic acid
isomer targeted visualization and glycoproteomic workflows, discussed further in
Chapter 5.
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Chapter 5: Advanced Bioorthogonal Applications of
Azide Amidation
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5.1 Introduction
The development of a click chemistry amenable azide amidation protocol
(AAN3) in Chapter 4 and its successful implementation in a biotin-avidin-based
histochemical staining approach led us to further speculate on more advanced
click chemistry applications. The simplicity of click chemistry is key to its
widespread applicability: an alkyne-cargo links to a biomolecule-azide (or an azidecargo with biomolecule-alkyne in the reversed sense) in a selective reaction which
is generally indifferent to the conjugates. Thus, the introduction of bioorthogonal
azide or alkyne handles into living systems serves as a starting point for further
modifications with various labeling agents, probes and reporters. This also allows
for specific conjugation of tagged molecules on beads, chromatography columns
or surfaces, all facilitated by copper- or otherwise-catalyzed azide alkyne
cycloaddition

reactions

(CuAAC)429,431,432,443,454.

Many

sialic

acid-targeted

bioorthogonal applications have been developed, some of which use azido sugar
analogues like azidoacetylmannosamine (Ac4ManNAz)436,437,455. Glycoengineered
cell libraries with 60+ click-modified Ac4ManNAz sialic acid variants dramatically
increased epitope affinity in siglec binding screens456. Modification of sialic acids
with azido-sugars introduces a searchable mass tag onto sialylated peptides and
may serve as the attachment point for further derivatization agents to boost
ionization efficiency in glycoproteomic experiments457. Novel drug delivery
approaches have also capitalized on this technology, where azido-sugar
glycoengineered viral envelopes are modified with cancer-targeting motifs to home
oncolytic viral vectors to the tumor458,459. A limitation inherent to all of these
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techniques, however, is that they require living systems to provide metabolic
machinery to uptake and metabolize the derivatives for incorporation into cellular
glycoconjugates. As demonstrated in Chapter 4, our derivatization scheme does
not require such biological machinery and thus is applicable to clinical tissue and
biofluid samples which are typically not targeted by bioorthogonal sugar analog
approaches.
Direct detection of sialic acids by fluorescence imaging is historically
challenging. The ability of individual sialic acid sugar monomers to rotate around
the axes of their bonds as part of a larger structure, combined with the complexity
of multiply branched linkages in N-glycans, results in an epitope topology that is
constantly in flux. Accordingly, carbohydrate-binding fluorescent probes designed
to target sialic acids often lack the specificity or affinity conferred by antibodies in
immunofluorescence experiments. These shortcomings notwithstanding, lectin,
antibody and recombinant protein bioaffinity probes are frequently used to profile
sialylation in cells and tissues or are fluorescent tags for flow cytometry and other
separation techniques460. Recombinant sialyltransferases offer an alternate
labeling approach for imaging through the direct attachment fluorophoreconjugated sialic acid analogues to N- and O-linked glycans461. Whether or not
these recombinant enzymes and their xenobiotic substrates have an impact on the
natural glycobiological functions of the cell, however, is an open question. An
obvious application of azido-sugar-based bioorthogonal strategies is labeling sialic
acids with click chemistry fluorescent probes, which has been successfully
demonstrated by multiple groups462–465. Common to all of these approaches is the
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loss of sialic acid linkage information and subsequently insights into isomerspecific biological functions.
Enrichment of sialylated glycoproteins has been traditionally done using
affinity chromatography techniques coupled to LC-MS/MS. Titanium dioxide,
hydrazine chemistry, strong cation exchange, silica dioxide and other liquid
chromatography (LC) column formats take advantage of the charged sialic acid
carboxylate group to retain sialylated glycoconjugates, however any sufficiently
charged molecule will co-elute with analytes of interest, complicating downstream
analysis466,467. Lectin affinity chromatography using a wheat germ agglutininconjugated (WGA) stationary phase often can enrich sialylated species from a
general matrix of released glycans, although the affinity of WGA for GlcNAccontaining carbohydrates precludes specific capture468. Bead formats offer an
alternate to chromatography for solid phase enrichment and allow for expanded
purification, desalting or derivatization treatments prior to mass spectrometry
analysis. Early enrichment approaches with hydrazide beads used harsh reaction
conditions which limited the number of identifiable glycans and glycopeptides 469.
More recently, Lingjun Li and colleagues demonstrated the use of azide-beads to
oxidize, alkylate and covalently enrich sialylated glycopeptides through click
chemistry for analysis by LC-MS/MS439. Regrettably, the aforementioned
approaches forgo the ability to be isomer selective in favor of bulk capture of
sialylated glycoconjugates.
Chapter 5 details the development of two new protocols, one for fluorescent
labeling of sialic acid-containing molecules and the other for selective enrichment
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and proteomic analysis of sialylated glycoproteins, both of which are further click
chemistry applications of the azide amidation (AAN3) derivatization strategy
presented in Chapter 4. Accordingly, both strategies are isomer specific to α2,3
and α2,8 sialic acid linkages. The first approach, Sialic Acid Fluorescent
Enhancement Reaction (SAFER), biotinylates AAN3-derivatized α2,3 and α2,8
sialic acids with a biotin-alkyne conjugate which is used to further capture a
streptavidin fluorescent dye. SAFER was initially tested in both FFPE tissue
sections and fixed, cultured cells. After the click reaction SAFER follows a standard
immunostaining protocol, therefore we envision that this technique may one day
be used in conjunction with other fluorescent probes to link the expression of sialic
acids to specific molecules or tissue features of interest. The second approach
stemming from AAN3, Sialic Acid Bead Enrichment Reaction (SABER) uses a
streptavidin-resin

to

enrich

click-biotinylated

α2,3-

and

α2,8-sialylated

glycopeptides from the tissue milieu followed by on-bead digestion, purification and
proteomic analysis by LC-MS/MS. An initial comparison was made between a
SABER-enriched, AAN3-derivatized prostate cancer FFPE tissue and a nonenriched serial tissue section to test SABER’s ability to select for α2,3 and α2,8
sialylated species from the total glycoprotein matrix. Although still in development,
SABER has the potential to not only gain information on the α2,3 and α2,8sialylated proteins in a sample, but to gain site and N-glycan specific detail through
expanded functionality. Together, these two extended applications broaden the
reach of AAN3 beyond imaging mass spectrometry to provide a cross-disciplinary
tool set to study sialylation in biological systems.
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5.2 Materials and Methods
5.2.1 Materials
1X phosphate-buffered saline (PBS), 12M HCl, 1M tris HCl pH 8, 16%
formaldehyde, acetone, acetonitrile (ACN), citraconic anhydride, formic acid,
HPLC H2O, methanol, Pierce Microplate BCA Protein Assay Kit, sodium chloride,
StageTips (C18), streptavidin-Cy5, trifluoroacetic acid (TFA), trypsin protease
(MS-grade), Tween-20 and xylenes were obtained from ThermoFisher Scientific
(Waltham, MA). 1,2-cyclohexanedione, 10M sodium hydroxide (NaOH), 2-2-2trifluoroethanol (TFE), ammonium bicarbonate, bovine serum albumin (BSA),
calcium

chloride,

DL-dithiothreitol

(DTT),

iodoacetamide

(IAA),

tris(2-

carboxyethyl)phosphine hydrochloride (TCEP), sodium cyanoborohydride, sodium
phosphate monobasic monohydrate and ZipTips (µ-C18) were obtained from
Sigma (St. Louis, MO). Ethanol (EtOH) was obtained from Decon Labs (King of
Prussia, PA). Streptavidin Sepharose high-performance affinity resin was obtained
from Cytiva (Marlborough, MA). VectaShield Hardset with DAPI was obtained from
Vector Laboratories (Newark, CA). Triton-X 100 was obtained from MP
Biomedicals (Irvine, CA). AsPC-1 human pancreatic cancer cells (CRL-1682),
HPAC human pancreatic carcinoma cells (CRL-2119), PANC-1 human pancreatic
carcinoma cells (CRL-1469), PL45 human pancreatic carcinoma cells (CRL-2558)
and Trypsin-EDTA solution were obtained from ATCC (Manassas, VA).
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5.2.2 SAFER
5.2.2.1 SAFER Sample Preparation
Prior to SAFER staining, prostate cancer FFPE tissue slides were
derivatized with AAN3 and biotinylated via click chemistry as described in Chapter
4, sections 4.4.2 and 4.4.9. Alongside the FFPE tissues, PANC1, ASPC1, HPAC
and PL45 pancreatic cancer cells were cultured and fixed as described in section
4.4.7203, then derivatized and biotinylated as were the tissues. Desiccated AAN3biotinylated tissue and cell slides were rehydrated in 1X phosphate-buffered saline
(PBS) for 2 min twice, antigen retrieved in citraconic anhydride buffer (25 µL
citraconic anhydride, 2 µL 12 M HCL, 50 mL HPLC-grade H2O, pH 3.0 ± 0.5) for
20 min in a preheated vegetable steamer then cooled at RT on the benchtop for
30 min. Once cooled, slides were washed in 1X PBS for 5 min twice, then the
tissues were outlined with a hydrophobic barrier pen. The slides were then blocked
in 200 – 500 µL PBST (0.05% Triton-X 100 in 1X PBS) with 3% bovine serum
albumin (BSA) added for 1 hr at RT. Blocked slides were then placed in a humidity
chamber and incubated in 10 µg/mL streptavidin-Cy5 in PBST for 2 hr at RT in the
dark. After incubation, slides were washed with PBST for 3 min twice then in 1X
PBS for 3 min. Finally, slides were dried with a kimwipe, sealed with a DAPIcontaining mounting medium and allowed to dry overnight before imaging.
5.2.2.2 Fluorescence Microscopy
SAFER-labeled FFPE tissue slides were imaged the next day after
overnight drying on an AMG EVOS cell imaging system (ThermoFisher Scientific,
Waltham, MA) which captured both DAPI (357 nm) and Cy5 (635 nm)-stimulated
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emission spectra. 16-bit monochromatic raw images were background subtracted
using a rolling ball radius of 50 px in Image J then transferred to Adobe Photoshop
for brightness adjustment and overlay in separate RGB channels to prepare
figures. All images presented as comparisons were captured with uniform imaging
parameters and manipulated equally post-acquisition.
5.2.3 SABER
5.2.3.1 Sample Preparation
Prior to SABER enrichment, prostate cancer FFPE tissue slides were AAN3
derivatized followed by click chemistry biotinylation as described in Chapter 4,
sections 4.4.2 and 4.4.9. Derivatized, biotinylated tissue slides were antigen
retrieved in citraconic anhydride buffer (25 µL citraconic anhydride, 2 µL 12 M HCL,
50 mL HPLC-grade H2O, pH 3.0 ± 0.5) for 30 min in a decloaker then buffer
exchanged at room temperature and dried in a desiccator for 15 min. After drying,
antigen-retrieved tissues were scraped from the glass slide into low-bind
Eppendorf tubes using a clean razor blade. 50 µL 25 mM ammonium bicarbonate
(AMBIC) and 50 µL 2-2-2-trifluoroethanol (TFE) were added to each scraped tissue
and the samples were sonicated 20 sec on and 30 sec off three times while on ice.
Sonicated tissue samples were briefly spun down then incubated at 60°C for 1 hr
on a thermomixer at 300 rpm. Following incubation, the tissue samples were
sonicated a second time as described above.
Sonicated tissue homogenates were cooled on ice for 5 min then reduced
with 1 µL 1M tris(2-carboxyethyl)phosphine hydrochloride (TCEP) in AMBIC and 5
µL 500 mM DL-dithiothreitol (DTT) in AMBIC for 30 min at 60°C. After incubation,
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the reduced homogenate was alkylated with 11 µL 500 mM iodoacetamide (IAA)
in AMBIC at RT for 40 min in the dark. Following alkylation, 383 µL AMBIC was
added to each sample to reduce the overall TFE concentration, samples were
centrifuged at 4°C for 5 min at 15,000 rpm and the protein-containing supernatant
was transferred to a new low-bind Eppendorf tube.
5.2.3.2 SABER Enrichment
Prior to enrichment, streptavidin resin was treated for protease resistance
according to a previously published protocol470. Briefly, streptavidin beads were
resuspended by inversion then 5 mL resin slurry was centrifuged at 1000 g for 5
min, after which the supernatant suspension buffer was discarded leaving only the
resin pellet. Pelleted resin was washed in 10 mL PBST (100 µL Tween-20 in 100
mL 1X PBS), centrifuged at 1000 g for 5 min and the supernatant was discarded.
Washed resin was resuspended in 14 mL CHD (120 mg 1,2-cyclohexanedione in
14 mL PBST, pH 13) then incubated rotating end-over-end for 4 hr at RT. After
incubation, the resin was centrifuged at 1000 g for 5 min and the CHD was
disposed of. Next, the resin was washed in 10 mL PBS, centrifuged at 1000 g for
5 min and the wash supernatant was discarded. Washed resin was resuspended
in 7 mL reagent A (2 mL 16% formaldehyde in 6 mL PBST), 7 mL reagent B (0.101
g sodium cyanoborohydride in 8 mL PBST) was added and the resin was
incubated at RT for 2 hr rotating end-over-end. After incubation in reagents A and
B, the resin was centrifuged at 1000 g for 5 min and the supernatant was
discarded. The resin pellet was then washed in 10 mL 0.1 M tris-HCl, pH 8 followed
by washing in 10 mL PBST with centrifuging and supernatant disposal in between
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as described. The washed resin was then finally resuspended in 5 mL PBST prior
to use.
The protease-resistant streptavidin resin was inverted to homogenize then
200 µL of the resulting slurry was transferred to a low-bind Eppendorf tub using a
wide-aperture pipette tip. 1800 µL binding buffer (20 mM sodium phosphate
monobasic monohydrate, 0.15 M NaCl) was added to the resin which was then
vortexed gently to wash and centrifuged at 1000 g for 5 min at which point the
supernatant was discarded. This wash procedure was repeated an additional four
times. Alkylated and reduced proteins were diluted with 1 mL binding buffer then
applied to the washed streptavidin resin and rotated end-over-end in the dark for
1 hr at RT to bind. Following binding, the resin was centrifuged at 1000 g for 5 min
and the supernatant was discarded without disturbing the resin pellet. The resinbound proteins were resuspended in 1800 µL binding buffer to wash away
unbound proteins, centrifuged at 1000 g for 5 min and the wash was discarded.
This washing step was repeated an additional nine times with binding buffer
followed by two washes in HPLC H2O and two washes in AMBIC to remove binding
buffer salts. The washed resin pellet was then stored on ice in preparation for
tryptic digestion.
Trypsin protease was diluted to 0.1 µg/µL in digestion buffer (100 mM trisHCl, 2 mM CaCl2, pH 8). The washed protein-resin complex was resuspended in
500 µL digestion buffer, 20 µL 0.1 µg/µL trypsin (2 µg) was added and the samples
were digested overnight at 37°C rotating end-over-end. After incubation, the resin
was centrifuged at 1000 g for 5 min then the digest supernatant was transferred to
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a new low-bind Eppendorf tube. The remaining resin pellet was gently
resuspended in 500 µL HPLC H2O, centrifuged at 1000 g for 5 min and the wash
supernatant transferred to the new Eppendorf tube. The resulting peptide digest
was then acidified with 2 µL trifluoroacetic acid (TFA), dried under vacuum
centrifugation and stored at -20°C prior to sample clean up.
5.2.3.3 Peptide Cleanup
Peptides were desalted with stop and go extraction (STAGE) tips according
to the manufacturer’s supplied protocol. Briefly, STAGE tips were retained by a
plastic adapter in low-bind Eppendorf tubes then initialized with 50 µL initialization
solution (5 mL formic acid and 15 mL HPLC H2O in 80 mL acetonitrile) by
centrifugation at 2000 g for 3 min. Following initialization, the tips were reequilibrated with 50 µL equilibration solution (5 mL formic acid in 95 mL HPLC
H2O) by centrifugation at 2000 g for 3 min. The STAGE tip and adapter were then
transferred to a new tube and the peptide digest – resuspended in 100 µL
equilibration solution – was applied to the tip. The samples were then centrifuged
at 2000 g for 15 min, the flowthrough was re-applied to the tip and residual peptides
were bound to the tip by centrifugation again at 2000 g for 15 min. The samplebound tips were then washed with 50 µL wash solution (5 mL formic acid in 95 mL
HPLC H2O) by centrifugation at 2000 g for 3 min three times. After washing, the
STAGE tip and adapter were transferred to a new Eppendorf tube and the peptides
were eluted from the column material with 50 µL elution solution (5 mL formic acid
and 15 mL HPLC H2O in 80 mL acetonitrile) by centrifugation at 2000 g for 3 min
3 times. 30 µL eluate was transferred to a separate tube for protein content
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analysis by BCA then the remaining peptides were dried under vacuum
centrifugation and stored at -20°C.
Following STAGE tip desalting, protein concentration in the samples was
assessed by BCA protein assay using a Pierce Microplate kit (ThermoFisher
Scientific, Waltham, MA). This was necessary to ensure that ≥ 2 µg peptides were
retained after STAGE tip cleanup to ensure a saturating amount of material for the
Zip Tip clean up step. The kit-provided protocol was followed and the results were
measured at 562 nm on a SpectraMax M3 microplate reader (Molecular Devices,
San Jose, CA). The resulting BSA standard absorbance values were plotted in
excel and used to construct a standard curve from which sample protein
concentrations were calculated. After the concentrations were determined to be ≥
2 µg, the samples were cleaned up by Zip Tip.
STAGE tip cleaned samples were applied µ-C18 ZipTips capable of binding
a total of 2 µg to desalt the digest and standardize the amount of peptide across
the samples. The C18 microcolumn tips were attached to the pipette for cleanup,
where solutions and samples were drawn into and expelled out of the tip. ZipTips
were hydrated with 10 µL acetonitrile (ACN) in triplicate which was disposed to
waste each time. Rehydrated tips were equilibrated with 10 µL equilibration
solution (1 µL TFA in 1 mL HPLC H2O) 3X which also was dispensed to waste
each time. Dried, STAGE tip-desalted peptide samples were reconstituted in 30
µL equilibration solution then bound to the microcolumn through aspiration and
dispensing of 30 10 µL volumes of reconstituted sample into and out of the ZipTip.
Bound samples were then washed with 10 µL washing solution (1 µL TFA and 5
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µL methanol in 994 µL HPLC H2O) 10 times, with the wash dispensed to waste
each time. Peptides were eluted from the tips through aspiration of 10 µL elution
solution (1 µL TFA in 500 µL ACN and 500 µL HPLC H2O) into the tip which was
then dispensed into a new collection tube. This elution step was repeated three
more times for a total elution volume of 40 µL, then the cleaned and desalted
peptides were dried under vacuum centrifugation and stored at -20°C until LCMS/MS analysis.
5.2.3.4 Glycoproteomic Analysis

Peptides were analyzed by LC-MS/MS on an EASY 1200 nanoLC in-line
with an Orbitrap Lumos Tribrid mass spectrometer (ThermoFisher) running
instrument control software version 4.2.28.14. A maximum of 2 μg of tryptic
peptides were pressure loaded at 1,180 bar on to a reversed phase C18 column
(Acclaim PepMap RSLC, 75 µm x 50 cm (C18, 2µm, 100 Å), ThermoFisher).
Peptides were separated by a 5 – 40% B gradient over 180 minutes at flow rate of
300nL/min at 50°C, where solvent A was 5% acetonitrile, 0.1% formic acid, in LCMS grade H2O and solvent B was 80% acetonitrile, 0.1% formic acid in H2O. Mass
spectra were acquired in data-dependent mode with a high resolution (60,000)
FTMS survey scan (mass range of 375-1575 m/z) followed by tandem mass
spectra (MS/MS) of the most intense precursors with a 3 second cycle time and a
4.0e5 automatic gain control target value for the survey MS scan. Higher energy
collisional dissociation (HCD) fragmentation was performed using a precursor
isolation window of 1.6 m/z, a maximum injection time of 22 ms, and a collision
energy of 35%. Monoisotopic-precursor selection was set to “peptide” and apex
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detection was not enabled. Precursors were dynamically excluded from
resequencing for 30 seconds with a mass tolerance of 10 ppm. Precursor ions with
charge states that were undetermined or > 5 were excluded.
To identify the peptides and infer the proteins present, Proteome Discoverer
version 1.4.0.288 (ThermoFisher) was used to search the tandem mass
spectrometric data against a human protein database (Uniprot). Briefly, the raw
data were run through two major processing nodes: Spectrum Selector and
Sequest HT. For the Spectrum Selector, a 15 minute retention time and precursor
mass of 350 Da defined the lower limits while the upper limits were bounded at
200 minutes with a precursor mass of 5000 Da. A 1.5 signal-to-noise (S/N) ratio
was set for the fourier-transform and MS2 activation was set at higher-energy
collision-dissociation. For the Sequest HT node, trypsin-digested peptides were
searched against a human protein database with a max missed cleavage site of 2,
minimum peptide length of 7 and maximum peptide length of 144 parameters
specified. 20 ppm and 0.02 Da mass tolerances were set for the precursors and
fragments, respectively. Finally, dynamic deamidation of asparagine or glutamine
(+0.984) and oxidation of methionine (+15.995 Da) modifications were included in
the search along with static modification of carbamidomethylation of cysteine (
+57.021 Da). A false discovery rate threshold determined by searching against a
reversed, human database was set at 0.01. An XCorr to charge state filter was
used to filter out low scoring peptides. A total of 9156 peptides were detected
corresponding to 782 protein groups, where at least 2 tryptic peptides were used
to identify a protein.
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5.3 Results
5.3.1 SAFER in FFPE Tissues and Cultured Cells
Following successful histochemical staining facilitated by AAN3 and click
biotinylation, we experimented with an alternate streptavidin-conjugated probe for
fluorescent visualization of α2,3 and α2,8-linked sialic acids. We initially
demonstrated this new staining system, sialic acid fluorescence enhancement
reaction (SAFER), in two pancreatic cancer FFPE tissues which were
morphologically separated by their stromal content. In 2018 Koay and colleagues
developed a stromal scoring system which categorized pancreatic ductal
adenocarcinoma tissues into “high delta” and “low delta” biophysical subtypes
based on stromal patterning, computed tomography (CT) volumetric contouring
and other characteristics471. A high Δ score – typified by lower levels of tumor
stroma – was associated with earlier metastasis and poorer overall survival.
Although these classifiers were absent from the clinical data associated with our
PDAC cohort, the stromal phenotypes of many of the tissues visually corresponded
to the classifications. Therefore, we considered these samples an ideal test bed to
characterize α2,3 and α2,8 sialic acid expression between morphologically distinct
tissues. Figure 40A shows H&E staining of the tumor stroma in a PDAC FFPE
tissue that phenotypically corresponds to a low delta score, with visually apparent
increases in extracellular matrix (ECM) and cells in the interstitium. In contrast, the
pancreatic cancer tissue in Figure 40B has a lower ECM volume and a more
homogenous mix of tumor and stromal cells which aligns with the high Δ stromal
phenotype. In accordance with Δ classification-associated survival trends, the
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Figure 40. Stromal Morphology Variations in Pancreatic Cancer Tissues. H&E staining of two pancreatic cancer tissue
samples. A) a low Δ stromal phenotype with increased ECM volume compared to B) a high Δ phenotype with decreased
ECM volume and C) their associated clinical outcome data.

patient with the high Δ stroma phenotype presented later with distant recurrence
following resection while the low Δ-like patient recurred only locally (Figure 40C).
The workflow for α2,3 and α2,8 sialic acid visualization by SAFER is
outlined in Figure 41. Briefly, FFPE serial tissue sections were derivatized with
azide handles through AAN3 and biotinylated by an overnight click chemistry
reaction with a biotin alkyne. The installed biotin on α2,3 and α2,8 sialic acid
isomers was then used to capture a commercially available fluorochromeconjugated streptavidin via a blocking and staining format adapted from a
previously published immunofluorescence protocol109. Figure 42 shows the first
SAFER staining analysis of pancreatic cancer tissues. Common to both tissues
was vivid fluorescence staining in neoplastic PDAC lesions, with polarized α2,3
and α2,8-sialic acid expression on the luminal face. Tissue 2893, which had a low
Δ stromal phenotype, exhibited decreased sialic acid staining in the stroma
surrounding primary tumor and lesion tissues as compared to the cancerous and
neoplastic cells in the sample (Figure 42 A-D). Conversely, stroma in the high Δ
phenotype tissue 4374 stained intensely for α2,3- and α2,8-linked sialic acids.
Increased ECM sialylation is linked to heightened metastatic potential in pancreatic
and other cancers and may in part explain why patient 4374 from our cohort
experienced distant recurrence post-resection472. Overall, these experiments
demonstrate the potential of SAFER to highlight sialylation differences between
disparate tissue morphologies.
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Figure 41. SAFER Schematic Workflow. Divided into 3 main parts, the SAFER
method entails 1) AAN3-derivatization of α2,3- and α2,8-linked sialic acids with a
polyethylene glycol (PEG)-extended azide handle followed by 2) biotinylation by
click reaction and 3) biotin-avidin affinity capture of a streptavidin-conjugated
fluorochrome (Cy5) and imaging by fluorescence microscopy.
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Figure 42. α2,3 and α2,8 Sialic Acid Staining with SAFER in PDAC FFPE Tissues. SAFER staining of morphologically
distinct pancreatic cancer tissues. A-D) 10X and 20X optical fluorescence images of two lesions within a low Δ stromal
phenotype PDAC tumor. Intense α2,3/α2,8 sialic acid staining (red, Cy5) was observed in the lesion cells as opposed to the
surrounding stroma. E-H) 10X and 20X optical fluorescence images of two lesions within a high Δ stromal phenotype PDAC
tumor. Intense α2,3/α2,8 sialic acid staining (red, Cy5) in both the lesions and surrounding stroma. Nuclei: blue, DAPI.

The next focus in the development of SAFER was to use this staining
technique to characterize sialylation patterns in healthy versus diseased tissue.
For this end, we applied SAFER to a normal kidney FFPE tissue section and to a
clear-cell renal cell carcinoma (ccRCC) sample (Figure 43). Here we focused on
the glomeruli, dense networks of blood vessels at the intersection of nephrons and
the renal tubules which are critical to the kidneys’ blood filtration function473. As
these structures are known to be affected by the development and progression of
ccRCC, we questioned whether there would be observable sialylation differences
between healthy and afflicted glomeruli474. Figure 43A shows SAFER fluorescent
staining of glomeruli from the non-diseased tissue while cancerous glomeruli are
shown in Figure 43B. Although not significant, healthy glomeruli tended to be larger
in size and contained more nuclei, while diseased structures had fewer nuclei and
were smaller overall (Figure 43C). Visually, diseased glomeruli appeared
deformed while healthy glomeruli were more circular. We quantified the intensity
of SAFER staining in each glomeruli, normalized to both glomerular area and
nuclear content, and demonstrated significantly increased α2,3 and α2,8 sialic acid
content in glomeruli from the ccRCC tissue (Figure 43D). The ability to reliably
quantitate SAFER fluorescence is a developmental benchmark and will be key to
its successful integration into more advanced fluorescent imaging experiments.
We further evaluated SAFER’s capacity to complement other staining
techniques in post-mortem SARS-CoV-2 (COVID-19) infected lung tissue
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Figure 43. Quantification of SAFER Staining in Healthy and Diseased Glomeruli. α2,3 and α2,8-linked sialic acid (red,
Cy5) visualization in a normal kidney tissue compared to a ccRCC tissue. A) 20X optical fluorescence images of 3 (out of
10 total) SAFER-stained glomeruli from a non-diseased kidney tissue sample. B) 20X optical fluorescence images of 3 (out
of 10 total) SAFER-stained glomeruli from a ccRCC tissue sample. C) measuring glomerular area and nuclear content. Left
axis (orange): glomeruli area (px, pixels) was increased in the healthy sample although not significantly. Right axis (green):
# of nuclei per glomeruli was increased in the healthy tissue, although not significantly. D) a significant increase (p =
0.000074) in area and nuclear content-normalized α2,3 and α2,8 sialic acid staining intensity in the diseased glomeruli.
Area, nuclei counting and staining intensity measurements performed in ImageJ. **** = p < 0.0001. Nuclei: blue, DAPI.

samples. Specifically, one of these tissues had areas of dense immune cell
infiltrate, presumably as a response to infection. This sample was stained by
SAFER which revealed intense α2,3 and α2,8-linked sialic acid expression on
some, but not all cells in the immune cluster (Figure 44A,B). The structure of this
infiltrate was interesting to us, as there were long chain-like groups of cells
studding the cluster overall, revealed by both SAFER and H&E staining (Figure
44C,D). We were subsequently driven to investigate the specific cellular
compositions of these immune areas to see if we could link α2,3 and α2,8 sialic
acid expression to a particular cell type. As part of a larger overall study, our
collaborators at the FDA immunohistochemically stained a serial section of this
tissue with CD8 and CD11b-targeted antibodies, which are cytotoxic T-cell and
pan-leukocyte markers, respectively (Figure 44D,E). Although not definitive, the
CD11b+ cells surrounding the CD8+ cell chains corresponded visually to the α2,3
and α2,8-linked sialic acid-expressing cells stained by SAFER. In the reverse
sense, the cells recognized as T-cells by CD8 IHC staining seemed to have lower
overall SAFER staining intensity when compared with their cellular neighbors. In
future experiments, fluorescent immune cell markers could be used in conjunction
with SAFER to specifically reveal the cell types which overexpress α2,3 and α2,8
sialic acid-containing glycoconjugates.
To determine whether SAFER was amenable to other sample formats, we
tested our approach on fixed, cultured pancreatic cancer cell lines. The workflow
for SAFER staining of cells is similar to that for FFPE tissues, except in that it omits
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Figure 44. SAFER, H&E and IHC Staining of Immune Cells in SARS-CoV-2-Infected Lungs. Post-mortem COVID-19infected lung tissue serial sections were treated with SAFER for sialic acid expression, IHC for CD8 and CD11 and were
histologically stained. A) 10X and B) 20X optical fluorescence images of immune infiltrate showing variable cell surface
expression of α2,3 and α2,8-linked sialic acids (red, Cy5) within the cluster. C) 10X and B) 20X H&E staining revealing
differential cellular morphologies within the infiltrate. E) CD8 + and F) CD11b+ positive immunohistochemical staining of
different immune cell populations within the area of interest. Nuclei: blue, DAPI.

the antigen retrieval step. Pancreatic cancer cell lines were cultured and fixed for
SAFER staining following a published protocol and as previously described during
the development of AAXL203. SAFER staining images of the ASPC1, HPAC,
PANC1 and PL45 pancreatic cancer cell lines used in Chapter 4 are shown in
Figure 45. Phenotypic expression differences were observed for each cell type.
ASPC1 cells showed intense α2,3 and α2,8 sialic acid staining specific to the cell
surface (Figure 45A), as compared to the PANC1 cells where staining was heavy
but polarized in a manner suggestive of endoplasmic reticulum or Golgi localization
(Figure 45B). SAFER staining was not specific to a particular cellular compartment
in the HPAC cell line, rather expression appeared to be ubiquitous across the cell
(Figure 45C). PL45 cells stained less intensely than did the others, with very low
levels of α2,3 and α2,8 sialic acid expression detected (Figure 45D). In an effort to
quantify SAFER staining in the cell lines, we first used the Otsu thresholding
function for image binarization in ImageJ to generate masks to control for staining
artifacts (Figure 45E). The resulting intensities as outlined within the masks were
controlled for the number of nuclei within the field of view, however without a cell
membrane marker could not be controlled for differences in cell size. With this
caveat in mind, the PANC1 cell line showed the most intense SAFER staining for
α2,3 and α2,8-linked sialic acids, with similar staining levels for the ASPC1 and
HPAC cells and minimal staining in the PL45 line (Figure 45F). Collectively, these
experiments demonstrate the potential of SAFER for both qualitative and
quantitative characterization of sialic acid isomer expression in cultured cells.
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Figure 45. SAFER Staining Reveals Disparate Sialic Acid Expression in Cultured PDAC Cells. 40X optical
fluorescence images of SAFER-stained A) ASPC1, B) PANC1, C) HPAC and D) PL45 cell lines. E) Otsu thresholding
function defined masks to control for staining artifacts in ImageJ. F) nuclei-normalized intensities of SAFER staining in each
cell line. α2,3 and α2,8 sialic acids: red, Cy5; Nuclei: blue, DAPI.

5.3.2 SABER Applied to Prostate Cancer Tissues
Our successful application of AAN3 in SAFER inspired us to explore even
more creative approaches for the characterization of sialylated glycoconjugates. A
fundamental problem in glycomics is this: the very substantive link between
glycans and their protein carriers often needs to be severed in order to release
these sugars for analysis. In doing so, these proteins are left behind along with the
important biological context which they convey. Intact glycoprotein profiling is able
to retain the glycan:protein connection during analysis, however these strategies
often hinge on non-specific enrichment techniques to pull glycoproteins from the
total protein matrix en bloc. To date, a sialic acid isomer-selective solid phase
enrichment strategy has not been demonstrated. To address this technological
gap, we developed SABER (sialic acid bead enrichment reaction), where we use
the AAN3 and click chemistry-installed biotin handle on α2,3 and α2,8-sialic acids
to selectively retain these glycans and their underlying glycoconjugates on an
immobilized recombinant streptavidin resin. Captured glycoproteins can then be
processed for analysis by LC-MS/MS. The general workflow for SABER is outlined
in Figure 46.
We initially tested SABER on the prostate cancer FFPE tissues which were
examined in Chapter 4 in an attempt to link the α2,3-sialylated N-glycans revealed
by our prior experiments with their glycoprotein carriers. This sample had areas of
intense α2,3-sialic acid expression localized to tumor tissue regions, therefore we
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Figure 46. SABER Schematic Workflow. The SABER method entails 1)
derivatization of α2,3- and α2,8-linked sialic acids with an amine-azide by AAN3
followed by 2) click biotinylation, 3) biotin-avidin affinity capture on an immobilized
streptavidin resin and 4) tryptic digestion and peptide cleanup for LC-MS/MS.
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considered it an ideal proving ground for SABER (Figure 35E). As summarized in
Figure 46, the SABER workflow begins with AAN3 derivatization and click
biotinylation as previously described. Following installation of the biotin handle, the
tissue was antigen retrieved then scraped from the slide, homogenized, reduced
and alkylated. A protease-resistant streptavidin resin was then used to selectively
retain α2,3- and α2,8-linked sialic acid-containing glycoproteins from the tissue
homogenate. Captured glycoproteins were digested on-bead and the resulting
peptides were cleaned up, desalted and concentrated for subsequent LC-MS/MS
analysis. Alongside the derivatized tissue, a non-derivatized serial tissue section
was identically prepared as a control for the specificity of SABER for biotinylated
sialic acids. Additionally, a third non-derivatized serial tissue section was
homogenized, reduced, alkylated, digested with trypsin and cleaned up while
omitting SABER enrichment to represent the sample’s total proteome for
comparison.
Following LC-MS/MS analysis, higher energy collisional dissociation
(HCD)-fragmented spectra were annotated by their b and y ion fragmentation
patterns to assign a peptide amino acid sequence with high confidence. A protein
identification search was then performed where detected peptides were mapped
to their full sequences against a human database to confirm protein assignments.
Likely contaminants, mostly keratins, were filtered out of the results. 7312 peptides
corresponding to 747 proteins were identified in the non-enriched sample while
1844 peptides and 106 proteins were detected in the SABER tissue. The nonderivatized, SABER-enriched sample did not contain a detectable amount of

214

protein during a quality control check in sample clean up, thus confirming the
specificity of SABER for biotinylated targets (data not shown). Of the SABERenriched proteins, 71 were also identified in the non-enriched sample while 35
were unique to SABER. These 35 proteins, along with their accession numbers,
coverage, number of unique peptides and molecular weights are listed in Table 14.
Prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP), two well
characterized glycoproteins elevated in prostate cancer, were identified in both the
enriched and non-enriched samples. Overall, SABER demonstrated a greater than
7-fold enrichment in the number of identified proteins between the non-enriched
and SABER-treated sample.
To characterize expression differences between proteins identified in this
proof-of-concept experiment, label free quantification (LFQ) was performed in
Perseus based on precursor signal intensity (Figure 48A,B). 13 proteins were
determined to be enriched in the SABER tissue by LFQ. Of these 13, 8 were
extracellular matrix or adhesion junction proteins, which preliminarily suggests a
role for α2,3 and α2,8 sialic acids in the interaction between tumor cells and the
local microenvironment in prostate cancer (Figure 48C). This is consistent with
studies of sialylation in prostate cancer which have shown increased ST3GAL1
expression to be correlated with a more metastatic phenotype472,475.
To gain more biological context from the identified α2,3 and α2,8-linked
sialoproteins in the initial SABER experiment we performed a gene ontology (GO)
enrichment analysis using the panther classification system (Table 15). We first
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Table 14. Proteins Unique to the SABER Treated Sample.
Accession Description
P63267

Actin, gamma-enteric smooth muscle

Q86YZ3

Hornerin

Q02413
P81605

Coverage Unique Peptides MW [kDa]
32.98

3

41.850

8.84

7

282.228

Desmoglein-1

13.06

11

113.676

Dermcidin

22.73

3

11.277

P29508

Serpin

28.21

9

44.537

P31944

Caspase-14

20.66

7

27.662

7.98

5

93.776

14.04

2

12.139

Q08554-2 Desmocollin-1 (Isoform 1B)
Q71UI9-2

Histone H2A.V (Isoform 2)

P04350

Tubulin beta-4A chain

8.33

4

49.554

Q6NXT2

Histone H3.3C

15.204

16.3

3

Q13835-2 Plakophilin-1 (Isoform 1)

7.85

5

80.445

P02751-12 Fibronectin (Isoform 12)

3.49

5

221.152
35.984

P22626-2

Heterogeneous nuclear ribonucleoproteins A2/B1 (Isoform A2)

14.66

3

Q6UWP8

Suprabasin

12.2

2

60.505

Q5D862

Filaggrin-2

3.35

5

247.928

P31151

Protein S100-A7

12.87

3

11.464

P01040

Cystatin-A

41.84

3

11.000

P02545-3

Prelamin-A/C (Isoform Aδ10)

9.46

4

70.618

Q08188

Protein-glutamine gamma-glutamyltransferase E

P0DOX5

Immunoglobulin gamma-1 heavy chain

Q15517

Corneodesmosin

P05089

Arginase-1

P02788-2

3.46

2

76.584

10.69

2

49.298

4.35

2

51.490

14.29

5

34.713

Lactotransferrin (Isoform δLf)

8.26

5

73.114

Q96P63

Serpin B12

8.15

3

46.247

O75223

Gamma-glutamylcyclotransferase

18.09

3

20.994

P26599-3

Polypyrimidine tract-binding protein 1 (Isoform 3)

19.03

2

59.596

P47929

Galectin-7

16.18

3

15.066

P60174-4

Triosephosphate isomerase (Isoform 3)

14.97

2

17.947

P31025

Lipocalin-1

12.5

2

19.238

P00709

Alpha-lactalbumin

37.32

2

16.214

P09525-2

Annexin A4 (Isoform 2)

8.86

2

27.046

P68363-2

Tubulin alpha-1B chain (Isoform 2)

8.06

2

37.194

P08246

Neutrophil elastase

5.62

2

28.500

P05090

Apolipoprotein D

14.29

3

21.262
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Figure 47. Label Free Quantification of SABER-Enriched Glycoproteins. LFQ
intensities for the non-enriched sample (LFQ intensity 3) plotted against the
SABER sample (LFQ intensity 1) are shown in A) and enlarged in B) with protein
names annotated. C) Table of the 13 enriched proteins in the SABER tissue
including gene ID, protein name, subcellular location and molecular function.
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Table 15. GO Enrichment Analysis of SABER-Identified α2,3 and α2,8
Sialoproteins.
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searched for biological processes enriched in our SABER-identified proteins,
which included cell-cell adhesion, peptide crosslinking, bacterial defense
response, humoral immune response, response to oxidative stress and oxidant
detoxification amongst other functions. Generally, the biological processes could
be subdivided into either immune, extracellular or stress response capacities. To
gain insight into which signaling pathways these proteins are participating in, we
also performed a GO Reactome pathway search which again revealed a host of
enriched networks biased towards extracellular, immune and stress functions of
the

cell.

Collectively,

these

results

are

in

line

with

the

apoptotic,

immunosuppressive, and extracellular adhesion properties attributed to sialylated
glycoconjugates in cancer. Although these results are preliminary and further
developmental work remains to be done, this initial experiment demonstrates the
potential for SABER to provide deep biological insights into the roles of α2,3 and
α2,8-linked sialic acids in health and disease.
5.4 Discussion
The expanded applications for AAN3 described in this chapter are a
promising start for the development of advanced tools to study α2,3 and α2,8
sialylation. The major advantage conveyed by both SAFER and SABER is the
ability to be isomer selective. To date, neither fluorescent labeling strategies
targeting sialylation nor solid phase enrichment approaches for sialylated
glycoconjugates can discriminate between the major sialic acid isomers present in
living systems. Our approaches address this technological gap through the
preferential incorporation of azide tags directly into α2,3 and α2,8-linked sialic
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acids. Critically, our new tools do not require active metabolic machinery to install
their click-reactive handles and therefore are applicable clinical tissue and biofluid
samples. Another strength of SABER and SAFER is that these techniques rely on
the well-characterized specificity of biotin:avidin interactions to generate their
expanded functionality476. Not only does give us high confidence the selectivity of
our probes and enrichment surfaces for their click-chemistry biotinylated targets,
but the commercial availability of recombinant streptavidin-conjugated molecules
suggests that these are just the first in a line of enhanced approaches potentiated
by AAN3.
Although the approach targets many well described tumor carbohydrate
antigens that are α2,3-sialylated, a shortcoming of both SAFER and SABER is
their inability to recognize α2,6-sialylated molecules. This is especially unfortunate
given our understanding of the role α2,6-sialylated glycans play in immune
suppression within the tumor microenvironment, amongst other functions. The
differential formation of stable α2,6 amides and α2,3 or α2,8 intramolecular
lactones under the same reaction conditions during amidation derivatization
reactions is strongly dependent on the derivatizing nucleophile used in the 1 st
reaction step427,477,478. It is worth exploring whether an alkyne-containing weak
nucleophile could be substituted for the current dimethylamide reagent used in the
1st amidation step of AAN3. Complicating downstream analyses, the protocols we
have developed do not allow us to discriminate between α2,3 and α2,8-linked sialic
acid isomers, which are identically labeled or selected for by SAFER and SABER.
Fortunately, this obstacle can be overcome by the use of α2,3 or α2,8-sialic acid-
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targeted sialidases to clear a particular isomer from the tissue prior to
derivatization, biotinylation and SABER or SAFER treatment. In a partnership with
our academic and industrial collaborators, we are currently evaluating isomer
specific sialidases for use in our systems.
Both protocols are still in the developmental stage. For SAFER, use with
complementary fluorescent probes still needs to be explored so that this staining
technique can be integrated with more traditional immunofluorescence
experiments. As SAFER continues to evolve, so too should our methods for
staining quantification. While the initial results were promising, SABER requires
further refinement. Optimization of capture conditions, reagents and sample
cleanup is ongoing and should produce a more robust protocol. We are also
interested in increasing the amount of starting material through the use of multiple
serial sections to generate a larger number of protein identifications downstream.
Collectively, both protocols represent the first steps in a much larger exploration of
sialic acid biology by our group. We hope that one day both SAFER and SABER
will see routine implementation in our glycobiological workflows and reveal
previously unknown mechanisms of disease driven by sialylation.
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Chapter 6: Conclusions, Limitations and Future
Directions
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6.1 Global Overview
The work presented in this dissertation covers three key areas: 1)
determining N-glycans and N-glycan structural motifs that are altered in pancreatic
ductal adenocarcinoma, then linking these changes with canonical biomarker
expression to better discriminate between cancerous and non-transformed tissue;
2) the development of bioorthogonal chemical derivatization strategies to
differentiate between sialic acid linkage isomers and their application to FFPE
tissues, clinical biofluids and cultured cells; and 3) the translation of this
derivatization approach into two novel methods for fluorescent labeling of sialic
acid isomers and selective enrichment of sialylated glycoconjugates for
glycoproteomic analyses. Each chapter represents a significant step forward in
their respective glycobiological fields. The broader implications of each of these
research efforts, along with their limitations and potential future directions, are
outlined further below.
6.2. N-glycosylation Changes in PDAC
6.2.1 Conclusions
Aim 1, described in Chapter 3 of this dissertation, focused on analyzing the
distribution of N-glycans in a pancreatic ductal adenocarcinoma patient cohort by
MALDI-IMS to uncover specific N-glycan or glycan structural motifs associated
with cancerous tissue regions. Initial investigations into N-glycosylation in normal,
healthy pancreas tissues revealed previously undocumented high-mannose Nglycans associated with acinar regions. It is possible that the presence of these
glycans, which are heavily associated with protein folding, is a function of the
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secretory nature of the pancreas, where digestive enzymes are synthesized,
packaged and secreted in large quantities. Accordingly, protein translation and
folding – and concomitantly the high-mannose glycans critical to these events –
may be elevated at baseline when compared to other organ tissues. Another novel
finding was the detection of sulfated, terminally galactosylated N-glycans specific
to pancreatic Islets of Langerhans. These unique structures had not been detected
in previous N-glycan analyses of pancreatic nor other cancers by our group and
warrant further investigation.
Although pancreatic cancer tissues were used during the prior development
of N-glycan IMS workflows in our lab, conclusions from those analyses were
towards characterization of the method and not the disease itself. Thus, ours
represents a first-of-its-kind study to spatially profile the N-glycome in PDAC. The
analyses revealed increased N-glycan branching, fucosylation, sialylation and
bisecting GlcNAc residues in pancreatic cancer tissue regions as compared to
normal adjacent tissue. This data is consistent with the literature, where altered
expression of the glycosyltransferases responsible for the above motifs is well
characterized in PDAC239–242. While some of these findings are not novel for the
study of pancreatic cancer in general, they have never before been linked directly
to tumor tissue via a comprehensive spatial analysis.
What is novel, however, is the link between N-glycosylation and pancreatic
cancer biomarkers explored by this study. Although we could not directly detect
the CA19-9 or sTRA epitopes as part of the N-glycans analyzed by IMS, we did
conclude that multiply branched N-glycans with both core and outer arm
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fucosylation were significantly associated with CA19-9-expressing tumor tissue
cores in the tissue microarrays. sTRA-expressing cores tended to have less
branched N-glycans which lacked outer arm fucosylation. Whether or not these Nglycans host CA19-9 and sTRA motifs in pancreatic cancer remains an open
question. Critically, we were able to translate our findings into a multi-marker panel
by combining 11 differentially expressed N-glycan analytes with biomarker
immunofluorescence data. Models using this panel as a data source outperformed
models using IMS or IF data alone in discriminating between pancreatic cancer
tissue cores and adjacent normal cores. This work, along with other projects from
out lab, highlights the potential of N-glycan imaging mass spectrometry as a tool
for biomarker discovery. Moreover, the novel combination of orthogonal glycan
analyses in this study shows the utility of glycans in general as prognosticators of
disease in pancreatic cancer.
6.2.2 Limitations
As discussed in Chapter 3, one of the greatest limitations to our study was
the enormous structural complexity of the N-glycans present in the pancreatic
cancer tissues. Every major feature of N-glycosylation was represented in our
dataset, including sialyation, core fucosylation, outer arm fucosylation, branching,
bisecting GlcNAc, polylactosamine extensions, terminal HexNAc and sulfation. We
addressed fucosylation isomers through the use of EndoF3, which determined that
most structures containing one or more fucose were core fucosylated. The precise
assignment of outer arm fucose residues to specific termini, however, is not
currently possible using traditional N-glycan IMS workflows. The use of ion-mobility
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separated mass spectrometers in the future may deconvolute some of this
complexity, although more must be understood about the behavior of fucosylated
glycans in these instruments. By stabilizing sialic acids with Wuhrer’s amidation
reactions, we were able to evaluate linkage isomer expression in our tissues.
Unfortunately, this workflow reduced overall N-glycan signal in the treated tissues
and led to the spectral overlap of analytes, inspiring our later developmental work
in Chapters 4 and 5.
An additional challenge was the analysis of high mass N-glycans in this
study. Our imaging mass spectrometry methods were designed for optimal signal
intensity across the nominal N-glycan mass range (~m/z 700 – 4000), however
higher mass glycans ranging above m/z 10000 have been detected in other
studies479. These ultra-large N-glycans are particularly relevant to the study of
cancer, as the overexpression of fucosylation and polylactosamine-creating
enzymes in malignant tissues may drive their synthesis. The instrument and
method optimization required to reliably detect high mass glycans was beyond the
scope of this study, however future investigations should focus on these
understudied species. Here, chemical derivatization and secondary laser
positronization instrumentation approaches would be useful205,479.
A final limitation of this study was the lack of clinical information supplied
with the sample cohort. Although basic metrics like age, race, biological sex,
disease stage and histological characteristics were provided, detailed recurrence
and survival data was absent for most patients. Without these features, we could
not associate the detection of specific glycans or glycan phenotypes with patient
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survival and therefore could not draw many biological conclusions about the impact
of glycosylation themes recognized by this study on patient outcomes. Additionally,
we would have been eager to incorporate associated clinical data like BMI,
comorbidities, socioeconomic background and other factors into our modeling,
which in many cases has been shown to improve the sensitivity and specificity of
disease detection480. Overall, a follow up study in a larger patient cohort with more
complete clinical information may be warranted.
6.2.3 Future Directions

There are two main directions in which this research could be furthered to
enhance N-glycan-based detection of pancreatic cancer. Firstly, while our
comparison between normal pancreatic tissue and cancerous tissue was suitable
to highlight cancer-associated N-glycan alterations, a more apt comparison for
early detection efforts would include a pancreatitis patient cohort. By studying the
progression from normal pancreas to the chronic inflammatory state of pancreatitis
through to malignant disease, we could better understand the glycobiological
hallmarks and drivers of this transformation. More critically, N-glycan changes
associated with the transition from chronic pancreatitis to pancreatic cancer could
be used as biomarkers for earlier detection of the disease. Although less than 10%
of pancreatic cancers are thought to arise from chronic pancreatitis, this patient
population is under constant surveillance for the neoplastic progression of their
disease into early stage PDAC33. Accordingly, N-glycan changes discovered by
future analyses of the CP → PDAC evolution could be translated into more
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impactful biomarkers in a smaller, more disease prone population which is already
being routinely monitored.
The second major research direction that should be pursued in light of this
study is the link between N-glycans in PDAC tumors and serum N-glycosylation in
pancreatic cancer patients. The relationship between these two N-glycomes is
complex. Over 90% of serum proteins are hepatic in origin, meaning that N-glycan
motifs detected in the blood of PDAC patients are not likely to have originated in
the tumor but rather are a hepatic glycosylation response to the immune system’s
fight against the tumor. Pancreatic tumors have, however, been shown to leak
proteins into the circulation, thus depletion approaches targeted towards the more
common serum proteins may reveal low abundance glycoproteins which could be
linked directly to the disease. Circulating tumor cells are another attractive target
in pancreatic cancer, where glycosylation changes in these cells are immediately
representative of tumor glycobiology. Our biofluid N-glycan profiling approach
outlined in Chapter 4 and a novel method for slide-based capture and analysis of
specific cell types being developed in our labs are directly applicable to these ends
and are being pursued. The accessibility and minimal invasiveness of biofluid
collection means that N-glycan PDAC markers found in this matrix could be directly
translated into a clinical diagnostic application. Whether hepatic or pancreatic in
origin, surveilling serum N-glycan changes in pancreatic and other cancers is the
ultimate thrust of our long-term clinical research efforts.
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6.3 Sialic Acid Derivatization by AAXL and AAN3
6.3.1 Conclusions
Aim 2 of this dissertation was divided into two main parts: 1) the
development of click chemistry-compatible sialic acid derivatization schemes and
2) advanced bioorthogonal applications of these reactions. The development and
publication of our azide and alkyne-based labeling techniques was the focus of
Chapter 4. These methods, based on a substantial body of knowledge, integrate
α2,3-linked sialic acid lactone amidation reactions and bioorthogonal sugar azide
labeling to produce a multi-functional set of sialic acid-targeted tools with
applications for N-glycan imaging mass spectrometry and histochemical staining.
At their most reductive functions, the AAXL and AAN3 reactions introduce
favorable mass shifts in α2,3 and α2,6-linked sialic acids facilitated by the
differential stereochemistry between isomers. The small alkyne handle installed
through use of a propargylamine reagent by AAXL is ideally suited for imaging
mass spectrometry experiments, as its low molecular weight means that labeled
glycans remains spectrally close to their original underivatized m/z. AAXL was able
to distinguish between α2,3 and α2,6-sialylated N-glycans in FFPE tissues, clinical
biofluids, and cultured cells in IMS experiments. Because of the robustness of our
protocol and its demonstrated performance for labeling in solution, we foresee
utility for AAXL in liquid chromatography and electrospray ionization mass
spectrometry experiments as well.
In terms of bioorthogonal functionality, the short alkyne handle installed by
AAXL is unable to penetrate the aqueous click chemistry reagents and showed
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inconsistent labeling of α2,3 and α2,8-sialylated glycans by DAB histochemistry.
Conversely, in the AAN3 reaction, the PEG3 linker separating the NH2-PEG3-N3
derivatization reagent extends the azide handle well away from the hydrophobic
tissue surface, thereby making it much more receptive to click biotinylation.
Consequently, AAN3 is much better suited for bioorthogonal conjugation of imaging
reporters, as demonstrated by our streptavidin-peroxidase staining experiments.
An advantage of our protocols is that unlike traditional bioorthogonal
approaches, they do not rely on the metabolic incorporation of azido sugars by the
biological

machinery

of

living

systems

for

their

click

chemistry

functionality429,432,435. Thus, our labeling approaches are suitable for formalin fixed
clinical tissue specimens meaning there are potentially millions of stockpiled
samples which can be analyzed. Additionally, the compatibility of our systems with
patient biofluids opens up the possibility that they may one day see clinical
implementation. To this end, a final strength of the AAXL and AAN 3 reactions is
their simplicity. Many chemical labeling approaches targeting sialic acids require
lengthy, even overnight, incubations in various expensive reactants and
considerable post-reaction clean up384. In contrast, our syntheses add only 4 hours
of sample preparation time to a traditional N-glycan IMS workflow. Despite the
brevity of our reactions, AAXL and AAN3 routinely manage upwards of 90%
labeling efficiency in FFPE tissues. Furthermore, the reagents for AAXL and AAN 3
are cheap, commercially available and are well-characterized components of more
established chemical labeling approaches. These propargylamine and azidoPEG3-amine reaction components are key to the synergism between the two
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workflows, which differ only in the secondary derivatization reagent used. The
result is an effectively tunable chemistry, where the substitution of one reagent for
the other changes the downstream readout or capability. Collectively, these
features would allow an unskilled operator to carry out our labeling reactions,
potentiating their in-clinic implementation for the analysis of sialic acid isomers in
patient samples.
6.3.2 Limitations
In an ideal scenario, the imaging data from AAXL-based IMS and AAN3based staining would be co-registered for deeper biological insights. A challenge
to their integration, however, is the specificity of the sialylated readouts generated
by each approach. AAXL-treated tissues are integrated into our group’s N-glycan
imaging mass spectrometry workflow, which relies on the use of an N-glycan
specific enzyme. Thus, only sialic acids on N-linked glycans are detected and
differentiated by IMS in this analysis. In contrast, AAN3-enabled biotinylation and
histochemical staining is indifferent to the glycan carrier of the labeled sialic acid,
which occur naturally on N-linked and O-linked glycans as well as on glycolipids394.
Consequently, AAN3-HC recognizes more sialylated biomolecules than does
AAXL IMS, which detects only the subset attached to N-glycans. In integrating the
data through image coregistration, it is currently impossible to distinguish whether
the sialylated N-glycans visualized by AAXL-enabled IMS correspond to those
molecules visualized by AAN3-enabled histochemistry. Similar IMS workflows to
ours for N-glycans utilizing O-glycan-specific release agents are being developed,
which may help resolve some of this complexity.
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A related issue arises when trying to determine whether an AAXL or AAN3labeled sialic acid observed by IMS or histochemistry is in the α2,3 or α2,8
configuration, which are identically labeled by both syntheses. Currently, our
reactions – as well as other approaches in the field – are not designed to resolve
this population. The stereochemical positions of the carboxylate group in α2,3 and
α2,8 linkages both favor internal lactonization during the first amidation
step427,477,481. In order to distinguish between the two, new chemical reactions
which are not based on ring-opening aminolysis must be created. Alternatively,
this issue is can be solved by the use of isomer-specific sialidases to clear the
tissue of one isomeric linkage or another prior to labeling and staining, leaving only
α2,3 or α2,8-linked species for analysis. Nevertheless, the study of α2,8-sialylated
molecules remains challenging.
The chemistry upon which our syntheses are based is well characterized,
and we have confirmed the specificity of both AAXL and AAN 3 derivatization by
NMR analysis at multiple steps along the reaction pathway. In addition, we have
demonstrated that both methods label their sialylated targets with greater than
90% efficiency, giving us confidence that the data they generate is truly
representative of the natural sialylation state of the tissue, cell or biofluid sample.
Our confidence notwithstanding, orthogonal confirmation by another sialic acid
isomer characterization method would be advisable. Recent experiments in our
working group using AAXL are being verified by LC-MS/MS and we expect this
data to align with ours.
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6.3.3 Future Directions

A goal of ours moving forward is to streamline AAXL and AAN3 into a single
synthesis capable of both imaging mass spectrometry visualization and clickenabled biotinylation. As previously described, AAXL uses a propargylamine
handle which is small and ionizes well, making it ideal for IMS applications. The
proximity of this alkyne handle to the surface of the tissue, unfortunately, limits its
use for click chemistry, as it generally fails to enter the aqueous milieu of the click
reaction. Concomitantly, AAN3’s azide handle is stereochemically-extended from
the tissue surface via a PEG linker and thus is extremely sensitive to clickbiotinylation. The high molecular weight of the NH2-PEG3-N3 label in AAN3,
however, leads to less-efficient ionization of AAN3-labeled glycans and restricts its
utility for IMS experiments. This unresolved dichotomy not only results in a more
labor-intensive sample preparation when both IMS and histochemical applications
are desired, but also presents a major challenge to the integration of these data.
Because AAXL and AAN3 covalently label their target sialic acids, it is not possible
to perform both syntheses on the same tissue section. Thus, serial tissue sections
must be utilized, which complicates the coregistration of IMS and HC data. We
concede that a single, bifunctional synthesis would be more ideal than two with
singular functionality. Designing such a system requires exploring alternative clickcompatible handles. An ideal label would be of low molecular weight, ionizes
efficiently and generates stereochemical distance between the sialic acid and the
click-handle. One possible class of molecules that satisfy these requirements are
amine-azides (or amine-alkynes) separated by a cleavable linker452,453. In theory,
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a cleavable linker strategy would work as follows: 1) α2,3 and α2,8 sialic acids
would be derivatized with the cleavable azide, biotinylated by click chemistry and
histochemically stained then 2) the molecule would be enzymatically or
photochemically severed, leaving behind a small mass tag which would label these
sialic aids for separation by imaging mass spectrometry. Thus, we could generate
multiple datasets from the same tissue which would perfectly co-register, providing
deeper biological insight into the sialobiology of our sample. Accordingly, our group
is currently pursuing these such reagents as the next generation replacement for
the syntheses presented here.
6.4 Advanced Glycomic Studies with SABER and SAFER
6.4.1 Conclusions
Chapter 5 of this dissertation focused on the development of two novel
extensions of the AAN3 azide derivatization approach. Termed SAFER and
SABER, these applications allow for the fluorescent labeling and solid phase
enrichment, respectively, of α2,3 and α2,8-linked glycoconjugates. The sialic acid
fluorescent enhancement reaction (SAFER) uses the AAN3 and click-installed
biotin on α2,3 and α2,8 sialic acid isomers to capture a streptavidin-fluorochrome
dye so that these molecules can be visualized by fluorescence microscopy. In
FFPE tissues, we showed that SAFER staining could highlight sialylation
differences between morphologically separated PDAC tumors, align with other
histological images to correlate sialic acid expression to immune cell type and
reveal α2,3 and α2,8 sialic acid isomer increases in diseased glomeruli. Further,
we demonstrated SAFER staining in cultured pancreatic cell lines which showed
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differential sialic acid expression phenotypes as visualized by our system. SAFER
is quantifiable in both FFPE tissue and cell culture analyses and with further
development, including the use of cell membrane markers, may be able to
quantitate sialylation in single cell experiments. The defining feature of SAFER is
the ability to generate isomer-specific readouts, making it unique amongst a field
of other sialic acid fluorescent detection methods which forgo this selectivity in
favor of pan-sialic acid labeling. We expect that with optimization, SAFER can
integrate into more traditional immunofluorescence experiments at the point of
secondary incubation, allowing the visualization of α2,3 and α2,8-sialylated
glycans alongside other markers.
The sialic acid bead enrichment reaction (SABER) we developed relies on
biotin affinity capture as does SAFER, where AAN3-derivitzed, click-biotinylated
sialylated glycoconjugates are retained from the total protein matrix through the
use of an immobilized streptavidin resin. SABER-enriched α2,3 and α2,8sialoproteins can then be digested on-bead and the resulting peptides analyzed by
LC-MS/MS. Our proof-of-concept experiment using this system was able to identify
over 100 proteins, as compared to 700+ in a non-enriched sample. A significant
subset of the enriched proteins were also identified in the non-enriched data,
however 35 were unique to the SABER. Although preliminary, this result suggests
that SABER may be able to enrich low-abundance sialoproteins which are normally
lost in the “proteomic noise” when analyzing a non-enriched sample. Label-free
quantification of our data showed a number of proteins which were significantly
enriched in the SABER sample as compared to the untreated control. Once again,
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SABER’s most unique strength is its ability to be isomer-selective, which sets it
apart from other glycan enrichment approaches that retain sialylated glycoproteins
in bulk. As we further refine SABER, we hope to increase the number of identified
proteins while streamlining the workflow. A fully developed SABER may deepen
our understanding of the protein carriers of α2,3 and α2,8-linked sialic acids and
better define their glycobiological functions.
6.4.2 Limitations
As described for AAXL and AAN3, SAFER is limited in its ability to
distinguish α2,3 and α2,8-linked sialic acid isomers, which are identically
derivatized and biotinylated by the AAN3-click chemistry reactions. This obstacle
can be overcome by the use of α2,3 or α2,8-specific sialidases to clear a particular
isomer from the tissue prior to imaging, however there may be a cleverer approach
that allows both isomers to be imaged and delineated in the same experiment.
α2,8 sialic acids occur naturally as part of α2,8 and α2,9-linked polysialic acid
chains, with a degree of polymerization ranging from as few as 8 units to over
400482. Each α2,8 linkage in this chain serves as a possible installation point for
an azide handle, biotin alkyne and streptavidin dye molecule during SAFER
staining, meaning each polysialic acid chain could contain tens to hundreds of
fluorochromes. Accordingly, a polysialic acid-containing glycan may be
substantially brighter during fluorescent excitation than glycans modified with α2,3linked sialic acids, which are limited by the number of possible attachment points
on any given N- or O-linked glycan. With the use of techniques like single-molecule
localization super-resolution microscopy483, it may be feasible to observe individual
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α2,3 and α2,8-sialylated glycoconjugates and distinguish them by their fluorescent
signal intensity via a thresholding function. Although this approach would require
significant optimization of SAFER including the use of new dyes, advanced
microscopy systems, sialic acid standards and novel data analysis tools, the
specific discrimination between α2,3 and α2,8-sialylation using SAFER as a
technological base is theoretically possible.
As it stands today, SABER has two major areas for improvement. Firstly,
the number of protein identifications from our samples were low, slightly over 100
in the enriched sample and 700+ in the untreated sample. This is in comparison to
other studies which are able to identify thousands of proteins from a single FFPE
tissue sections using specialized digestion and separation procedures 484,485.
Currently, we are aiming to increase the number of identifications by increasing
the amount of AAN3-derivatized, click-biotinylated starting material. A recent
experiment using the pooled material from pancreatic cancer cells grown and
derivatized on four glass slides was able to identify over 1000 SABER-enriched
proteins. In a similar fashion, combining serial FFPE tissue sections should boost
downstream peptide signal intensity leading to a greater number of protein IDs.
Another explanation for the low number of identified proteins is that the AAN 3
derivatization reaction is expected to amidate carboxylate-containing protein
groups as well as α2,6 sialic acids, where the + 27 Da mass shift is likely to confuse
the search algorithm. By including static dimethylamide modifications on glutamic
acid (Glu), aspartic acid (Asp) and C-terminal amino acids in our search
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parameters, we may be able to increase the number of peptides detected and thus
protein identifications.
A second limitation of SABER was discovered in our data analysis, where
several non-glycoproteins were identified in the enriched dataset. These proteins,
including gamma-enteric smooth muscle actin, hornerin, histone family proteins
and lipocalin, amongst others, do not contain N- or O-linked glycan sites as
currently understood. There are a few explanations as to why these proteins might
be enriched by SABER. Firstly, it is likely that these non-glycoproteins may be
binding non-specifically to either the immobilized streptavidin or the resin particles
themselves. Characterization studies have shown that various commercially
available bead materials in combination with different streptavidin formats have
disparate binding capacities, where some resins are able to retain non-biotinylated
molecules486. Experimenting with different resin products and optimization of
binding and washing steps may be able to reduce this non-specific binding in
further iterations of SABER. Secondly, it is possible that the non-glycosylated
proteins in our enriched samples are being retained in complex with the sialylated
proteins we enrich for. The binding and wash buffers used for affinity capture are
mild, and likely are not astringent enough to disrupt protein-protein interactions. By
tailoring buffer strength, we may be able to dissociate these complexes and retain
only sialylated glycoproteins, however there is a risk of disrupting biotin-avidin
interactions under harsher conditions. Ultimately, if these non-glycosylated
proteins are shown to be in complex with our enriched sialoproteins, this feature
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of SABER might one day be considered a strength, leading to interaction
proteomics applications after further optimization.
6.4.3 Future Directions

Each method has areas for improvement, optimization and application. Both
are in their infancy, requiring more development work to characterize their
specificity, accuracy, precision, limits of detection and quantification and
robustness amongst other factors. The initial experiments with both SABER and
SAFER are meant to be the starting point for establishing standardized protocols
and the eventual publication of a methods paper to highlight the downstream
capabilities of AAN3. Their recency notwithstanding, the preliminary data
generated by both SAFER and SABER suggests exciting new research
opportunities ahead.
As previously mentioned, a major developmental milestone for SAFER
would be implementation in traditional immunofluorescence workflows alongside
other fluorescent markers. Our current data suggests that SAFER staining images
can be co-registered with other optical imaging data, however performing SAFER
and immunostaining in the same experiment could show direct colocalization
between α2,3 and α2,8 linked glycoconjugates and hundreds of potential
molecules of interest. This data could lead to discoveries of the protein carriers of
these sialic isomers or the molecules with which they interact, amongst other
potential insights. The number of molecules identified in a single experiment is
typically limited by spectral overlap between fluorophores, however with multi-
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round immunofluorescence techniques like the one demonstrated in Chapter 3,
tens of markers could be imaged215,399. In combination with new machine learning
tools for cellular segmentation and identification487, SAFER could one day be used
to gain deep biological context into cell-type specific α2,3 and α2,8 sialic acid
isomer expression and the roles which these cells play in their biological
neighborhoods.
The initial enrichment strategy for SABER identified only the trypsindigested peptides for captured glycoproteins, however the sialic-acid modified
peptides remained bound to the beads. Thus, critical biological information
regarding glycan site occupation and the types of sialylated glycans in our samples
was lost. Two future iterations of SABER could be imagined, one which releases
the peptide from the glycan and one which releases the biotinylated glycopeptide
from the streptavidin resin. The simpler of these two approaches, analytically,
would be to chemically or enzymatically cleave the N- or O-linked glycan
containing the derivatized sialic acid from the remaining peptide which it modified.
In doing so, we could map the released peptides back to their full protein
sequences identified from the tryptic digest and determine the exact site at which
these proteins were α2,3 or α2,8 sialylated. While more straightforward, this
approach would still fail to determine the specific sialic-acid modified glycans in
our sample. Alternatively, astringent washes could be used to dissociate the biotinstreptavidin interaction and release the sialylated glycopeptides from the beads.
Released glycopeptides could then be analyzed via an intact glycopeptide
strategy488, which may be aided by using derivatization and biotinylation of α2,3
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and α2,8 sialic acids as a mass tag to refine downstream searching and ID. These
glycan modifications would likely be hyper-variable between peptides and even on
the individual glycan site itself, requiring significant computational effort to ensure
confident identifications. Nevertheless, SABER has the potential to characterize
the specific sialic acid-containing glycan, localized to a specific glycan site on a
specific protein, with further development.
6.5 Final Thoughts

Collectively, the work presented in this dissertation was a journey of
discovery, where insights from our N-glycan analysis of pancreatic cancer led to
the development of novel tools for the separation and characterization of glycan
isomers. Each major section of this dissertation offers key advancements in their
respective research areas. We demonstrated improved detection of PDAC through
the integration of N-glycan IMS and biomarker IF in Chapter 3. In Chapter 4, new
sialic-acid specific derivatization reactions were established which showed utility
for IMS and histochemical staining of cultured cells, FFPE tissues and clinical
biofluids. Finally, advanced bioorthogonal applications for fluorescent labeling and
selective enrichment of sialylated glycoconjugates were presented in Chapter 5.
Ultimately, the work outlined herein may lead to the discovery of novel
carbohydrate biomarkers with therapeutic or early detection potential in pancreatic
cancer and other diseases.
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